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ABSTRACT
A large number of heterocyclic compounds has been prepared and tested for 
antimalarial activity.
Di-Mannich bases derived from 4-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)- 
phenol have been prepared from 5-trifluoromethylpyridin-3-amine through the new 4- 
chloro (and 4-hydroxy)-7-trifluoromethyl-l,5-naphthyridine followed by nucleophilic 
displacement of the chloro substituent with 2,6-di-Mannich bases of 4-aminophenol. Di- 
Mannich bases derived from 4-(7-trifluoromethylquinazolin-4-ylamino)phenol and 4-[7- 
chloro (and 7-trifluoromethyl)quinolin-4-ylamino]-3-methylphenol were prepared similarly.
Series of mono-Mannich bases such as 4'-chloro-3-(substituted amino)methyl-5-[7- 
bromo (and 7-trifluoromethyl)-l,5-naphthyridin-4-ylamino]biphenyl-2-ols ("Tebuquine" 
analogues) and analogous compounds which incorporated the 7-trifluoromethyl (quinolin- 
4-yl and quinazolin-4-yl) substituents, and mono-Mannich bases derived from 4-[7-bromo 
(and 7-trifluoromethyl)-l,5-naphthylidin-4-ylamino]-5,6,7,8-tetrahydronaphth-l-ols have 
also been described.
The mefloquine analogue, a-(piperidin-2-yl)-a-(7-trifluoromethylquinolin-4-yl)- 
methanol has been prepared, and syntheses attempted for the a-[7-trifluoromethyl (and 7- 
bromo)-1,5-naphthyridin-4-yl] analogues.
Physical properties such as n.m.r. and 13C n.m.r. (including two dimensional 
n.m.r. studies); some u.v. and i.r. spectra; and ionization constants have been determined 
and discussed.
All of these compounds were evaluated for antimalarial activity in a preliminary in 
vitro screen against the chloroquine-sensitive strain of the human malaria Plasmodium 
falciparum (the FCQ-27 isolate) using the incorporation of [3H]-hypoxanthine as a measure 
of parasite growth. Some of the more active compounds were also tested using a 
morphological technique in an in vitro test against both chloroquine-sensitive and
chloroquine-resistant (K-l) isolates, respectively, of P. falciparum', and the suitability of the 
visual microtest technique as a preliminary screen was also investigated.
Selected compounds were also examined for activity in vivo against P. vinckei 
vinckei in mice.
The most active compounds in the in vitro tests against the FCQ-27 isolate of P. 
falciparum, were the di-Mannich bases derived from 4-(7-trifluoromethyl-l,5-naphthyridin- 
4-ylamino)phenol and 4-(7-chloroquinolin-4-ylamino)-3-methylphenol. In comparative 
tests against the FCQ-27 and K-l isolates, no significant differences were observed for 
each compound examined.
The in vivo tests against P. vinckei vinckei in mice revealed that some of the di- 
Mannich bases derived from 4-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)phenol and 
the "Tebuquine" analogues which incorporated the 7-bromo (and 7-trifluoromethyl)-l,5- 
naphthyridin-4-yl substituent were effective when adminstered in a single dose of 200 
mg/kg.
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CHAPTER I
1CHAPTER I Introduction 
1-1 Malaria: Historic background
The word "malaria" comes from the Italian mal'aria, meaning bad air, because it 
was thought to result from bad air issuing from swamps and marshy ground. It was also 
known as Ague, Jungle Fever, Marsh Fever or Periodic Fever. In 1880, the causative 
agent of malaria was discovered by Alphonse Laveran1 when he observed the presence of 
minute parasites in the corpuscles of blood of soldiers in Algeria. Golgi2 in 1889 produced 
clear evidence of the existence of multiple species of malaria parasites by defining the 
characteristic periodicity of the fever in relation to the rupture of schizonts in the blood.
The curative property of the bark of the Cinchona tree (now known to contain 
quinine) was exploited for the treatment of malaria at least 350 years ago, long before the 
discovery of the causative agent. Quinine is still used to-day as a life-saving medicant in 
severe cases of Plasmodium falciparum. An old Chinese herbal treatment, using Qinghao 
(a febrifugine) known now to contain Qinghaosu or Artemisinin,3»4 although toxic, was 
also used for the treatment of malaria in that part of the world.
In the early part of the 20th century considerable effort, particularly by German 
workers, was directed at the synthesis of compounds for evaluation as antimalarials to 
replace or supplement quinine. Pamaquine was the first of many successful synthetic 
antimalarials such as chloroquine, amodiaquine and more recently mefloquine.
The widespread use of chloroquine for the treatment of malaria in Latin America, 
South-east Asia, the South-west Pacific and Africa has led to the widespread development 
of chloroquine resistance. This was recognised in the early 1960s, and it is caused by 
spontaneous mutation of the malaria parasites.53 Quinine retains a high level of efficacy for 
the control of P. falciparum and the radical cure of chloroquine-resistant infections. The 
development of drug resistance by malaria parasites has led to the use of drug 
combinations, such as pyrimethamine with sulphadoxine (and later sulphalene) for radical 
cures of such infections.6'8
Concern about drug resistance in the last three decades has stimulated research 
directed towards the development of malaria vaccines.
2Malaria presently occurs principally in the tropical areas of Africa, Asia (and the 
Pacific) and Central and South America. The distribution as at 1988, provided by the 
World Health Organisation in 1990,9 is indicated in Figure 1-1.
According to WHO,10 about 100 million people are clinically ill with malaria at any 
given time and of the four species which affect humans (P. falciparum, P. vivax, P. ovale 
and P. malariae)', P. falciparum is responsible for the most severe infections and the highest 
mortality rates.
1-2 The Malaria Parasites 
1-2.1 Introduction
In 1898, Sir Ronald Ross11 was able to demonstrate the genus Anopheles as the 
insect in which development of the malaria parasite takes place. All malaria parasites are 
members of the subphylum Sporozoa, the family Plasmodiidae, and the genus 
Plasmodium. For convenience, the genus is split into a number of subgenera; there are 
three in mammals {Plasmodium, Laverania and Vinckeia), four in avians {Haemamoeba, 
Giovannolaia, Novyella and Huffia), and two in reptiles (Carinamoeba and Sauramoeba). 
There are at least one hundred species of malaria parasites, of which only four species occur 
in humans i.e. Plasmodium falciparum, P. vivax, P. ovale and P. malariae. The first 
species belongs to the subgenus Laverania, and the latter three species belong to the 
subgenus Plasmodium.
P. falciparum and P. vivax are the most important and widespread infections in 
man. P. malariae is also widespread, but more patchy in distribution than P. falciparum or 
P. vivax. P. malariae is most common in parts of Central and North Africa, and it also 
occurs in India, Malaysia, Indonesia, Papua New Guinea and parts of South America. 
P. ovale primarily occurs in tropical Africa, and also in South-east Asia and Papua New 
Guinea.
Another subgenus that occurs in mammalian parasites is Vinckeia, which includes 
many species such as P. berghei and P. vinckei', most of these occur in lower mammals, 
such as rats, mice and bats.
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4In nature, malaria parasites have two hosts, a mosquito and a vertebrate, and malaria 
parasites are transmitted by female anopheline mosquitoes.
1-2.2 General life cycle of human malaria parasites
A concept of the life cycles of the Plasmodium species is not only essential 
knowledge in chemotherapy, but also in epidemiology, pathogenesis and immunology. 
Different groups (mammalian, avian and reptilian) of malaria parasites, of course, have 
different life cycles.
The life cycle of Plasmodium consists of three different phases or cycles of 
development (Figure 1-2).12a Two types of host are involved, mosquitoes and vertebrates 
(i.e. man). The sexual phase occurs in the mosquitoes, and two asexual cycles occur in the 
vertebrate, one in blood cells and the other in liver tissues. Both exo- and intra-erythrocytic 
stages are developed in the vertebrate host. The male and female gametocytes are also 
produced in the erythrocytes, and malaria pigment (haemazoin) is formed during the intra- 
erythrocytic stages in man.
1-3 Investigations of Malaria Vaccines: Future Prospects
The spread of drug-resistant P. falciparum in many areas, and the occurrence of 
severe epidemic outbreaks of this disease, lend particular urgency to recent attempts to 
develop a malaria vaccine.13
In recent years, since the development of the first in vitro cultures by Träger and 
Jensen14 in 1976, the contribution made by various techniques for purification and 
characterisation of antigens (such as chromatography, affinity chromatography, electro- 
focalisation, HPLC, autoradiography, etc), and lastly a better knowledge of laboratory 
animals suitable for use in the study of human malaria,15»16 have helped to make some 
promising progress in vaccine investigation.
Theoretically, against the Plasmodium species, four types of vaccines are possible: 
those affecting sporozoites, exoerythrocytic forms, asexual blood forms, and gametocytes.
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6In practice, three types of vaccines have been investigated, an anti-sporozoite vaccine to 
abort the infection at its source,17 an anti-merozoite or anti-blood stage vaccine to prevent 
the clinical disease,18 and an anti-gamete vaccine which would block transmission.19
Efforts to develop a malaria vaccines to 1983, have been reviewed.20 In 1984, 
successful cloning of the genes coding respectively for surface antigens of P. knowlesi21 
and P. falciparum?2 and of the genes expressing P. falciparum schizont and merozoite- 
specific polypetides23 were reported.
Despite much research effort directed to the development of malaria vaccines, no 
successful vaccine has yet been developed. Two articles published in 199010>24 discuss 
this situation at some length.
1-4 Mode of Antimalarial Drug Action 
1-4.1 Definition of "chemotherapy”
There is a number of definitions of the term "chemotherapy". Dr Frank 
Hawking,25 defined chemotherapy as: "The search for chemical compounds which will 
destroy infective parasites or an organism without destroying their animal host, and 
employment of such compounds to corresponding diseases".
1-4.2 Development of antimalarial drugs
The bark of the Cinchona tree was reputed to have introduced into Europe (from 
South America) about 1630-1640. It was shown by the French chemists, Pelletier and 
Caventou26’27 in 1820, to contain the alkaloids quinine (I.la) and cinchonine (I.lb). The 
interesting history of quinine has been reviewed by many authors including McHale.28
In 1891, Guttman and Ehrlich,29 were the first to attempt to treat patients suffering 
from malaria with a synthetic dyestuff, methylene blue (1.2).
Stimulated by the lack of quinine during World War I, German workers, in 1925 
produced the first synthetic antimalarial compound, pamaquine (I.3).30 This was closely
7Me Me
I
MeO
c,^ Ctnh~C-NHIIHN— CH(CH2)3NH2 .NH .
Me
1.6 1.7
CHMe2
1.8 1.9 a; NR2=N Et2
b; NR2= pyrro lid in-l-y l
8followed, in 1930, by mepacrine (quinacrine or Atebrin) (1.4) which was the first synthetic 
blood schizontocidal drug.31
Chloroquine (1.5), first known as Resochin, was prepared in 1934 by Andersag et 
al.32 and was released as a commercial antimalarial about 1946. It is generally considered 
as one of the most fascinating, useful and versatile antimalarial drugs.
During World War II, antimalarial drug research was actively promoted in 
Germany, United States, United Kingdom and in Australia. This programme ultimately 
yielded the 4-aminoquinolines, such as chloroquine (as mentioned above) as blood 
schizontocidal drugs, and the improved 8-aminoquinolines, such as primaquine (1.6) as 
tissue schizontocidals. British scientists also developed dihydrofolate reductase-inhibiting 
compounds, such as proguanil (i.e. Paludrine, 1.7)33 and pyrimethamine (Daraprim, 
1.8) ,34 which became widely used.
Amodiaquine (I.9a), a Mannich base-type antimalarial and related compounds 
(I.9b), were also developed35'3? in which the 7-chloroquinoline nucleus was attached 
through the amino group to a mono-Mannich base derivative of /7-aminophenol.
Schmidt et a/.38 highlighted the advantage of amodiaquine (1.9a) and 
amopyroquine (1.9b) against chloroquine-resistant strains of P. falciparum in Aotus 
monkeys.
During the 1950s and 1960s, superior antimalarial drugs, such as chloroquine, were 
employed on a massive scale for suppressive treatment, and this led to the development of 
drug resistance in the major human parasite, P. falciparum. Events in South-east Asia 
caused the US Army Research and Development Command, based on the Walter Reed 
Army Institute of Research (WRAIR), since 1964, to carry out a massive antimalarial 
research development programme. This involved the primary screening of over 300,000 
candidate compounds and basic studies of the biology and immunology of malaria.
From this programme, a new antimalarial drug, i.e. mefloquine (1.10), a quinoline 
methanol, was developed. It was subjected to clinical trials in areas where multiple-resistant 
P. falciparum is a major problem such as in South-east Asia39 and South America.40 
This drug has a long half-life in man, and it is now commercially available.
9/ ~ \
1.11
1.15
O
1.16 a; R=Me 
b; R=H
10
More recently, new compounds such as hydroxypiperaquine (1.11), pyronaridine 
(1.12) and halofantrene (1.13) have been subjected to clinical trials.41-44 Halofantrene is 
now in use in the Francophone regions of West Africa.
Qinghao, a constituent of the plant Artemesia annua, has been used by the Chinese 
as an antimalarial since 168BC.5b In 1972 the chemical structure (1.14) of the active 
component Qinghaosu or antemisinin was determined4 as an endoperoxide of a 
sesquiterpenoid lactone; quite different from any other human antimalarial agents. This 
compound is a highly potent blood schizontocide, but it has poor solubility. Semi-synthetic 
derivatives have been prepared and evaluated. Two of these, artesunate (1.15) and 
artemether (1.16a) are more soluble and active, and artesunate is currently being developed 
for further clinical trials in the treatment of cerebral malaria3’45 (one of the more severe 
complications seen in patients ill with P. falciparum malaria).
1-4.3 Terminology and site of drug action
Expressed simply, the specific actions of antimalarials can be summarised as in 
Figure 1-3.
Tissue schizontocides
Hypnozoitocides i
TISSUE SCHIZOGONY Blood schizontocides
Sporontocides —*-SP
HYPNOZOITI
GAMETOCYTOCIDES
Gametocytocides
Figure 1-3 Diagram of specific actions of antimalarials
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Terminology and site of drug action are explained further as following:
Blood schizontocide (erythrocytic schizontocide) - refers to a drug that destroys asexual 
parasites in the blood.
Tissues schizontocide (exoerythrocytic schizontocide) - refers to a drug which destroys 
asexual parasites in the tissues. It was commonly divided into 'primary' and 'secondary' 
tissue schizontocides:
a. Primary tissue schizontocide - denotes a drug which acts on pre-erythrocytic (primary
exoerythrocytic) forms.
b. Secondary tissue schozontocide - denotes a drug which acts on secondary
exoerythrocytic forms.
Gametocytocide - refers to a drug which destroys the sexual forms of the parasite in the 
blood.
Sporontocide - refers to a drug which acts on the sporogonic forms in the mosquito after 
having fed on a treated host.
The activity of the major antimalarial drugs against different forms of P. vivax and 
P . falciparum are summarised in Table 1-1.
1-5 Mechanism of Antimalarial Drug Action
The compounds listed in Table 1-1 possess different mechanisms of action. Some 
of these are discussed below under the headings folate pathway antagonists, blood 
schizontocides, antibiotics, Qinghaosu, naphthoquinone derivatives and tissue 
schizontocides.
1-5.1 Folate pathway antagonists
(a) Sulphonamides (1.17) and sulphones (1.18)
These drugs act on all multiplying stages in the life-cycle of the malaria parasites. In 
animals, they act on both tissue and blood schizogony, and thus effect only the asexual 
blood cycle. In the insect vector they act on sporogony.
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Table 1-1 Activity of the major antimalarial drugs against different forms
12aof P. falciparum  and P. vivax
Drug
Blood schizontocidal 
activity
Tissue schizon­
tocidal activity
Gametocidal activity
P . fa lc ip a r u m P . v iv a x P . v iv a x P . fa lc ip a r u m  P . v iv a x
Chloroquine + + - -
Mefloquine + + - -
Quinine + + - ±
Primaquine - ± + +  +
Pyrimethamine + + - -
Sulfonamides + ± - -
and sulfones
Tetracyclines ± ? 9 ? ?
+ active, - inactive, ± slightly active, ? effect unknown
Sulphonamides are not used alone, but usually used in combination with 
dihydrofolate reductase inhibitors, such as pyrimethamine (1.8) with which they are 
synergistic, and effect the production of tetrahydrofolic acid which is necessary for the 
synthesis of malarial DNA.
p-Aminobenzoic acid (PABA) is an essential growth factor for both P. berghei46 
and P. falciparum.^ The effectiveness of sulphonamides as antimalarials is due to their 
competition with PABA (antagonist of PABA) for binding sites to the enzyme, 
dihydropteroate synthase.48 This effect is indicated in Figure 1-4.
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HOST 
FA—
pyrimethamine 
FH2------1||--------  FH4
sulfonamides
PABA + pteridine-
W W  AA/V
MICROORGANISM ®
Folate Cofactors 
for DNA synthesis
Figure 1-4 Folate cofactor biosynthesis pathway48
FA, folic acid; FH2, dihydrofolate; FH4, tetrahydrofolate. 
Wavey lines indicate loci of action of inhibitors.
(A) Folate reductase;
(B) PABA + pteridine condensing system;
(C) Dihydrofolate reductase;
(D) Systems for addition of 1-carbon units to FH2
(b) Dihydrofolate reductase inhibitors*9
Dihydrofolate reductase (DHF) is a key enzyme in folate metabolism as indicated in 
Figure 1-4. Both parasite and host convert dihydrofolate to tetrahydrofolate using 
dihydrofolate reductase. 2,4-Diaminopyrimidines, such as pyrimethamine and the triazines, 
such as cycloguanil, are considered as DHF inhibitors. These drugs bind more tightly to 
plasmodial DHF than to that of host tissue.50 Some relevant data are given in 
references.51-53
1-5.2 Blood schizontocides: chloroquine and related compounds
The mechanism(s) of action of chloroquine have been reviewed recently by 
Howell54 and by Wernsdorf er and Trigg.55a Two proposals are discussed below.
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(a) Proposed mechanism of action: pigment clumping
Blood schizontocides such as chloroquine (1.5), amodiaquine (1.9a), quinine 
(I.la) and mefloquine (1.10) exhibit effects on the erythrocytes of malaria parasites. 
These compounds have been divided into two groups, on the basis of chemical structure 
and the effects on the morphology of malaria p a r a s i t e s .T h e  first group, exemplified by 
chloroquine, causes swelling and fusion of the adjacent digestive vacuoles,56 followed by 
encirclement of the membrane to give an antophagic vacuole57*58 (so called chloroquine 
induced pigment clumping, CIPC59) which causes the aggregation of hemozoin pigment. 
Peters,60 and Warhurst and Thomas59 have proposed that the clumping disrupts the 
production of amino acids required by the parasite.
O'Brien and Hahn61 have proposed that the quinoline ring of chloroquine 
intercalates between base pairs of deoxyribonucleic acid (DNA), and Marquez et alß2 
suggests that the conformation of the quinoline and phenol rings of amodiaquine may be 
important with respect to its interaction with DNA.
The second group exemplified by quinine and mefloquine, do not cause pigment 
clumping59 but morphological change can be observed, such as swelling and vesiculation 
of outer parasite membranes, swelling of the digestive vacuoles and decrease of their 
pigment density which is then followed by cytoplasmic degeneration and vacuolisation.
Davidson et a/.63*64 could find no evidence for intercalation of mefloquine (and its 
analogues) with DNA but they did find that mefloquine binds weakly to DNA phosphate 
groups. Mefloquine is an active competitive inhibitor59 of chloroquine-induced pigment 
clumping (CIPC), with an affinity for the "clumping site" of 100 times that of quinine.
(b) Chloroquine-ferriprotoporphyrin IX (FP)-complex formation
Fitch and his coworkers65 have proposed that within P. berghei, chloroquine 
complexes with ferriprotoporphyrin IX (FP)66 (a degradation product of haemoglobin 
within the parasites). This ultimately leads to damage to the parasite membrane as shown in 
Figure 1-5.
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Haemoglobin
Haembinder-FP
complex
' Chloroquine 
FP ..... ^
t
Malaria pigment
Chloroquine-FP complex
Damaged
membrane
Abnormal permeability
Figure 1-5 Diagrammatic respresentation of a hypothesis to explain 
the mode of action of chloroquine as an antimalarial drug
1-5.3 Antibiotics
The first reports of an antimalarial effect by antibiotics appeared in 1949, when 
Chlortetracycline was found effective against avian and human malaria parasites.67’68 
Coatney and Greenberg69 in 1952 further reported that only nine of 31 antibiotics tested 
showed any antimalarial activity. The antibiotics, chlortetracyclines, Oxytetracycline and 
chloramphenicol, have blood schizontocidal, as well as causal prophylactic activity, and are 
of potential value for malaria chemotheraphy. However they are relatively slow acting 
compared to chloroquine. Other antibiotics such as clindamycin, lincomycin, minocycline, 
doxycycline and erythromycin also have been shown to have blood schizontocidal effects. 
Minocycline and doxycycline have useful activity against the liver stages,556 and 
erythromycin70 has a synergistic effect with chloroquine against chloroquine-resistant 
P. berghei.
The mode of action of antibiotics in malaria has not yet been established. Their 
primary mode of action in bacteria is by inhibition of ribosomal protein synthesis 71
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1-5.4 Qinghaosu and its derivatives
Qinghaosu (1.14) (artemisinine, qing hau sau, QHS), meaning active principle of 
qing hao, is a novel antimalarial drug, and it was isolated in 1971 from the leafy portions of 
the traditional Chinese herbal remedy, Qinghao (Artemisia annua). QHS is a sesquiterpene 
lactone that bears a peroxide group and; unlike most other antimalarials, lacks a nitrogen- 
containing heterocyclic ring system. It shows marked activity against both chloroquine- 
sensitive and chloroquine-resistant strains of P. falciparum. In 1987, Luo and Shen 
reviewed the chemistry, pharmacology and clinical application of Qinghaosu and its 
derivatives.72
Derivatives of QHS, such as artemether (I.16a); dihydroquinghaosu (I.16b), and 
the water-soluble sodium artesunate (1.15), appear to be more potent than QHS itself.
The actions of this novel drug are different from other antimalarials in that it has no 
detectable prophylactic effects on the preerythrocytic stages,73 no competition with CIPC 
inhibition733 as well as no interference with the folic acid metabolism of the parasite.73»74 
Gu and co-workers75 have suggested that the prevention of protein synthesis may be the 
primary target of the QHS family of drugs, rather than the inhibition of nucleic acid 
synthesis. These workers75 showed that the incorporation of tritiated isoleucine (as 
essential exogenous amine) into protein by P. falciparum was inhibited by QHS.
Another possible mechanism may involve the peroxide part of the molecule (see 
compound 1.14). It has been shown3 that QHS (1.14) gives the three metabolites (1.19, 
1.20, and 1.21) (which lack the peroxide moiety), and these are inactive against 
P. berghei in mice.
Me H Me
Me
OH
Me
O
1.19 1.20 1.21
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1-5.5 Naphthoquinones
In the early 1940s, the hydroxynaphthoquinones,76 such as hydrolapachol (1.22), 
originally prepared by Hooker77 in 1936, were found to have antimalarial properties.78 
Structure-activity relationships among the naphthoquinones against P. lophurae in ducks 
have been summarised by Fieser et a/.78 As the alkyl chain of hydrolapachol was 
lengthened, the activity of the resulting compounds increased to a maximum at nine carbon 
atoms and thereafter decreased. Other groups such as alicyclic or aryl groups appeared to 
shift the peak activity. Compound 1.23 was the most potent compound examined in this 
work, and the trans-isomer (depicted) was 13 times more potent than its cis-isomer.
Naphthoquinones show activity against both primary tissue and blood forms, and 
could have a role to play as causal prophylactic drugs. The mode of action of these drugs is 
unknown, but inhibition of the plasmodial electron transfer process has been 
proposed.79’80
1-5.6 8-Aminoquinolines as tissue schizontocides
The 8-aminoquinoline, pamaquine (I,3)3°’8l was the first effective synthetic 
antimalarial. Primaquine (1.6),82 in fact is clinically effective against the persistant tissue 
stages of P. vivax or P. ovale. This drug acts on all stages of the malaria life-cycle, but is 
generally only used as a tissue schizontocide and a gametocytocide, because of its 
significant toxicity in man and its limited blood schizontocidal activity.
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The molecular mechanism of the mode of action of primaquine is unknown. 
Nevertheless, this drug has been shown to cause mitochondrial swelling in both the 
exoerythrocytic83 and erythrocytic stages84 of malaria parasites. New tissue schizontocidal 
antimalarial drugs have been reviewed by Davidson et alß$
1-6 Mannich Bases as Potential Antimalarial Agents
Burckhalter and his colleagues86 in 1946 reported the synthesis of a series of 
Mannich base compounds, of which compound 1.24, 5-r-butyl-3-diethylaminomethyl- 
biphenyl-2-ol (SN 7,744) and compound 1.25 (bialamicol, SN 6,771) showed antimalarial 
activity. This work was later extended to heterocycles as detailed below.
CH2NEt2
1.25
1-6.1 Di-Mannich (and mono-Mannich) base derivatives of 4-(quinolin-4- 
ylam ino)phenols
In 1948, Burckhalter and coworkers35 reported the synthesis of amodiaquine (SN 
10,751; trade name, camoquin)36 (I.9a), which joined the 7-chloroquinoline portion 
present in chloroquine and quinine, through a nitrogen atom at position 4 to a Mannich base 
of a phenol. This compound exhibited high antimalarial activity as did its analogue (SN 
8,617) (I.26)35 [which proved to be as active as quinacrine (SN 390) (1.4)].
Singh and coworkers87’88 and Elslager and coworkers89 (and others) have studied 
modifications to the side chain and to the quinoline ring system respectively in analogous 
compounds.
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The di-Mannich compound, cycloquine (Haloquine)90 (1.27) was synthesised and 
widely used as an antimalarial in the USSR in 1965.
It was also shown91 that when the 7-chloro substituent of chloroquine was replaced 
by a trifluoromethyl group, the resulting compound (1.28) retained potent antimalarial 
activity. Various 7-trifluoromethylquinolinemethanols such as compound 1.29 have been 
prepared92 and evaluated for activity against P. berghei in mice. The test data indicated that 
the 7-trifluoromethyl compounds such as 1.29 were more potent than the chloro analogue; 
the curative dose of compound 1.29 was 40 mg/kg.
CH.NEt
CH.NEt
1.26 1.27
Me
HN-CH(CH2)3NEt2
1.28
In the mid 1980s, two independent groups of workers, Shen et a/.93 
and Barlin et a/.94*95 reported the synthesis of Mannich base derivatives of 4-(7- 
trifluoromethylquinolin-4-ylamino)phenol and studies of their antimalarial activity. Shen et 
al.93 found that the compound 1.30 and 1.31 suppressed P. berghei infections in mice at a 
dosage of 2.5 mg/kg, whereas Barlin et al,94 found that compound 1.30 (and others) were 
highly effective against P. vinckei vinckei in mice.
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Hu et al?6 and Scott et a /.97*98 have shown independently that the above 
compounds are also effective against a chloroquine-resistant ANKA strain (EC 123) of 
P. berghei in mice.96 Scott et a l97»98 have studied the effect of their compounds on a 
chloroquine-sensitive (FCQ-27) and a chloroquine-resistant (K-l) strain of P . falciparum 
in vitro, and many were found to be highly effective. For example, compound 1.30 gave 
IC50 values of 0.7 and 1.1 nmol H  against the FCQ-27 and K-l strains, respectively.
/  \
1.30 ; Z=CH2
1.31 ; Z=0
1- 6.2 Mono-Mannich base derivatives of 5-(quinolin-4-yIamino)biphenyl-
2 - ols
In 1969, prompted by the antimalarial activity of Mannich base derivatives of 5-t- 
butylbiphenyl-2-ols86 such as 1.24 (SN 7,744) and 1.32 (n=l, R=Me) (SN 7,282) and 
amodiaquine (I.9a),35 Duncan and Henry99 further investigated the synthesis and 
biological activity of biphenyl-2-ols (1.32). Compound 1.32 (n=l, R=Me) was the most 
active member of this series, and the activity decreased as "n" was increased. The 
compound 1.32 (n=2, R=Me) possessed significant antimalarial activity, but it was less 
potent and more toxic than 1.32 (n=l, R=Me). The demethyl analogue 1.32, (n=2, R=H) 
was completely inactive.
Compounds WR-194,965 (1.33) and WR-204,165 (1.34), synthesised 
subsequently, had similar levels of efficacy to compound 1.32 (n=l, R=Et) in owl
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monkeys infected with the multidrug-resistant "Vietnam Smith" strain of P. falciparum}^ 
and they did not show acute toxicity at 640 mg/kg.
1.32
Recently, Werbel et a/.101 described the synthesis of 3-(r-butylaminomethyl)-4- 
chloro-5-(7-chloroquinolin-4-ylamino)biphenyl-2-ol ["Tebuquine" (1.35)], a series of 
analogues, and some V-oxides. The antimalarial activity and quantitative structure-activity 
relationships of this series were also reported.
1-6.3 Mono-Mannich base derivatives of 4-(quinolin-4-ylamino)-5,6,7,8- 
tetrahydronaphth-l-ols
Some 1,4-naphthoquinones show considerable antimalarial activity78’102’103 and 
their mode of action appears different from the 4-ami noquinoline-type antimalarial s. In 
1972, Nabih et a/.104 prepared compounds such as compound 1.36 and 1.37 in the hope 
that these compounds might exhibit interesting antimalarial activity.
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Compound 1.36, (R=NEt2) was subsequently shown to have both curative and 
prophylactic effects against P. berghei in mice; but in further tests105 it was less potent than 
a series of biphenyl-2-ols.
Twelve years later, Shen et prepared 2-(r-butylaminomethyl)-4-(7-trifluoro- 
methylquinolin-4-ylamino)-5,6,7,8-tetrahydronaphth-l-ol hydrochloride (1.38), and 
showed that it suppressed P. berghei in infected mice at a dosage of 2.5 mg/kg.
1.37 1.38
1-6.4 Mannich base derivatives of 4-(l,5-naphthyridin-4-ylamino)phenoIs
The antimalarial activity shown by the 4-aminoquinolines such as chloroquine 
stimulated interest in aza-analogues, including the 1,5-naphthyridines. 4-Amino-1,5- 
naphthyridine may be regarded as such an analogue of either 4- or 8-aminoquinoline.
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Adams et ü/.106 prepared compound 1.39 and Goldberg et <2 /.107 prepared 
compound 1.40 (R=H): the former was active against P. gallinaceum in chicks and against 
P. berghei in mice107 but compound 1.40 (R=Me) was inactive.107
1.39 1.40
In 1970 McCaustland and Cheng108 synthesised several 1,5-naphthyridine 
congeners (1.41 and 1.42) of chloroquine and found that the compound 1.4lb possessed 
very good antimalarial activity against P. berghei in mice, also it was much less toxic than 
the existing 4- and 8-aminoquinoline drugs. No acute toxicity was noted at a dose of 640 
mg/kg, whereas chloroquine was 100% lethal at a dose of 320 mg/kg. In contrast, 
compounds 1.41a and I.41c were inactive when tested in the same model.
Me
I
HN—CH(CH2) 3 NEt2
N Y
1.41 a; X=C1, Y=OMe 
b; X=C1, Y=H 
c; X=H, Y=OMe
More recently, several unsubstituted and 2,6-disubstituted 1,5-naphthyridines 
carrying di-Mannich basic chains of /7-aminophenol (e.g. I.42a) were synthesised by Chen 
and his colleagues,109 and these proved to be effective antimalarials.
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Di-Mannich bases of 4-[7-chloro-(and 7-bromo)-l,5-naphthyridin-4-ylamino]- 
phenols (1.43) were prepared by Barlin and Tan95»110’111 in 1986. These compounds 
were shown to exhibit activity in in vivo tests against P. vinckei vinckei in mice. 
Subsequent tests by Scott et a/.97’98 against P . falciparum in vitro revealed significant 
activity against both the chloroquine-sensitive (FCQ-27) and chloroquine-resistant (K-l) 
strains. The chloro compound (I.43a) and the bromo compound (I.43b) showed only a 
small difference in activity.
1.42 a; R1=R2=H, NR2=NC4H8 1.43 a; R ^ C l
b; R1=OMe, R2=Me, NR2=NEt2 b; R!=Br
c; Rx=OMe, R2=Me, NR2=NC5H 10
1-7 Quinazoline Derivatives as Potential Antimalarials
Prior to the present work no Mannich base derivatives of 4-(quinazolin-4- 
ylamino)phenol had been tested for antimalarial activity. However the di-Mannich base, 
changrolin (I.44)112»113 has been described as an effective antiarrhythmic agent, and some 
articles114»115 claim a relationship between antimalarial and antiarrhythmic activity.
Magidson and Golovchinskaya,116 Price et a/.117 and Chapman et a/.118 have 
prepared a variety of quinazolines for evaluation as antimalarials. The compound 1.45, the 
quinazoline analogue of chloroquine, was found to have suppressive activity against the 
blood forms of P. gallinaceum in chicks at a dosage of 20 mg/kg118 and was equivalent or 
slightly superior to quinine.117
25
Antimalarial activity has been demonstrated119 in compound 1.46, and the 
compound 1.47 showed marked activity120 against asexual blood forms of P. gallinaceum 
in chicks; but no activity against the tissue stages.
Me
1.46 1.47 R=C1, R1 = (CH2)2NEt2
In 1970, Davoll and Johnson121 prepared compound 1.48 (n=2, R=Me, X=OH), a 
folate antagonist, which was shown to have good oral activity against P. berghei injections 
in mice.122 Much effort has since been directed to the study of folate antagonists including 
the 6-substituted 2,4-aminoquinazolines (the so-called non-classical folate antagonists). In 
early work, compound 1.49 showed strong antimalarial activity against P. berghei in mice 
(4 to 11 times as potent as quinine)119 and many compounds of this type have been 
examined.123-130
26
CH-NH-CO
I
(CH^COjH
NH2
1.48: n= l, 2; R=H, Me; X=OH, NH2
1.49
1-8 Mefloquine and its Analogues as Potential Antimalarials131»132
The preparation and antimalarial activity of mefloquine (WR 142,490) (1.10) and 
its 2,6- and 2,7-bistrifluoromethyl isomers was first reported in 1971 by Ohnmacht et a/.133 
Like quinine (I.la) and the active antimalarial (1.50; WR 30090),134 mefloquine (1.10) is 
a quinolinemethanol; the active antimalarials (1.51; WR 122,455)135 and halofantrine 
(1.13; WR 171,669)136 are also methanol derivatives. Mefloquine was 100% curative at 
40 mg/kg against P. berghei in mice, twice as effective as the 2,7-isomer and 4 times as 
effective as the 2,6-isomer. 133 In a test involving increased survival time of mice infected 
with P. berghei, mefloquine was at least 8 times better than chloroquine and 64 times better 
than quinine.137 Further details of testing in animals are reported in references 131 and 
132.
Mefloquine is now available for clinical use. It acts as a potent blood schizontocide 
and is effective against the multi-drug resistant "Smith" strain of P. falciparum.^
Compound 1.52, an analogue of mefloquine containing a trans-aziridine ring, was 
devoid of antimalarial activity in the standard P. berghei mouse model.139 Other structural 
analogues of mefloquine which also showed potent antimalarial activity are WR 184,806 
(I.53)140 and WR 226,253 (1.54). 141
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1.52 1.53
1.54
1-9 Scope of the Present Work
Chemical syntheses of Mannich base derivatives of heterocyclic amino phenols, the 
synthesis of a mefloquine analogue, and preliminary testing of these compounds for 
antimalarial activity have been undertaken in this work. The aim was to prepare novel 
compounds which may be more effective antimalarials than the classical compounds (such
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as chloroquine and amodiaquine), particularly against the chloroquine-resistant strain of 
P . falciparum.
In the present work new di-Mannich base derivatives of 4-(7-trifluoromethyl-l,5- 
naphthyridin-4-ylamino)phenol, 4-(7-trifluoromethylquinazolin-4-ylamino)phenol, 4-[7- 
chloro (and 7-trifluoromethyl)quinolin-4-ylamino]-3-methylphenols, 4-(7-bromo-l,5- 
naphthyridin-4-ylamino)-3-methylphenol; mono-Mannich base derivatives of 4-chloro-5-[7- 
bromo (and 7-trifluoromethyl)-l,5-naphthyridin-4-ylamino]biphenyl-2-ols and 4-chloro-5- 
[7-trifluoromethylquinolin (and quinazolin)-4-ylamino]biphenyl-2-ols ("Tebuquine" 
analogues) and 4-[7-bromo (and 7-trifluoromethyl)-l,5-naphthyridin-4-ylamino]-5,6,7,8- 
tetrahydronaphthols; and the 7-trifluoromethylquinolin-4-yl analogue of mefloquine have 
been prepared. The physical properties (such as ^  n.m.r., 13C n.m.r., ultraviolet, 
infrared and mass spectra, and ionization constants) of these compounds are also reported 
and discussed.
These compounds have been tested for antimalarial activity against P. falciparum in 
vitro and in vivo tests against P. vinckei vinckei in mice, and the results compared with 
those for analogous compounds.
CHAPTER II
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CHAPTER II 4-Chloro-(and 4-Hydroxy)-7-(trifluoromethyl-l,5-naphthy- 
ridine, Di-Mannich Bases of 4-(7-Trifluoromethyl-l,5-naphthyridin-4-yl- 
amino)phenol and V4-(4-Diethylamino-l-methylbutyl)-7-trifluoromethyl- 
l,5-naphthyridin-4-amine
The work reported in this Chapter relates to the preparation of di-Mannich bases 
of 4-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)phenol for testing for antimalarial 
activity. This work was undertaken because the high activity of di-Mannich bases of 4- 
(7-trifluoromethylquinolin-4-ylamino)phenol93*94’98 and the curative properties of di-
Mannich bases of 4-[7-chloro (and 7-bromo)-l,5-naphthyridin-4-ylamino]- 
phenol97*984 ll against malarial plasmodia have been described previously. In addition, 
the 7-halogeno-l,5-naphthyridin-4-amines97’108 have been found to have lower toxicity
than the corresponding quinolines (See Chapter 1-6.1 and 1-6.2). Thus it was decided 
that the di-Mannich bases derived from 4-(7-trifluoromethyl-l,5-naphthyridin-4- 
ylamino)phenol should be examined.
In this Chapter, the literature relating to the preparation and to the chemical and 
physical properties of simple 1,5-naphthyridines is surveyed; the methods employed for 
the present synthetic work are discussed; and the physical properties (such as n.m.r., 
i.r., u.v. and pKa values) of these compounds are then reported and discussed. Results 
of testing for antimalarial activity by in vitro tests against P. falciparum and by in vivo 
tests against P. vinckei vinckei in mice will be described in Chapter VIII.
II-l Simple 1,5-Naphthyridines
1,5-Naphthyridine (II. 1) is a heterocyclic system consisting of two fused six- 
membered aromatic rings, each ring containing one nitrogen atom. Alternatively, it can 
be considered as 5-azaquinoline or a pyridopyridine; it has ten delocalised 7t-electrons. 
The doubly bound ring nitrogen atoms withdraw electrons from other parts of the ring 
system and render it electron-deficient (such ring systems are said to be 7t-electron
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deficient): accordingly they are highly susceptible to nucleophilic attack, particularly at 
the 2- and 4-positions, and correspondingly deactivated to electrophilic attack.
I I .1
II -l.l Syntheses of simple 1,5-naphthyridines
Two principal methods are generally employed in 1,5-naphthyridine syntheses, 
namely, the Skraup reaction and the ethoxymethylenemalonic ester (EMME) reaction. In 
addition to these methods, there are some modifications which are mentioned below:
(a) The Skraup reaction
Unsubstituted 1,5-naphthyridine can be synthesised easily by heating pyridin-3- 
amine (II.2) with glycerol (II.3) in the presence of concentrated sulphuric acid and of 
arsenic pentoxide142 as a condensing agent.
c h 2oh  
+ (*:h -oh
d:H2OH
II .2 I I .3 I I .1
Several modifications143*144a of this reaction have been described. Likewise, 
substituted 1,5-naphthyridines can be prepared by using substituted pyridin-3-amines 
with different condensing agents, such as a methylacrolein and acetaldehyde. Some 
literature preparations of 1,5-naphthyridines are summarised in Table II-1, in which 
reagents, products and references are listed.
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Table II-l Some literature preparations of 1,5-naphthyridines
Substituted Condensing agent Substituted Reference
3-aminopyridine 1,5-naphthyridine
- Glycerol - 145
- Crotonaldehyde 2-Methyl- 145
- Methyl vinyl ketone 4-Methyl- 145
- 2-Ethylacrolein 3-Ethyl- 145
4-Hydroxy Glycerol 4-Hydroxy- 146
6-Hydroxy Acetaldehyde + acetone 6-Hydroxy-2,4-dimethyl- 147
6-Chloro Acetaldehyde 6-Chloro-2-methyl- 148
Rapoport and Batcho145 reported that the cyclisation of pyridin-3-amine with 
anhydrous glycerol gave 1,5-naphthyridine, by cyclisation at the 2-position. No 1,7- 
naphthyridine (which could have been formed by cyclisation to the 4-position) could be 
detected in the reaction products.
When the 2-position in pyridin-3-amine was blocked by another group differing 
results were obtained. For example, 3-aminopyridin-2-ol gave l,7-naphthyridin-8-ol149 
(formed by cyclisation to the 4-position) but 2-halogenopyridin-3-amine gave 1,5- 
naphthyridine144a (presumably involving replacement of the 2-halogeno substituent).
(b) The ethoxymethylenemalonate ester (EMME) reaction
The synthesis of 4-hydroxyquinoline-3-carboxylic esters from aniline and 
ethoxymethylenemalonic ester developed by Price and Roberts150 following the earlier 
work of Gould and Jacobs151 has been extended to the preparation of 1,5-
naphthyridines.1 142*150
In this modification pyridin-3-amine (or substituted pyridin-3-amines) were 
heated with ethyl ethoxymethylene malonate (EMME) (II.4) in refluxing "Dowtherm A" 
(an eutectic mixture of diphenyl ether and biphenyl) to afford ethyl 4-hydroxy-1,5- 
naphthyridine-3-carboxylate (IL5). This compound (II.5) was hydrolysed and 
decarboxylated to give the l,5-naphthyridin-4-ol (II.6) in good yields.106-108’152
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R- +
n h 2
Et0CH=C-(C02Et)2
(EMME)
II.4
OH
C 02Et
aq. NaOH
The EMME reaction applied to pyridin-3-amine 1-oxide (II.7) gave the 1,7- 
naphthyridine N7-oxide (II.8);153 but interestingly, compound II.7 under the condition 
of the Skraup reaction gave 1,5-naphthyridine (II.1).153 [Deoxygenation of pyridine N- 
oxides in the presence of acid and oxidising agents has been reported.154*155 Therefore 
under the condition of the Skraup reaction compound II.7 was probably first 
deoxygenated to form pyridin-3-amine153 which then underwent the Skraup reaction to 
give compound II. 1].
This EMME reaction was also used in the present work for the 
synthesis of 7-trifluoromethyl-l,5-naphthyridin-4-ol.
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(c) Miscellaneous preparations
The following preparations of 1,5-naphthyridines have also been described. 
Ziegler and Noelken156 prepared the 1,5-naphthyridine (II. 10) by the 
condensation of compounds II.9 and II.2.
Baumgarten et a/.157 converted the 2,3-disubstituted pyridines, compounds 
11.11 and 11.13, into l,5-naphthyridin-2-ol (11.12) and its 2-methyl derivative (11.14) 
respectively,157 as in the reaction sequences illustrated below.
NH 3, FeS04
NaOMe
NH2OH
reflux N XH=CH-C02H
11.12 11.11
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N . . C 0 2H
^ ^ - N H 2
MeC0CH2C 02Et
11.13
OH
I
\
OH
11.14
Oakes and Rydon158 have reported the preparation of 1,5-naphthyridin-2,4- 
diol (11.17), the 2,4-dichloro derivative (11.18), and (2-amino-4-chloro- and 4-chloro- 
2-hydroxy)-l,5-naphthyridines. Dieckmann cyclisation of the substituted malonamic 
ester (11.15) gave the ester 11.16 which after hydrolysis and decarboxylation afforded 
1,5-naphthyridin-2,4-diol (11.17).
OH
,N .  ^ C 0 2Et N ^ C 0 2Et
<  CH2(C 0 2Et)2 S  ^
NHC0CH2C02Et car
11.15 11.16
11.18 11.17
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II.1.2 Physical properties of simple 1,5-naphthyridines
Physical properties of 1,5-naphthyridine [^H n.m.r., i.r., u.v. and mass spectra; 
and ionization constant (pKa)] have been tabulated by Paudler and Kress.1446 The keto- 
enol tautomerism of l,5-naphthyridin-4-ol (II.6 , R=H) has been studied by i.r. 
spectroscopy both in solution and the solid state by Bailey et a/.159 They found that in 
polar solvents, the keto form (11.19) predominates, whereas the enol form (II.6) is 
predominant in non-polar solvents. The infrared absorption bands such as the C=0 and 
N-H stretching regions have been reported for several other hydroxy- 
naphthyridines.160’^ !
OH
I O
"S .
H
II .6 ; R =H 1 1 .1 9
II-1.3 Reactivity of halogeno substituents in 1,5-naphthyridines
In unsubstituted 1,5-naphthyridine (II.l) there are only three different ring- 
positions (2-, 3- and 4-), which are activated to nucleophilic substitution both by 
resonance and by induction. The reactions involving displacement of a halogeno 
substituent from substituted naphthyridines have been reviewed.162
Oakes and Rydon,158 by application of an approximate quantum mechanical 
calculation,163-165 were able to calculate that the 2-chloro substituent in 2,4-dichloro- 
1,5-naphthyridine is more reactive towards nucleophiles than the 4-chloro substituent. 
Accordingly preferential displacement, by water, ammonia or hydrazine, occurs at the 2- 
position to give 4-chloro-2-substituted-1,5-naphthyridines (11.20).158 No differential 
reactivity of the 2- and 4-chloro substituents in compound 11.18 was observed when it 
was allowed to react with aniline or benzylamine and the 2,4-disubstituted compound
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(11.21, R^NHPhr) was formed, even with only one equivalent of aniline in dioxane 
solution.158
EL21; R1=NHPh, NHCH2Ph
McCautland and Cheng108 studied the nucleophilic substitution of 2,4,7- 
trichloro-l,5-naphthyridine (11.22) with one equivalent of sodium methoxide in 
methanol, using iH n.m.r. They found that the major product was 4,7-dichloro-2- 
methoxy-l,5-naphthyridine (11.23) rather than its 4-methoxy isomer.
Cl
11.22 11.23
As expected compounds (11.25)108 and (II.26)95 were produced by 
nucleophilic displacements involving 4,7-dichloro-l,5-naphthyridine (11.24) (both 
compounds II.25 and 11.27 showed good antimalarial activity).
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Cl
11.24
Me
I
H2N-CH(CH2)3NEt2
120°
Me
I
11.25
(CH20)„ , c 4h 8n h
EtOH
11.26 11.27
II-2 Syntheses of 7-Trifluorom ethyl-l,5-naphthyridin-4-ol and 4- 
Chloro-7-trifluoromethyI-l,5-naphthyridine
3-Bromo-8-chloro-l,5-naphthyridine110 (11.35; Scheme II-1) has been prepared 
previously from the known ethyl 7-bromo-4-hydroxy-l,5-naphthyridine-3-carboxy- 
late166 (11.32). This compound (11.32) was prepared from nicotinic acid (11.28) 
through 5-bromonicotinic acid (H.29),167,168 its amide (II.30)168 and 5-bromopyridin- 
3-amine (II.3 1 ) .168»169 The compound 11.31 was condensed with EMME and ring- 
closed in boiling diphenyl ether (instead of "Dowtherm A" in reference 166) to give 
compound 11.32. This ester (11.32) was hydrolysed in aqueous sodium hydroxide to 
give the corresponding acid (11.33) which was decarboxylated in refluxing quinoline to 
afford the 7-bromo-l,5-naphythridin-4-ol (11.34). Chlorination of this hydroxy 
compound (11.34) by refluxing with phosphoryl chloride for 10 h, gave 3-bromo-8- 
chloro-l,5-naphthyridine (11.35) in good yields (Scheme II-1).
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CONR,
OH OH
OH
NH,
Scheme II-l
Scheme II-2
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In the present work 7-trifluoromethyl-l,5-naphthyridin-4-ol (11.41) and 
4-chloro-7-trifluoromethyl-l,5-naphthyridine (11.42) were prepared by a similar 
method. These two compounds were prepared from the known 3-chloro-5-trifluoro- 
methylpyridine (11.36) (commercially available) by an initial treatment with 28% 
aqueous ammonia in the presence of cuprous chloride at 170° in a high pressure vessel 
for 48 h, and gave good yields of 5-trifluoromethylpyridin-3-amine (11.37).170 This 
compound (11.37) was subsequently allowed to react with EMME (i . e . the EMME 
reaction) at 100° for 2 h and gave diethyl 5-trifluoromethylpyridin-3-ylamino- 
methylenemalonate (11.38), which was then heated in refluxing diphenyl ether to yield 
ethyl 4-hydroxy-7-trifluoromethyl-l,5-naphthyridine-3-carboxylate (11.39). This ethyl 
ester (11.39) was hydrolysed in 10% aqueous sodium hydroxide to give the 
corresponding acid (11.40) which was decarboxylated in boiling quinoline to give 
7-trifluoromethyl-l,5-naphthyridin-4-ol (11.41). Chlorination171 of compound 11.41 
with a mixture of phosphorus pentachloride and phosphoryl chloride at 110° for 3 h, 
readily gave 4-chloro-7-trifluoromethyl-l,5-naphthyridine (11.42) in excellent yields, as 
shown in Scheme II-2.
II-3 Synthesis of New Di-Mannich Bases of 4-Nitrophenol
Barlin and Ireland172 have described the preparation of the di-Mannich bases of 
4-aminophenol from the inexpensive 4-nitrophenol with paraformaldehyde and 
appropriate amines, through the readily purified di-Mannich bases of 4-nitrophenol (for 
further detail of Mannich reaction see Appendix 2).
In the present work, the new 2,6-bis(4-benzylpiperidin-l-ylmethyl)-4-nitrophenol 
(11.46) and the corresponding 4-amino compound (II.47h) were prepared by a similar 
procedure, as shown in Scheme II-3.
4-Nitrophenol (11.43) with a considerable excess of 4-benzylpiperidine (11.45) 
and paraformaldehyde (11.44) in a small volume of ethanol at reflux for 16 h gave 
compound 11.46. This nitro compound (IL46) was readily purified by recrystallisation 
and was catalytically reduced with hydrogen gas in the presence of Raney nickel to afford
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the corresponding amine (II.47h) which was sufficiently pure for condensation directly 
with 4-chloro-7-trifluoromethyl-l,5-naphthyridine (11.42).
11.43
OH + (CH20 ) n
11.44
+
11.45
CH2Ph
1. EtOH/reflux
2. H2/Ra-Ni
11.46, Z=N02
II.47h, Z=NH2
Scheme II-3
II-4 Syntheses of Di-Mannich Bases of 4-(7-Trifluoromethyl-l,5-naph- 
thyridin-4-ylamino)phenol
The preparation of compounds such as the di-Mannich bases of 4-(7-trifluoro- 
methylquinolin-4-ylamino)phenol by the condensation of di-Mannich bases of 4-amino- 
phenol with 4-chloro-7-trifluoromethylquinoline has been described172 recently. In the 
present work, the di-Mannich bases of 4-(7-trifluoromethyl-l,5-naphthyridin-4-yl- 
amino)phenol (11.48) were also prepared in a similar way by condensation of 
appropriate di-Mannich bases (11.47) with 4-chloro-7-trifluoromethyl-l,5-naphthyridine
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(11.42) in refluxing aqueous methanol solution (approximately at pH 2.5-3.0) containing 
a few drops of concentrated hydrochloric acid for 3.5 h to 8 h (Scheme II-4).
11.4711.42
MeOH/H20
reflux
11.48
11.47, 11.48
n r 2 NR2
a NEt2 e 3-methylpiperidin-l-yl
b NPr2 f 3,5-dimethylpiperidin-
c pyrrolidin-l-yl g 4-methylpiperidin-l-yl
d piperidin-l-yl h 4-benzylpiperidin-l-yl
Scheme II-4
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I I -5 Synthesis of A4-(4-DiethyIamino-l-methylbutyl)-7-trifluoromethyl- 
l,5-naphthyridin-4-amine
Literature methods for the preparation of the A4-substitutedquinolin-4-amines171 
and naphthyridin-4-amines106' 108’110 have been described. Some of these compounds 
have shown antimalarial activity, for example 7-chloro-/V4-(4-diethylamino-l-methyl- 
butyl)quinoline (chloroquine) and 7-chloro-Ar4-(4-diethylamino-l-methylbutyl)-l,5- 
naphthyridin-4-amine. 108,109
Replacement of the 7-halogeno substituent in the quinoline nucleus of known 
antimalarials by a trifluoromethyl group have given compounds with potent activities, 
e.g. compound II .4991 and II .50,95 the novel drug, mefloquine, also contains 
trifluoromethyl groups. Accordingly it was decided to investigate A4-(4-diethylamino-l- 
methylbutyl)-7-trifluoromethyl-l,5-naphthyridin-4-amine (11.51).
The compound 11.51 was prepared similarly to the 7-bromo analogue.98»11° 
Compound 11.42 was heated with A1 ,Ad-die thy lpentane-1,4-diamine (11.52) in heptane 
at 150° in a Teflon-lined reaction vessel for 20 h and gave A4-(4-diethylamino-l- 
methylbutyl)-7-trifluoromethyl-l,5-naphthyridin-4-amine (11.51) as shown in Scheme 
II-5.
n.49 Z=CH 
11.51 Z=N 11.50
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heptane
150°
Me
I
HN-CH(CH2)3NEt2
11.51
Scheme II-5
II-6 Physical Properties
II-6.1 Nuclear magnetic resonance spectra
The ^ n .m .r . spectrum of unsubstituted 1,5-naphthyridine (II. 1) has been 
published,14415’173 as an A2B2X2 spin system.174 As both rings in unsubstituted 1,5- 
naphthyridine are symmetrical, the protons at position 2, 3 and 4; and at 6, 7 and 8 are 
equivalent. In deuterochloroform, the chemical shifts of these protons were found to be 
at 5 8.97, 7.58 and 8.40 for H2 (H6), H3 (H7) and H4 (H8), respectively, with 
coupling constants of J23 4.1 Hz, J2,4 1.8 Hz, 13^ 4 8.0 Hz and J4,8 0.6 Hz.144b*174
In contrast, the 4-substituted-7-trifluoromethyl-l,5-naphthyridines, prepared in 
the present work, showed relatively simple n.m.r. spectra (Table II-2, II-3 and 
Experimental section).
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Examination of Table EE-2 revealed that the ring protons in compound 11.41 (as 
an anion) appeared upfield of those in compound 11.42 (as neutral molecule); the effects 
were greatest at the 3- and 2-positions. This is due to a combination of the electron- 
donating qualities of the anion of compound 11.41, and the electron-withdrawing 
qualities of the chloro substituent in compound 11.42. A similar pattern was observed in 
the bromo analogues (11.34 and 11.35) with the protons of compound 11.34 upfield of 
those in 11.35.
In contrast, the chemical shifts of 7-bromo (11.34) and 7-trifluoromethyl (11.41) 
derivatives of l,5-naphthyridin-4-ol (as anions) showed only small differences; as did 
similar derivatives (11.35 and 11.42) of 4-chloro-l,5-naphthyridine (as neutral 
molecules). These differences of 0.1-0.2 ppm implied that the bromo and trifluoro- 
methyl groups had similar electron-withdrawing (inductive) effects, which were slightly 
greater in the trifluoromethyl derivatives.
Inspection of the ^ n .m .r .  spectra in the Experimental section for the 
compounds II.48a-II.48h revealed that, of the protons attached to the naphthyridine 
ring, H6 was the most deshielded due to the adjacent ring nitrogen atom and 
trifluoromethyl group; and the most shielded proton was H3. The ring protons occurred 
for H2 at 5 8.58-8.60, for H3 at 6.95-7.06, for H6 at 8.92-8.94 and for H8 at 8.51- 
8.53; and the coupling constant applicable to each position was consistent, e.g. J23 was 
5.5 Hz and J6,8 was 2 Hz.
The methylene group in all Mannich side chains appeared as a singlet; and its 
position was dependent on the amine present in the Mannich base. For those compounds 
containing the dialkylamino substituent it occurred at 5 3.72-3.73, for the pyrrolidinyl 
substituent at 5 3.80 and for the various piperidinyl derivatives at 5 3.63-3.70.
The iHn.m.r. spectra of the 7-trifluoromethyl-1,5-naphthyridine (11.51) and 
the 7-bromo-1,5-naphthyridine (11.53) are listed in Table II-3. As expected (and in 
agreement with the data in Table II-2) there were only slight differences in the spectra of 
these two compounds. For the aromatic protons this difference was 0.09-0.17 ppm and 
for the protons of the side chain it was 0.01-0.1 ppm.
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Table II-3 *H n.m.r. spectral data (5 )a for A 4-(4-diethylamino-l-methyl-  
butyl)-7-substituted-l,5-naphthyridin-4-amine
Me
HN-CH(CH2)3NEt;
Compound X H2 H3 H6 H8 l ’-Me CHMe (CH2)2 c h2n NCH2Me NCH2Me
11.51 c f3 8.60 6.61 8.82 8.47 1.36 3.72 1.66 2.41 2.53 1.01
11.53 Brb 8.48 6.52 8.65 8.36 1.33 3.62 1.60 2.50 2.52 1.01
a Chemical shifts are reported as 5 values downfield from tetramethyl silane (TMS) as
internal standard in deuterochloroform as solvent. 
b Data from reference 110.
The 13C n.m.r. spectrum of 4-chloro-7-trifluorom ethyl-l,5-naphthyridine 
(11.42) (w ith  1 ,5 -n a p h th y rid in e 173*175 for com parison) and 2,6-bis 
(diethylaminomethyl)-4-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)phenol (II.48a) 
are recorded in Table II-4 and Figure II-1, respectively.
The assignments of the 13C chemical shifts were carried out by running a 
decoupled 13C n.m.r. spectrum, 2-D heteronuclear one-bond correlated (HETCOR) 
spectrum and 2-D heteronuclear multiple-bond correlated (HMBC) spectrum [for example 
see Appendix 1 (Figure A1 and A2)]. The HETCOR spectrum was used to determine the 
C-H connectivities present in the molecule; and the HMBC spectrum, to determine the C- 
H long-range coupling (especially for determining the quaternary carbons which do not 
appear in the HETCOR spectrum).
Table II-4 13C n.m.r. spectra (ppm) in CDCI3 of 4-chloro-7-trifluoro- 
methyl-l,5-naphthyridine (11.42) and 1,5-naphthyridine173’175 (for 
comparison)
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6 ^
X Y C 2 C3 C 4 C 6 C 7 C 8 C 9 CIO c f 3
H H 151.0 124.1 137.2 151 .0 124.1 137.2 144.0 144.0 -
C l c f 3 152.2 126.2 143.2 147.2 124.6 135.9 144.5 142.5 127.8
As both rings in unsubstituted 1,5-naphthyridine (X=Y=H) are equivalent, four 
peaks only were observed for C2(C6), C3 (C7), C4 (C8) and CIO (C9) as shown in 
Table II-4. In the spectrum of 4-chloro-7-trifluoromethyl-1,5-naphthyridine (X=C1, 
Y=CF3), the most deshielded carbon was C2; and the least deshielded was C7.
The assignments of the 13C chemical shifts for compound II.48a (Figure II-1) 
revealed that the most deshielded carbon was Cl in the phenolic ring (at 154.4 ppm), 
followed by C2' (at 153.4 ppm) in the naphthyridine ring, and the most shielded carbon 
was the methyl group (at 11.4 ppm). In the naphthyridine ring, obviously C6' (at 142.5 
ppm) was more shielded than C2' (at 153.4 ppm) due to the adjacent trifluoromethyl 
group at position-7.
In the proton decoupled 13C-spectrum, the carbon atom of the trifluoromethyl 
group appeared as a quartet with a coupling constant ca 30 Hz, due to C-F coupling.
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c h 2c h 3/
154.4
II.48a
Figure II-l The chemical shifts (ppm) of the carbon atoms in 
2,6-bis(diethylaminomethyl)-4-(7-trifluoromethyl-
l,5-naphthyridin-4-ylamino)phenol (II.48a)
II-6.2 Ionization constants; ultraviolet spectra and infrared spectra
The basic ionization constant (pKa) of 7-trifluoromethyl-l,5-naphthyridin-4-ol 
(11.41) was determined by spectrophotometric methods176 to be 1.05±0.03. Ionization 
constants have been published for 1,5-naphthyridine (pKa 2.84)177 and 1,5- 
naphthyridin-4-ol (basic pKa 2.85, acidic pKa 10.01).178 Thus compound 11.41 is a 
weaker base by 1.8 units compared to its 7-unsubstituted analogue; and this is due to the 
electron-withdrawing properties of the trifluoromethyl group which reduces basic 
strength. Protonation of compound 11.41 probably also involves N-5. Ionization 
constants of the more complex (and less soluble) Mannich bases were not examined.
The ultraviolet spectrum of compound 11.41 (basic pKa 1.05) was measured at 
pH 5.27 (It was unchanged in the range pH 4.6-6.2). This spectrum is probably the 
neutral species of the keto form because it has been shown that a- and y -hydroxy 
derivatives of nitrogen heterocycles as neutral species in aqueous solution exist 
predominantly in this form.179 The spectrum consisted of two main absorption bands at 
248 nm (log e 4.27) and 336 nm (log e 3.85). These absorption maxima are at longer 
wavelengths than in l,5-naphthyridin-4-ol [^max 240 nm (log £ 4.43), 322 nm (log £
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4.02) at pH 6.0] *80 and the bathochromic shift (red shift) is due to the 7-trifluoromethyl 
substituent (which withdraws electrons from the ring system).
The ultraviolet spectrum of compound II.48a was measured in aqueous solution 
at pH 8.15 (it was constant in the range pH 7.6-8.42) and consisted of three main 
absorption bands at ^max 261 nm (log £ 4.35), 320 nm (log £ 3.72) and 370 nm (log £ 
3.84).
The infrared spectrum of the l,5-naphthyridin-4-ol has been examined in the solid 
state and in chloroform solution.160 It displayed N-H and O-H stretching at 3202 (w) 
and 3108 (m) cm-1, and double bond stretching at 1624 (s) and 1586 (m) cm-1 indicative 
of both keto and enol tautomeric forms. The spectrum of 7-trifluoromethyl-1,5- 
naphthyridin-4-ol (11.41), measured in the present work in KBr disc, shows N-H 
stretching at 3470 (w) cm-1, and double-bond stretching at 1624 (s), 1614 (s) (indicative 
of the keto form) and 1517 (s) cm-1; and C-F stretching at 1136 cm-1.
The infrared spectrum of 2,6-bis(4-methylpiperidin-4-ylmethyl)-4-(7-trifluoro- 
methyl-l,5-naphthyridin-4-ylamino)phenol (II.48g) displayed strong O-H and N-H 
stretching absorptions at 3460 and 3400 cm-1, and was devoid of absorption in the 
carbonyl region.
II-6.3 Mass spectra
Mass spectra of the unsubstituted 1,5-naphthyridine and its methyl derivatives 
have been reported.181 In unsubstituted 1,5-naphthyridine, the major cleavage involves 
loss of HCN and C2H2 , and the fragmentation pattem is depicted in Scheme II-6.
In this work, the mass spectra of the 4-substituted-7-trifluoromethyl-l,5- 
naphthyridines [(11.41), (11.42) and (II.48d)] were examined. The spectrum of 
compound 11.41 shows an intense peak for the molecular ion (m/z 214) and another 
strong peak at m/z 186 (M+-CO) and peaks at m/z 195, 167, 159 and 140. The 
fragmentation pattem is depicted in Scheme II-7, and involves the loss of CO, HCN 
and F.
50
-HCN
m/z 103
-HCN
m/z 130
m/z 104
m/z 77
- - + p
- c 4h 2
.
m/z 76 m/z 50
Scheme II-6 Fragmentation of 1,5-naphthyridine
The mass spectrum of the chloro compound (11.42) shows the two 
molecular ion peaks at m/z 232 and 234 with relative intensities of the lines in the ratio 
3:1. This is characteristic of ions from chlorine-containing compounds and is engendered 
by the 35C1 and 37C1 isotopes.182 The fragmentations observed involve the loss of Cl, 
2HCN and F, and it is shown in Scheme II-8.
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The fragmentation of the di-Mannich base (II.48d; piperidinyl derivative; M+ 
499) differed from the above two compounds; the most intense peak is due to the loss of 
C5H10N (piperidinyl group) (m/z 84) to give the fragment of M-C5H10N (m/z 414).
m/z 186 (66.8%) m/z 167 (9.3%)
-HCN -HCN
m/z 159 (9.3%) m/z 140 (4.1%)
Scheme II-7 The major fragmentation pattern of 7-trifluoromethyl- 
l,5-naphthylidin-4-ol (11.41)
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F3C
+
m/z 213 (5.7%) m/z 163 (5.60%)
m/z 170 (21.4%) 
-HCN
\ _________+
/ \H H
m/z 143 (5.2%)
m/z 171 (3.3%) 
-HCN
m/z 144 (1%)
Scheme II-8 The major fragmentation pattern of 4-chloro-7- 
trifluoromethyI-l,5-naphthylidin-4-ol (11.42)
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II-7 Experimental 
II-7.1 General Topics
(a) Melting points (m.ps.) were taken in Pyrex capillaries with a Gallenkamp melting 
point apparatus and were uncorrected.
(b) Infrared (i.r) spectra were recorded on a Unicam SP 1000 infrared 
spectrophotometer as potassium bromide discs. The following abbreviations were 
adopted: br (broad); s (sharp); m (medium); mw (medium weak); w (weak). Assignment 
of the absorptions were attempted if appropriate. The 1602 cm-1 and 1495 cm-1 regions 
of the i.r spectra were calibrated by the absorption of polystyrene film.
(c) U ltraviolet (u.v.) spectra were recorded on a CARY 219 UV-visible 
spectrophotometer between 200-500 nm, in aqueous solution at 18-20° and at the specific 
pH. The wavelengths of absorption maxima (^max) and the extinction coefficients (e) 
were checked on a Perkin-Elmer Lamba I uv-visible spectrophotometer. The buffers were 
of constant ionic strength, 1=0.02.183
(d) Ionization constants were determined using the spectrophotometric method of 
Albert and Serjeant.176
(e) Nuclear magnetic resonance spectra (JH n.m.r.) were recorded either at 90 
MHz and 30° on a Jeol FX90Q or at 200 or 300 MHz on a Varian XL200E or VXR300 
fourier-transform spectrometer. Data were presented in the following order: chemical 
shift (5) relative to tetramethylsilane in organic solvent or sodium 3-trimethylsilylpropane 
sulfonate in deuterated sodium hydroxide/deuterium oxide; multiplicity; coupling constant 
(J) in Hz; and assignment (where possible). Samples were run in CDCI3 unless specified 
otherwise. The following abbreviations were adopted: s (singlet); d (doublet); t (triplet); 
br s (broad singlet); m (multiplet); dd (doublet of doublets). Exchangable protons were 
identified by their disappearance upon addition of deuterium oxide.
(f) 13C Nuclear magnetic resonance techniques were performed at 300 MHz on a 
Varian VXR300 instrument at 25°. Samples were run in CDCI3. Data were presented in 
the following order: chemical shift (ppm) relative to deuterated solvent peak and 
assignments where appropriate.
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(g) Two dimensional (2-D) nuclear magnetic resonance spectra such as the 
heteronuclear one-bond correlated (HETCOR) spectra, the multiple-bond correlated 
(HMBC) spectra and the proton-proton correlation spectroscopy (COSY) spectra run by 
Ms P. Simmonds, University Nuclear Magnetic Resonance Centre, the Australian 
National University, using a Varian VXR 300 spectrometer.
(h) Low resolution mass spectra (MS) were recorded on an Incos data system 
attached to a VG-Micromass 7070F double focusing mass spectrometer using electron 
impact (El) at 70 eV or chemical ionization (Cl) with ammonia at the Research School of 
Chemistry under the supervision of Dr J.K. MacLeod. Data are presented in the 
following order: m/z value; relative intensity as a percentage of the base peak. The mass 
spectra are El unless specified otherwise.
(i) Microanalyses were performed by The Australian National University Analytical 
Service Unit, Canberra. All solids were dried for at least 4 hours under vacuum (0.2 
mmHg) and at 60-100° prior to analysis, unless otherwise specified.
(j) Analytical thin layer chromatography (t.l.c.) was performed on glass plates and 
aluminium plates with Merck Kieselgel 60 F254 or Merck aluminium oxide 60 F254 
neutral (type E) of 0.25 mm and 0.2 mm thickness, respectively. Preparative thin layer 
chromatography (PTLC) was performed on glass plates precoated with Merck aluminium 
oxide 60 F254 (type E) of 2 mm thickness, or with Merck silica gel 6OF254 of 2 mm 
thickness. Columns for chromatography were packed using Merck aluminium oxide 90 
active neutral (0.063-0.200 mm, 70-230 mesh ASTM) or aluminium oxide for 
chromatography (M&B Laboratory Reagent, MX6390).
(j) Reaction temperatures refer to external oil bath temperatures unless stated 
otherwise.
(l) Where full experimental details are not recorded, percentage yields are given in 
brackets.
(m) Dry solvents were obtained by standard procedures according to D.D. Perrin, 
W.L.F. Armarego, and D.R. Perrin, Purification of Laboratory Chemistry (2nd Ed., 
Pergamon Press, 1980).
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II-7.2 Synthetic work
5 -Trif luorom ethy lpyr id in -3 -am ine170 (11.37)
A mixture of 3-chloro-5-trifluoromethylpyridine (10.0 g), cuprous chloride 
(Prepared by passing sulphur dioxide into a solution of 70.0 g cupric sulphate 
pentahydrate and 18.3 g sodium chloride in 250 ml water), and aqueous ammonia (190 
ml; 28-30%) was heated with stirring in a bomb at 170° for 48 h. After cooling, the 
reaction mixture was extracted with methylene chloride, the extract dried (Na2SC>4), and 
the solvent evaporated to leave an oil (7.72 g). It was purified by chromatography in 
methylene chloride over a column of alumina (18 cm) to give the title compound as a 
white solid (7.49g), m.p. 40-41.5° (Found, for a sample dried in air at 20° for 24 h: C, 
44.3; H, 2.9; N, 17.2. Calc, for C6H5F3N2 : C, 44.4; H, 3.1; N, 17.3%). n.m.r. 5 
3.82, br, NH2; 7.13 br s, H4; 8.21, s, H 2; 8.24, s, H 6 .
Die thyl (5*-tr if luoromethylpyrid in-3'-y laminomethylene)malonate  (11.38)
A mixture of 5-trifluoromethylpyridin-3-amine (2.976 g) and diethyl ethoxy 
methylenemalonate (3.888 g) was heated at 100° for 2 h. On cooling it gave a waxy 
solid which was dissolved in methanol (36 ml), heated to 50° and diluted with an equal 
volume of water. On scratching and chilling it gave diethyl (5'-trifluoromethylpyridin-3- 
ylaminomethylene)malonate (6.00 g), m.p. 65-67° (Found, for a sample dried at 20° in 
vacuo for 2 days: C, 50.3, H, 4.5; N, 8.3. C14H15F3N2O4 requires C, 50.6; H, 4.6, N, 
8.4%). 1H n.m.r. 5 1.35, t, J 7 Hz, 1.39, t, J 7 Hz, MeCH2; 4.28, q, J 7 Hz, 4.33, q, 
J 7 Hz, MeCH2; 7.66, br s, H4’; 8.39, s, 8.53, s, NCH=; 8.65, br s, H2\6\
E t h y l  4 - h y d r o x y - 7 - t r i f l u o r o m e t h y l - 1 , 5 - n a p h t h y r i d i n e - 3 - c a r b o x y l a t e  
(11.39)
Diethyl (5'-trifluoromethylpyridin-3'-ylaminomethylene)malonate (4.8 g) was 
added cautiously and in small portions to refluxing diphenyl ether (65 ml) and when the 
addition was complete it was refluxed for 2-3 h. After cooling, the mixture was diluted 
with hexane (260 ml), and the pale solid (2.1 g; m.p. >300°) was filtered off and washed 
with acetone to give the title compound (Found: C, 50.3; H, 3.1; N, 10.0.
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C12H9F3N2O3 requires C, 50.4; H, 3.2; N, 9.8%). *H n.m.r. (CD3SOCD3 + 
Na0D/D20) 5 1.27, t, J 7 Hz, MeCH2; 4.19, q, J 7 Hz, MeCH2; 8.25, br s, H8; 8.72, 
br s, H6; 8.74, s, H2.
4 -Hydroxy-7-tr if luoromethy l - l  ,5 -naphthyrid ine-3-carboxyl ic  ac id  (11.40)
Ethyl 4-hydroxy-7-trifluoromethyl-l,5-naphthyridine-3-carboxylate (7.69 g) was 
refluxed with 10% aqueous sodium hydroxide (89.0 ml) at 120°; all the solid had 
dissolved after 30 min. The refluxing was continued for a further 1 h and on cooling a 
solid separated. This mixture was diluted with water (295 ml), heated to boiling to 
dissolve the solid, filtered with charcoal, and the filtrate adjusted with hydrochloric acid 
to pH 2-3 and chilled. A light grey precipitate separated and it was filtered off to give 4- 
hydroxy-7-trifluoromethyl-l ,5-naphthyridine-3-carboxylic acid (6.14 g), m.p. >300° 
(Found: C, 46.7; H, 2.0; N, 10.9. C10H5F3N2O3 requires C, 46.6; H, 2.0; N, 10.9%). 
*H n.m.r. (D20  + NaOD) 5 8.44, br s, H8; 8.64, s, H2; 8.87, br s, H6.
7-Tr i f luoromethy  l - l  , 5 - naphthyri  d in-4-o l  (11.41)
4-Hydroxy-7-trifluoromethyl-l,5-naphthyridine-3-carboxylic acid (6.14 g) was 
added in small portions to boiling quinoline (230 ml) and then the mixture was refluxed 
for 1 h. After cooling, the mixture was diluted with three volumes of acetone to give a 
precipitate. The grey product (4.7 g) was filtered off, washed with acetone and 
recrystallised from water or methoxyethanol to give 7-trifluoromethyl-l,5-naphthyridin- 
4-ol, m.p. >300° (Found: C, 50.7; H, 2.4; N, 12.8. C9H5F3N2O requires C, 50.5; H, 
2.4; N, 13.1%). *H n.m.r. (D20  + NaOD) 5 6.75, d, J2,3 6 Hz, H3; 8.39, d, J2,3 6 Hz, 
H2; 8.45, br s, H8; 8.87, d, J6,8 2 Hz, H6. I.r. vmax 3470 (w) (NH st), 2800 (br s), 
2080 (m), 1640 (s) + 1517 (s) (0=0 st, C=C st), 1624 (s), 1614 (s) (ar skeletal st), 
1570 (m) (ar skeletal st), 1437 (m), 1376 (m), 1136 (m), 940 (mw), 841 (m) cm'1. U.v. 
^max (pH 5.27) 248 nm (log e 4.27), 336 nm (log e 3.85). MS m/z 214 (M+) (100%), 
195 (M+-F) (5.6%), 186 (M+-CO) (66.8%), 167 [(M+-F)-CO] (9.3%), 159 [(M+-CO)- 
HCN] (9.3%), 140 (4.1%).
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4 -C hloro-7- tr i f luorom ethy l-1 ,5 -naphthyr id ine  (11.42)
7-Trifluoromethyl-l,5-naphthyridin-4-ol (0.122 g), phosphorus pentachloride 
(0.255 g) and phosphoryl chloride (2.5 ml) were refluxed at 110° for 3 h, and excess 
phosphoryl chloride was distilled under reduced pressure. The residue was treated with 
ice and then saturated sodium carbonate solution until it was basic; the mixture was 
extracted with chloroform, the extract dried (Na2SC>4), and the solvent evaporated. The 
product was subjected to column chromatography (alumina; benzene) and recrystallised 
from heptane to give white crystals of 4-chloro-7-trifluoromethyl-1,5-naphthyridine 
(0.119 g), m.p. 147-149° (Found, for a sample dried at 20° and 0.2 mmHg for 24 h: C, 
46.5; H, 1.7; N, 11.9. C9H4CIF3N2 requires C, 46.4; H, 1.7; N, 12.0%). *H n.m.r. 5 
7.89, d, J 5 Hz, H3; 8.73, br s, H8; 8.97, d, J 5 Hz, H2; 9.27, d, J 2 Hz, H6. MS m/z 
232 (M+) (100%), 234 (M++2) (31%), 213 (M+-F) (5.7%), 197 (M+-C1) (41.5%), 171 
(3.3%), 170 [(M+-C1)-HCN] (21.5%), 163 (M+-CF3) (5.6%), 144 (1%), 143 (5.2%).
2 .6 -  Bis( die thy laminome thy l ) -4 - ( 7 r- t r i f lu o ro m e th y l -1 ' f5 f-n a p h th y r id in -4 ,- 
y lam ino)pheno l  (II.48a)
A mixture of 4-chloro-7-trifluoromethyl-l,5-naphthyridine (0.066 g), 4-amino-
2.6- bis(diethylaminomethyl)phenol172 (0.080 g), methanol (1.3 ml), water (0.4 ml) and 
concentrated hydrochloric acid (4 drops) was refluxed at 100° for 4 h. The methanol was 
evaporated under reduced pressure and the residue diluted with a little water and adjusted 
with N ammonium hydroxide to pH 9-10. The product was extracted into chloroform, 
and subjected to PTLC (alumina; 7% methanol in methylene chloride; then alumina; 1% 
methanol in chloroform) to give, as a yellow oil, 2,6-bis(diethylaminomethyl)-4-(7'~ 
trifluoromethyl-1'y5'-naphthyridin-4'-ylamino)phenol (0.126 g) (Found: C, 63.2; H, 
6.9; N, 14.4. C25H32F3N5O requires C, 63.1; H, 6.8; N, 14.7%). *H n.m.r. 5 1.12, 
t, J 7 Hz, MeCH2; 2.65, q, J 7 Hz, MeCH2; 3.73, s, Ar CH2N; 6.99, d, J 5.5 Hz, H3'; 
7.15, s, H3,5; 8.36, br s, NH?; 8.53, br s, H8’; 8.60, d, J 5.5 Hz, H2'; 8.93, d, J 2 
Hz,H6’. U.v. Xm2LX (pH 8.15) 261 nm (log e 4.35), 320 nm (log 8 3.72), 370 nm (log 
e 3.84). The 13C n.m.r. data are presented in Figure II-1.
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2 .6 -  B i s ( d ip ro p y la m in o m e th y l ) -4 - (7 ' - t r i f lu o r o m e th y l - l ' ,5'-naphthyr id in-  
4 ,-y lam in o)pheno l  (II.48b)
In a similar manner to that described above (but refluxed for 5 h) 4-chloro-7- 
trifluoromethyl-l,5-naphthyridine (0.061 g) and 4-amino-2,6-bis(dipropylaminomethyl)- 
phenol172 (0.088 g) gave a crude product which was purified by PTLC (alumina; 
chloroform) to give the title compound as a yellow oil (0.104 g) (Found: C, 65.5; H, 
7.9, N, 13.2. C29H40F3N5O requires C, 65.5; H, 7.6; N, 13.2%). *H n.m.r. 5 0.90, t,
J 7 Hz, MeCH2; 1.56, m, MeCH2CH2N; 2.50, m, MeCH2CH2N; 3.72, s, ArCH2N; 
7.00, d, J 5.5 Hz, H3'; 7.16, s, H3,5; 8.33, br s, NH?; 8.53, br s, H8 '; 8.58, d, J 5.5 
Hz, H2'; 8.93, d, J 2 Hz, H6 '.
2 .6-  B i s ( p y r r o l i d i n - l ,-y lm e th y l ) -4 - (7”- tr i f luorom eth y l - l  ", 5 ”-naphthyridin  
- 4 n-y lam ino)phenol  (II.48c)
4-Chloro-7-trifluoromethyl-l,5-naphthyridine (0.125 g) and 4-amino-2,6-bis- 
(pyrrolidin-r-ylmethyl)phenol172 (0.148 g), treated similarly but refluxed for 8 h, and 
extracted with ether, gave a crude product which was purified by PTLC (alumina; 1% 
methanol/chloroform) to give the title compound as a yellow oil (0.156 g) (Found, for a 
sample dried at 20°/0.1 mmHg for 1 h: C, 63.5; H, 6.3; N, 14.5. C25H2sF3N5 0  0.2 
H20  requires C, 63.2; H, 6.0; N, 14.7%). *H n.m.r. 5 1.86, complex, H3,4; 2.67, 
complex, H2,5; 3.80, s, ArCH2N; 6.99, d, J 5.5 Hz, H3"; 7.13, s, H3,5; 8.29, br, 
NH; 8.53, br s, H8”; 8.60, d, J 5.5 Hz, H2"; 8.94, d, J 2 Hz, H6 ".
2.6-  B is (p ipe r id in - l  * -y lmethy l) -4 -(7  ”-tr if luoromethyl-1  ”y5 ”-naphthyridin-  
4 f,-y lamino)phenol  (II.48d)
4-Chloro-7-trifluoromethyl-l,5-naphthyridine (0.050 g) and 4-amino-2,6-bis- 
(piperidin-l'-ylmethyl)phenol172 were similarly refluxed for 3.5 h, and the product 
purified by PTLC (alumina; 1% methanol in methylene chloride), to give the title 
compound as a yellow oil (0.059 g) (Found, for a sample dried at 20°/0.2 mmHg for 4 
h: C, 64.3; H, 6.9; N, 13.7. C27H32F3N5O.0.3 H20  requires C, 64.2; H, 6.5; N, 
13.9%). *H n.m.r. 5 1.58, complex, H3',4',5'; 2.58, complex, H2',6'; 3.69, s,
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ArCH2N; 7.04, d, J 5.5 Hz, H3"; 7.17, s, H3,5; 8.31, br s, NH?; 8.52, br s, H8M; 
8.60, d, J 5.5 Hz, H2"; 8.92, d, J 2 Hz, H6 ". MS m/z 499 (M+) (26.8%), 414 (M+- 
C5H i0N) (97%), 84 (C5H10N) 100%).
2 .6 -  B i s ( 3 f-methylp iper id in-1  f-y lm e th y l ) -4 - (7" - t r i f lu orom eth y l - l  ",5"- 
naphthyridin-4” -ylamino)phenol  (II.48e)
This compound was prepared from 4-chloro-7-trifluoromethyl-l,5-naphthyridine 
(0.078 g) and 4-amino-2,6-bis(3'-methylpiperidin-r-ylmethyl)phenol172 (0.111 g) as 
above but refluxed for 5 h. It was purified by PTLC (alumina; chloroform) to give the 
title compound as a yellow oil (0.130 g) (Found: C, 66.0; H, 7.2; N, 12.9. 
C29H36F3N5O requires C, 66.0; H, 6.9; N, 13.3%). l H n.m.r. 5 0.88, d, J 5.5 Hz, 
Me; 1.72, complex, H3',4',5'; 2.91, complex, H2',6'; 3.70, s, ArCH2N; 7.06, d, J 5.5
Hz, H3"; 7.17, s, H3,5; 8.34, br s, NH(?); 8.53, br s, H8 "; 8.60, d, J 5.5 Hz, H2M,
8.93, d, J 2 Hz, H6".
2 .6-  B is (3 ' ,5 ' -d im e  thy lp iper id in-1  r-y lm ethy l ) -4 - (7  "-t r i f luoromethyl-  
1 ”, 5 ”-n aph thyr id in -4”-y lamino)phenol  (II.48f)
This compound was prepared in a similar manner from 4-chloro-7- 
trifluoromethyl-l,5-naphthyridine (0.034 g) and 2,6-bis(3',5'-dimethylpiperidin-r-yl- 
methyl)phenol172 (0.054 g). The product was purified by PTLC (alumina; 4% methanol 
in chloroform) to give the title compound (0.092 g) (Found, for a sample dried at 
20°/0.2 mmHg for 20 h: C, 66.7; H, 7.4; N, 12.4. C31H40F3N5O 0.2 H20  requires C, 
6 6 .6 ; H, 7.3; N, 12.5%). *H n.m.r. 8 0.85, d, J 5.5 Hz, Me; 1.70, complex,
H3',4',5'; 2.93, m, H2',6'; 3.65, s, ArCH2N; 7.00, d, J 5.5 Hz, H3"; 7.11, s, H3,5;
8.31, br s, NH(?); 8.53, br s, H8"; 8.59, d, J 5.5 Hz, H2"; 8.93, d, J 2 Hz, H6".
2 .6 - B is ( 4 ' -m e th y lp ip e r id in -1 ' -y lmethy l) -4 -(7  ”-t r i f luoromethyl-1  " ,5”- 
naphthyridin-4” -ylamino)phenol (II.48g)
4-Chloro-7-trifluoromethyl-l,5-naphthyridine (0.101 g) and 4-amino-2,6-bis(4'- 
methylpiperidin-r-ylmethyl)phenol172 (0.144 g) reacted as above, and the product was 
purified by PTLC (alumina; 1% methanol in chloroform) to give the title compound
60
(0.134 g) (Found: C, 65.8; H, 6.9; N, 13.2. C29H36F3N5O requires C, 66.0; H, 6.9; 
N, 13.3%). *H n.m.r. 5 0.94, d, J 4 Hz, Me; 1.55, complex, 2.12, m, 2.98, m, 
H2',3',4',5',6'; 3.65, s, ArCH2N; 6.97, d, J 5.5 Hz, H3’; 7.11, s, H3,5; 8.32, br s, 
NH?, 8.53, br s, H8M; 8.60, d, J 5.5 Hz, H2"; 8.93, d, J 2 Hz, H6". I.r. vmax 3460 
(w) (OH st), 3400 (w) (NH st), 2970 (w), 2940 (m) (CH2 st), 1595 (m) (ar. st), 1580 
(m), 1475 (s), 1372 (s), 1162 (s), 1136 (s).
2 ,6 - B i s ( 4 ' - b e n z y l p i p e r i d i n - l 9-y lm e th y l ) -4 -n i t roph en o l  (11.46)
Paraformaldehyde (0.86 g) and 4-benzylpiperidine (4.98 g) in ethanol (5.0 ml) 
were warmed until homogeneous. Then 4-nitrophenol (1.0 g) was added and the mixture 
was refluxed at 90-95° for 16 h. After cooling, the mixture was diluted with hexane and 
a little chloroform, and the yellow solid (3.74 g) was filtered off. It was recrystallised 
from a mixture of dichloromethane and light petroleum (b.p. 60-80°) to give yellow 
crystals of 2,6-bis(4,-benzylpiperidin-l,-ylmethyl)-4-nitrophenol (2.416 g), m.p. 110- 
111.5° (Found: C, 72.9; H, 8.1; N, 8.0. C32H39N303 0.8 H20  requires C, 72.8; H, 
7.8; N, 8.0%). *H n.m.r. 5 1.12-2.21, complex, 2.95, m, H2,,3,,4,,5,,6,; 2.53, br s, 
CH2Ph; 3.66, s, ArCH2N; 7.22, complex, Ph; 8.00, s, H3,5.
2 j6 -B is (4 ' -b en zy lp ip e r id in - l  f- y lm e th y l ) -4 - (7 ”- tr i f lu o ro m eth y l - l  ”,5"-  
naph thyr id in -4”-y lamino)phenol  (II.48h)
2,6-Bis(4'-benzylpiperidin-r-ylmethyl)-4-nitrophenol (0.402 g) was dissolved 
in ethanol (10.0 ml) and saturated ethanolic ammonia (30.0 ml) and shaken with 
hydrogen over Raney nickel until hydrogen uptake ceased and the yellow colour was 
discharged. The catalyst was filtered off on Celite and the filtrate evaporated on the 
rotary evaporator to give the amine as a purple liquid (0.116 g). *H n.m.r. 5 1.16 - 2.37, 
complex, 2.95, m, H2,,3',4,,5,,6'; 2.52, br s, CH2Ph; 3.53, s, ArCH2N; 6.46, s, 
H3,5; 7.21, complex, Ph.
A mixture of 4-chloro-7-trifluoromethyl-l,5-naphthyridine (0.056 g) and 4- 
amino-2,6-bis(4'-benzylpiperidin-r-ylmethyl)phenol (0.116 g) in aqueous methanol 
containing hydrochloric acid was refluxed for 8 h. The crude product was subjected to 
PTLC (alumina; methylene chloride, then 30% ethyl acetate in hexane) to give the title
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compound (0.106 g) (Found: C, 71.5; H, 6.8; N, 10.0. C41H44F3N5O requires C, 
71.4; H, 6.7; N, 10.1%). *H n.m.r. 5 1.20 - 2.20, complex, 2.95, m, H2’,3,,4,,5,,6,; 
2.54, br s, CH2Ph; 3.63, s, ArCH2N; 6.95, d, J 5.5 Hz, H3M; 7.09, s, H3,5; 7.22, 
complex, CH2C6H5; 8.29, br s, NH?; 8.51, br s, H8”; 8.58, d, J 5.5 Hz, H2"; 8.92, br 
s, H6".
N 4-(4 ' -D ie th y lam in o- l -m e th y lbu ty l ) -7 - t r i f lu orom eth y l - l  ,5-naphthyr id in-  
4-amine  (11.51)
4-Chloro-7-trifluoromethyl-l,5-naphthyridine (0.05 g), A^^-diethylamino- 
pentane-l,4-diamine (0.39 g) and heptane (1.0 ml) were heated in a Teflon-lined reaction 
vessel at 150° for 20 h. The solvents were then removed on a rotary evaporator, and the 
residue subjected to PTLC (alumina; 30% ethyl acetate in hexane) to give ^ -(4'-diethyl- 
amino-l'-methylbuty l)-7-trifluoromethy l-l ,5-naphthyridin-4-amine (0.68 g) as a yellow 
oil (0.068 g) (Found, for a sample dried at 55°/0.2 mmHg for 4 h: C, 60.5; H, 7.5; N, 
16.1%. Ci8H25F3N4 requires C, 61.0; H, 7.1; N, 16.1%. *H n.m.r. 5 1.01, t, J 7 Hz, 
MeCH2; 1.36, d, J 6.5 Hz, MeCH; 1.66, complex, CH2CH2CH2N; 2.41, complex, 
CH2N; 2.53, q, J 7 Hz, CH2Me; 3.72, complex, CHMe; 6.61, d, J 5.5 Hz, H3; 6.70, 
br s, NH?; 8.47, br s, H8; 8.60, d, J 5.5 Hz, H2; 8.85, d, J 2 Hz, H6.
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II -7 .3  D e term in at ion  of  the basic  ion izat ion  constant  of  7-
trifluoromethyl-l ,5-naphthyridin-4-ol (11.41)
S ubstance: 7-Trifluoromethyl-1,5-naphthyridin-4-ol 
C9H5F3N2O; MW 214.146
Concentration: 1.0 X 10*4 M. Recrystallised compound, m.p. >300°, was dried at 
20°/0.2 mmHg overnight and 0.0107 g was dissolved in boiling water (200 ml), then 
cooled and made up to 500.0 ml with water. This stock solution (3.0 ml) was diluted 
with appropriate buffers (1.0 ml).
Analytical wavelength: 332 nm; cell, 1 cm
Buffer: Hydrochloric acid and sulphuric acid buffers (1=0.1)
Species: Neutral and cationic species
Temperature: 20°
Result:
Hq value: 1.4 1.2 0.98 0.8 0.6
pKa calc.: 1.01 1.03 1.06 1.06 1.02
pKa = 1.04 ±0.03
CHAPTER III
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CHAPTER III Di-Mannich Bases of 4-(7-TrifluoromethylquinazoIin-4-yl- 
amino)phenol and A 4-(4-D iethylam ino-l-m ethybutyl)-7-trifluorom ethyl- 
quinazolin-4-amine
III-1 Introduction
In this chapter, the syntheses of di-Mannich bases of 4-(7-trifluoromethyl- 
quinazolin-4-ylamino)phenol, and N4-(4-diethylamino-1 -methylbutyl)-7-trifluoromethyl- 
quinazolin-4-ylamine are reported. The required intermediates for these two derivatives are 
di-Mannich bases of 4-nitrophenol, which have been mentioned in Chapter II; and 4-chloro 
(and 4-hydroxy)-7-trifluoromethylquinazoline, which will be discussed below.
There is a number of methods for the preparation of quinazolin-4-ol and its 
derivatives (III.l); these have been reviewed by Armarego.184 Most of these syntheses 
involved an o-disubstituted benzene (III.2) which was then condensed with the C2 N3 
segment to give quinazolines in various ways.184' 186 Quinazolines with substituents in the 
pyrimidine ring or benzene ring or in both rings could thus be prepared.
The most common synthesis, and that most relevant to the present 
work, was that known as Niementowski's synthesis.
III-2 Literature Preparations of Quinazolin-4-ol and its Derivatives via 
Niementowski’s Synthesis
The original method of Niementowski's synthesis involved the reaction of 
anthranilic acid with formamide at 120-130° for 3 h to give quinazolin-4-ol.187
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Homologous amides such as acetamide were also used to give 2-substituted quinazolin-4- 
ols.187
This type of the reaction also proceeds with substituted anthranilic acids containing 
substituents such as halogeno,188489 alkyl*90 and trifluoromethyl189’19l groups. Further 
details184 and the mechanism192» ^  of Niementowski's synthesis have been reported.
Quinazolin-4-ol as the neutral molecule in aqueous solution has been shown194495 
to exist mainly in the o-quinonoid form (III.3).
III-3 Synthesis of 2-Amino-4-trifIuoromethylbenzoic Acid
The necessary intermediate for the preparation of the 4-chloro (and 4-hydroxy)- 
7-trifluoromethylquinazolines described in this chapter was 2-amino-4-trifluoromethyl- 
benzoic acid (III.8). Two methods have been described for the synthesis of compound 
III.8 . The first pathway has been described by Simet196 (Simet's pathway) from 1- 
chloro-2-nitro-4-trifluoromethylbenzene (III.4) through (2-nitro-4-trifluoromethylphenyl)- 
acetic acid (III.5), 6-trifluoromethyloxindole (III.6) and 6-trifluoromethylisatin (III.7). 
The other pathway has been described by Hauptschein et al,197 (Hauptschein's pathway) 
from 2-nitro-4-trifluoromethylaniline (III.9) through 2-nitro-4-trifluoromethylbenzonitrile 
(III.10) and 2-nitro-4-trifluoromethylbenzoic acid (111.11) (shown in Scheme III-1).
In the present work, the procedure described by Simet was found to be the preferred 
route, mainly because of difficulties with the diazotisation in the alternative procedure. 
Details of these methods are discussed below.
The acid compound (III.5) was prepared by alkylation of l-chloro-2-nitro-4- 
trifluoromethylbenzene (HI.4) with ethyl malonate, in refluxing ethanol for 2.5 h; followed 
by hydrolysis and decarboxylation with 10% aqueous potassium hydroxide solution at 
reflux for 1.5 h. This compound III.5 was reduced by tin in boiling 9 N hydrochloric acid 
solution to give the corresponding oxindole (111.6). The compound III.6 reacted with 
bromine in refluxing carbon tetrachloride for 15 minutes, followed by hydrolysis with 5% 
sodium hydroxide to afford 6-trifluoromethylisatin (III.7). Oxidation of the isatin (III.7)
65
with 1.5% hydrogen peroxide solution in 2% sodium hydroxide at 80° afforded 2-amino-4- 
trifluoromethylbenzoic acid (III.8).
III.4
1 CH2( C 0 2Et)2
2 EtOH/KOH
NH3/EtOH
nT
III.9
Sn/HCl
III.6 III .10
1 Br2
2 NaOH
3 H30 +
III.8
Scheme III-l
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The second (less preferred) pathway required the diazotisation of 2-nitro-4-trifluoro- 
methylaniline (III.9) [prepared as described by Pettit and Tatlow198 by the reaction of 1- 
chloro-2-nitro-4-trifluoromethylbenzene (III.4) with saturated ethanolic ammonia in a 
sealed vessel at 120° for 5 h] to compound IIL10. This diazotisation was carried out in a 
mixture of glacial acetic acid and sulphuric acid as described for the isomer, 4-nitro-3- 
trifluoromethylaniline;199 the alternative method in aqueous sulphuric acid described by 
Hauptschein et al.197 was found to be less satisfactory. Thus a solution of compound 
III.9 in glacial acetic acid was diazotised by addition to a mixture of sodium nitrite in 
concentrated sulphuric acid at 10-20°, and then added to a solution of potassium nickel 
cyanide as described by Hauptschein et a/.197 Compound III. 10 was isolated from the 
reaction mixture by steam distillation. The nitrile (III. 10) was hydrolysed in 55% 
sulphuric acid at 165° for 1 h as described by Hauptschein et al. to the 2-nitro-4-trifluoro- 
methylbenzoic acid (III.ll) which was reduced by iron powder in aqueous ammonium 
chloride at 50° for 1 h to 2-amino-4-trifluoromethylbenzoic acid (131.8).
III-4 Syntheses of 4-Chloro (and 4-Hydroxy)-7-trifluoromethylquinazo- 
line
The above compounds were prepared as outlined by Armarego200 and Armarego 
and Smith191 from the reaction of 2-amino-4-trifluoromethylbenzoic acid with formamide 
followed by chlorination (as in Scheme III-2).
Scheme III-2
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2-Amino-4-trifluoromethylbenzoic acid (III.8) was allowed to react with 
formamide (III. 12) at 125° for 45 minutes and then at 171° for 2 h, and gave 4-hydroxy- 
7-trifluoromethylquinazoline (III.13).191,200 This hydroxy compound (III.13) with a 
mixture of phosphorus pentachloride and phosphoryl chloride, at reflux for 3 h,191 «200 
afforded 4-chloro-7-trifluoromethylquinazoline (IIL14).
III-5 Syntheses of di-Mannich Bases of 4-(7-Trifluoromethylquinazolin- 
4-ylamino)phenol
The starting materials required for the syntheses of the di-Mannich bases (III. 16) 
were the appropriate di-Mannich bases of p-aminophenol (M.15) [prepared previously by 
Mannich reactions on /?-nitrophenol, followed by catalytic reduction with hydrogen over 
Raney nickel as described by Barlin and Ireland;172 other compounds were prepared in a 
similar manner] and 4-chloro-7-trifluoromethylquinazoline (III. 14) described in Chapter 
III-4. A mixture of the compounds III. 14 and III. 15 (in 1:1 molar ratio) in aqueous 
methanol adjusted to pH ca 4.0-4.5 was refluxed for 5-10 h, and gave high yields of the 
desired di-Mannich bases (III.16) of 4-(7-trifluoromethylquinazolin-4-ylamino)phenol (as 
shown in Scheme HI-3).
III-6 Synthesis of V4-(4-Diethylamino-l-methylbutyl)-7-trifluoromethyl- 
quinazolin-4-amine
V4-(4-Diethylamino-l-methylbutyl)-7-trifluoromethylquinazolin-4-amine (III.18), 
the 3-aza-7-trifluoromethyl analogue of chloroquine, was synthesised from 4-chloro-7- 
trifluoromethylquinazoline (III.14) and A^^-diethylpentane- 1,4-diamine (III.17) in 
heptane in a Teflon lined screw-top reaction vessel at 140°, for 20 h.
Each of the compounds III. 16 and III. 18 was purified by preparative thin layer 
chromatography (PTLC). The results of testing of these compounds for antimalarial 
activity are given in Chapter VIII.
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III .16
III.15, 11.16
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b N E t 2
C N P r 2
d N ( C 5H u ) 2
e N B u M e
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g p i p e r i d i n - l - y l
h 3 - m e t h y l p i p e r i d i n - l - y l
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j 4 - m e t h y l p i p e r i d i n - l - y l
k 4 - b e n z y l p i p e r i d i n - l - y l
Scheme III-3
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III-7 Physical Properties
III-7.1 iH Nuclear magnetic resonance spectra
The ^ n .m .r .  spectra of l,2-disubstituted-4-trifluoromethyl (and 4-chloro) 
benzenes (III.8 - III.ll and III. 19 - III.21) are listed in Table III-1. All spectra are 
reported in CDCI3 solution, except for compound III.8 in CD3SOCD3 and III.19 in a 
mixture of CD3SOCD3 and CDCI3.
Table III-l The chemical shifts for l,2-disubstituted-(4-trifluoromethyl 
and 4-chloro)benzene
C o m p o u n d X Y Z S o lv e n t H3 H5 H 6
I I I . 8 COOH n h 2 c f 3 CD3 SOCD3 7.11(br s) 6.76(dd) 7.87(d)
I I I .9 n h 2 NC^ c f 3 CDCI3 8.43(s) 7.56(dd) 6.91(d)
I I I . 10 CN n o 2 c f 3 CDCI3 8.62(s) 8.14(s) 8.14(s)
I I I . l l COOH n o 2 c f 3 CDCI3 8 .2 0 (s) 8 .0 2 (s) 8 .0 2 (s)
I I I .1 9 a COOH n h 2 Cl CD3 SOCD3
/CDCI3
6.85(d) 6.5(dd) 7.8(d)
I I I .20 n h 2 NC^ Cl CDCI3 8 .1 2 (d) 7.32(dd) 6.78(d)
I I I .21 COOH NC^ Cl CDCI3 7.83(d) 7.67(dd) 7.92(d)
a CJ. Pouchert, The Aldrich Library ofNMR Spectra, Vol.2 (Aldrich Chemical Company,
Inc., 1983), p. 214B.
An examination of the spectra of compounds IIL8 to III .ll revealed that the 
protons in the cyano compound (III.10) were downfield of those of the corresponding 
acid (III.ll); and, as expected the signals in the corresponding amino compound (III.9) 
were upfield of those in compound III. 10 with the greatest effect on H6 . Although a 
direct comparison of the spectrum of compound III.8 (in CD3SOCD3) with compound
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III. 11 (in CDCI3) -was not possible the significant differences in spectra of the amino and 
corresponding nitro compounds were apparent.
Comparison of the spectra of the trifluoromethyl compounds (III.9) and (III. 11) 
with the corresponding chloro compounds (M.20) and (III.21) (all in CDCI3) confirmed 
the greater electron-withdrawing power of the trifluoromethyl group with the proton signals 
in compounds III.9 and III. 11 being downfield of those in the chloro compounds 
(III.20) and (III.21). The signals of compound III.8 (in CD3SOCD3) were also 
downfield of its chloro analogue (in. 19, in CD3SOCD3/CDCI3).
A comparison of the IH n.m.r. spectrum of 4-chloro-7-trifluoromethylquinazoline 
(III. 14) with that of the 4-hydroxy analogue (III.13) given in the Experimental section 
revealed that all protons of compound III.14 are downfield of those in compound 111.13; 
with the effect being most pronounced at H2. This is due to the strong inductive electron- 
withdrawal of the chloro substituent (relative to the hydroxy group).
An examination of the n.m.r. spectra of the di-Mannich bases of 4-(7- 
trifluoromethylquinazolin-4-ylamino)phenol given in the Experimental section revealed that 
the Mannich methylene protons occurred at 5 3.55-3.74, the phenolic protons at 8 7.35- 
7.43, and the protons of the quinazoline ring as follows: H2, 8 8.72-8.76; H5, 7.99-8.16; 
H6 , 7.64-7.71; and H8, 8.11-818.
III-7.2 Ionization constants
The basic ionization constant of 7-trifluoromethylquinazolin-4-ol (III. 13) was 
determined spectroscopically as pKa 1.43, and accordingly it is a weaker base than 
quinazolin-4-ol (basic pKa 2.06179). This reflects the strong electron-withdrawing 
properties of the trifluoromethyl group which usually exceeds that of the chloro substituent. 
Unfortunately, the basic pKa value of 7-chloroquinazolin-4-ol is unknown. However the 
superior electron-withdrawing effect of the trifluoromethyl group (compared to the chloro 
substituent) is revealed by a comparison of the pKa values of the following compounds: 
quinoline, 4.9;201 7-chloroquinoline, 3.85;202 7-trifluoromethylquinoline, 3.16;203
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quinazolin-8-ol, 5.02;204 7-chloroquinazolin-8-ol, 4.0;205 and 7-trifluoromethylquinazolin- 
8-ol, 2.4.206
}
Ionization constants (which probably overlap) for the more complex di-Mannich 
bases compounds (III.16a - III.16k) were not examined.
III-7.3 Ultraviolet, infrared and mass spectra
The ultraviolet spectrum of the neutral molecule of 7-trifluoromethylquinazolin-4-ol 
(pKa 1.43) was measured in aqueous solution at pH 6.7. Its spectrum consisted of four 
absorption bands (^max) as follows: 226 nm (log e 4.35), 264 nm (log e 3.85), 308 nm 
(log e 3.69) and 320 nm (log e 3.60).
This spectrum closely resembles the spectrum of the neutral molecule of quinazolin- 
4-ol:195*207 at 224 nm (log e 4.36), 265 nm (log e 3.81), 300 nm (log e 3.60) and 331 nm 
(log e 3.54).
The ultraviolet spectrum of the di-Mannich base (III.16b) was measured at pH 6.7 
(it was unchanged in the range pH 6.07-6.7) and displayed two main absorption bands at 
206 nm (log e 4.73) and 316 nm (log e 3.98) with a inflexion point at 246-248 nm (log e 
4.12).
The infrared spectrum of 7-trifluoromethylquinazolin-4-ol (III.13) (in KBr) 
displayed NH stretching absorption at 2900 cm*1 and CO stretching at 1720 and 1620 
cm*1; and it is similar to the spectrum of quinazolin-4-ol.208 Thus like quinazolin-4-ol, 
compound III.13 probably exists mainly as a mixture of the tautomeric forms [(III.22) 
and (III.23)].
O
f3c
III.22 III.23
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The mass spectrum of 2,6-bis(diethylaminomethyl)-4-(7-trifluoromethylquinazolin- 
4-ylamino)phenol (III. 16, R1=R2=Et), a representative of the di-Mannich compounds, 
showed a weak intensity molecular ion peak at m/z 475. The major cleavages appeared to 
be at the C-N bond of one or both Mannich bases to give (stable) fragments appearing as 
peaks at m/z 403 and 331, respectively. Other cleavages were also observed such as the 
loss of ethyl groups to give an ion peak at m/z 446, and the cleavage of the C4'-N bond to 
give the 7-trifluoromethylquinazoline fragment (m/z 197) and then the likely loss of 
hydrogen cyanide to give to peak at m/z 170.
III-8 Experimental 
III-8.1 Synthetic work
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2-Nitro-4-trifluoromethylphenylacetic acid (III.5)
This compound was prepared from l-chloro-2-nitro-4-trifluoromethylbenzene with 
ethyl malonate as described by Simet.196 It had m.p. 143-145° (lit.196 145-146.5°). 
!H n.m.r. 5 4.15, s, CH2; 6.35, br, COOH; 7.54, d, J5>6 8 Hz, H6; 7.89, br d, J5,6 8 Hz, 
H5; 8.42, br s, H3. I.r. vmax 3140 (br) (OH st), 1730 (s) (C=0 st), 1570 (m), 1520 (mw), 
1370 (mw), 1340 (s) (NO st), 1190 (s), 1100 (s), 875 (m), 780 (mw), 710 (w) cn r1-
6-Trifluoromethyloxindole (III.6)
This compound was prepared from 2-nitro-4-trifluoromethylphenyl acetic acid with 
tin in boiling 9 N hydrochloric acid as described by Simet.196 It had m.p. 186-188° 
(lit.196 186-188°). !H n.m.r. 5 3.63, s, CH2; 7.18, s, H7; 7.33, q, J5>6 8 Hz, H5,6; 
8.70, br, NH. I.r. vmax 3160 (br) (NH st), 1710 (s) (C=0 st), 1640 (w), 1470 (m), 1329 
(m), 1309 (m), 1265 (m), 1170 (s), 1120 (s), 1055 (m) cm'1.
6-Trifluoromethylisatin (III.7)
This compound was prepared from 6-trifluoromethyloxindole with bromine in 
refluxing carbon tetrachloride as described by Simet.196 It had m.p. 193-195° (lit.196 192- 
194.5°) (Found: C, 50.4; H, 1.8; F, 26.5; N, 6.4. Calc, for C9H4F3N 0 2: C, 50.2; H, 
1.9; F, 26.5; N, 6.5%). JH n.m.r. (CD3SOCD3) 5 4.5, br, NH; 7.12, s, H7; 7.41, d, J4,5 
8 Hz, H5(4); 7.71, d, J4,5 8 Hz, H4(5). I.r. vmax 3140 (br) (NH st), 1780 (s) and 1765 
(s) and 1730 (s) (C=0 st) 1650 (m) (C=0 st?), 1468 (m), 1330 (s), 1190 (s), 1145 (s), 
1065 (m) cm-1.
2 -Nitro-4-trifluoromethylaniline (III.9)
This compound was prepared from l-chloro-2-nitro-4-trifluoromethylbenzene with 
ethanolic ammonia at 120° as described by Pettit and Tatlow.198 It had m.p. 105-107° 
(lit.198 106-107°). !H n.m.r. 5 6.45, br s, NH2; 6.91, d, J5,6 8.5 Hz, H6; 7.56, dd, J5,6 
8.5 Hz; J3 5 2 Hz, H5; 8.43, s, H3. I.r. vmax 3518 (m) (NH st), 3390 (s) (NH sym st),
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1667 (s) (N02 st?), 1590 (m) (ar skeleton st), 1340 (s) (N02 st), 1290 (m), 1130 (s), 916 
(m), 840 (m), 700 (m), 630, (m) cm-1.
2-N itr o-4-trifluorome thy lb enzo nitrile (III. 10)
A solution of 2-nitro-4-trifluoromethylaniline (7.0 g) in glacial acetic acid (54.0 ml) 
was gradually poured into a stirred solution of sodium nitrite (2.58 g) in concentrated 
sulphuric acid (18.0 ml) maintained at 10-20°. The excess nitrous acid was decomposed 
with urea, and then the diazonium solution was then treated with potassium nickel cyanide 
as described197 and the product isolated by steam distillation to give the title compound 
(2.30 g) as a low melting solid (Found: C, 44.9; H, 1.4; N, 12.7. Calc, for CgH3F3N20 2: 
C, 44.4; H, 1.4, N, 12.9%). n.m.r. 5 8.14, s, H5,6; 8.62, s, H3.
2-Nitro-4-trifluoromethylbenzoic Acid (III. 11)
This compound was prepared as described by Hauptschein et a /.197 and 
recrystallised from a mixture of methylene chloride and benzene. It had m.p. 132-134° 
(lit.197 140-140.5°) (Found, for a sample dried at 20°/0.2 mmHg for 2 h: C, 40.8; H, 1.4; 
N, 5.9. Calc, for C8H4F3NO4: C, 40.8; H, 1.7, N, 6.0%). lH n.m.r. 6 8.02, s, H5,6; 
8.20, s, H3; 8.81, br s, COOH. I.r. v max 3300-2300 (br) (OH st), 3140 (w) (CH st), 
1732 (s) (C=0 st), 1570 (ms) (N02 st?), 1370 (m), 1340 (s) (N02 st), 1190 (s), 1100 (s), 
875 (m), 780 (m), 710 (w) cm'1.
2-Amino-4-trifluoromethylbenzoic acid (III.8)
This compound was best prepared according to Simet196 and recrystallised from 
aqueous methanol. It had m.p. 174-176° (lit.196 175-177°) (Found, for a sample dried at 
20°/0.2 mmHg for 2 h: C, 46.7 H, 2.9; F, 28.1; N, 6.8. Calc, for C8H6F3N 02: C, 46.8; 
H, 2.9; F, 27.8; N, 6.8%). n.m.r. (CD3SOCD3) 5 6.76, dd, J5,6 8.5 Hz, J3,5 1.5 Hz, 
H5; 7.11, br s, H3; 7.87, d, J5,6 8.5 Hz, H6. I.r. vmax 3550 (m) (NH aysm st), 3430 
(m) (NH sym st) 3100 (br) (OH st), 1706 (s) (C=0 st), 1610 (m), 1350 (m), 1250 (s), 
1190 (s), 1100 (m), 940 (m), 790 (m) cm'1.
It was also prepared from 2-nitro-4-trifluoromethylbenzoic acid as described by 
Hauptschein et al,197 but in our hands this method was less satisfactory.
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7-Trifluromethylquinazolin-4-ol (III. 13)
2-Amino-4-trifluoromethylbenzoic acid (1.705 g) was mixed with formamide (1.4 
ml) and heated at 125° for 45 min, and then at 171° for 2.5 h. After cooling, the mixture 
was diluted with water and the product filtered and washed. It was recrystallised from 
ethanol with charcoal filtration to give 7-trifluoromethylquinazolin-4-ol (1.24 g), m.p. 225- 
227° (lit.191 227°) (Found: C, 50.8; H, 2.3; F, 27.0; N, 13.1. Calc, for C9H5F3N2O: C, 
50.5; H, 2.3; F, 26.6; N, 13.1%). n.m.r. (CD3SOCD3) 5 7.83, br d, J5>6 8 Hz, H6 ; 
7.98, br s, H8; 8.24, s, H2; 8.33, br d, J5>6 8 Hz, H5. I.r. vmax 2900 br (w) (NH st), 
1720 (s) (C=0 st), 1620 (w), 1455 (mw), 1330 (m), 1265 (m), 1200 (m), 1140 (m), 890 
(mw), 800 (w) cm-1. U.v. Xmax (pH 6.7) 226 nm (log £ 4.35), 264 nm (log £ 3.85), 308 
nm (log £ 3.69), 320 nm (log £ 3.60).
4-Chloro-7-trifluoromethylquinazoline (III. 14)
This compound was prepared from 7-trifluoromethylquina?olin-4-ol by a literature 
procedure191»200 but the mixture of 7-trifluoromethylquinazolin-4-ol (2.35 g), phosphorus 
pentachloride (4.86 g) and phosphoryl chloride (15.0 ml) was refluxed for 3 h after all the 
solid had dissolved. After chromatography in benzene over alumina (15 cm) and 
recrystallisation from light petroleum (b.p. 60-80°) the 4-chloro-7-
trifluoromethylquinazoline (1.56 g) had m.p. 62-64° (lit.191 62°). JH n.m.r. 6 7.91, dd, 
J5>6 8.5 Hz, J6,8 1.5 Hz, H6 ; 8.36, br s, H8; 8.41, d, J5>6 8.5 Hz, H5; 9.14, s, H2. I.r. 
Vmax 3080 (w) (CH st), 1580 (m), 1330 (s), 1235 (m), 1150 (s), 1075 (m), 845 (m), 690 
(m) cm-1.
2f6-Bis(dipentylaminomethyl)-4-nitrophenol
Dipentylamine (2.10 g) was added to a chilled mixture of paraformaldehyde (0.402 
g) in ethanol (1.0 ml), p-nitrophenol (0.460 g) added and the mixture refluxed at 90-95° 
for 18 h. The solvent was then evaporated under vacuum and the crude product 
chromatographed in dichloromethane over a column of alumina to give as an oil, 4,6- 
bis(dipentylaminomethyl)-4-nitrophenol (0.905 g) (Found: C, 70.4; H, 10.6. C28H51N3O3 
requires C, 70.4; H, 10.8. n.m.r. 5 0.88, t, J 7 Hz, Me; 1.26, complex, NCH2CH2 
CH2CH2; 2.50, t, NCH2; 3.71, s, ArCH2N; 8.05, s, H3,5.
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2 .6 -  B is (N -bu ty l -N -m e  thy lami no m e th y l ) -4 -nitro ph en o l
A-Butylmethylamine (5.060 g), paraformaldehyde (1.740 g), ethanol (4.0 ml) and 
/?-nitrophenol (2.0 g) were allowed to react in a manner similar to that described above. 
The product was chromatographed in chloroform over a column of alumina and gave as an 
oil 2,6-bis(N-butyl-N-methylaminomethyl)-4-nitrophenol (4.592 g) (Found: C, 64.3; H, 
9.3. C18H31N 3O3 requires C, 64.1; H, 9.3%). *H n.m.r. 5 0.91, complex, CH2Me;
l .  46, complex, NCH2CH2CH2; 2.28, s, NMe; 2.50, t, J 7 Hz, NCH2CH2; 3.66, s, 
ArCH2N; 8.02, s, H3,5.
2 .6 -  B i s ( 4 ,-b e n zy lp ip e r id in - l  ,- y lm e thy l ) -4 -n i t ropheno l
4-Benzylpiperidine (4.980 g) paraformaldehyde (0.860 g), ethanol (5.0 ml) and p- 
nitrophenol (1.0 g) were allowed to react as above. After cooling, the mixture was diluted 
with hexane and the yellow solid was filtered off, and recystallised from a mixture of 
dichloromethane and light petroleum (b.p. 60-80°) to give the title compound (2.416 g),
m. p. 110-111.5° (Found: C, 7.29; H, 8.1; N, 8.0. C32H39N 3O3.O.8H2O requires C, 
72.8; H, 7.8; N, 8.0%). l H n.m.r. 5 1.12-2.21, complex, 2.95, m, m \3 'A \5 \6 ';  
2.53, br s, CH2PI1; 3.66, s, ArCH2N; 7.22, complex, Ph; 8.00, s, H3,5.
2 .6 -  B i s (d ip e n ty la m in o m e th y l ) -4 - (7 ,- t r i f lu orom eth y lqu in azo l in -4 ,-y lamino)-  
p h e n o l  (III.16d)
2,6-Bis(dipentylaminomethyl)-4-nitrophenol (0.400 g) was dissolved in a mixture 
of ethanol (15.0 ml) and saturated ethanolic ammonia (15.0 ml), Raney nickel added and 
the mixture shaken with hydrogen until uptake ceased. The catalyst was filtered off on 
Celite and the product subjected to PTLC (alumina; chloroform) to give the amine (0.370 g) 
which was used directly in the next reaction. It had *H n.m.r. 5 0.87, br t, Me; 1.28, 
complex, NCH2CH2CH2CH2; 2.46, t, J 7 Hz, NCH2CH2; 3.58, s, ArCH2N; 6.50, s, 
H3,5.
Treatment of this product (0.131 g) and 4-chloro-7-trifluoromethylquinazoline 
(0.068 g) as described above (but refluxed for 8 h) gave a crude product which was 
purified by PTLC (alumina; ethyl acetate/hexane, 3:7) to give the title compound (0.053 g) 
as an oil which solidified on standing (Found: C, 68.9; H, 8.7. C37H56F3N5O requires C,
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69.0; H, 8.8%). lH n.m.r. 5 0.89, complex, Me; 1.27, complex, NCH2CH2CH2CH2; 
2.54, complex, NCH2CH2; 3.72, s, ArCH2N; 7.43, s, H3,5; 7.59, br, OH, NH; 7.71, 
dd, J5-,6’ 8.5 Hz, J6-,8' 1-5 Hz, H6’; 8.01, d, J5',6’ 8.5 Hz, H5’; 8.18, br s, H8'; 8.76, s, 
H2'.
2 .6- B i s (N -b u ty l -N -m e th y la m in o m e th y l ) -4 - (7 '- tr i f luorom ethylqu inazo l in -4 '  - 
y la m in o )p h en o l  (III.16e)
2,6-Bis(N-butyl-./V-methylaminomethyl)-4-nitrophenol (0.800 g) was reduced with 
hydrogen over Raney nickel as for the dipentylamino analogue above. After column 
chromatography (alumina, chloroform) it gave as an oil 4-amino-2,6-bis(Ar-butyl-,/V- 
methylaminomethyl)phenol (0.552 g) which was used directly in the reaction below. It had 
*H n.m.r. 5 1.68, br t, CH2Me; 2.22, complex, NCH2(CH2)2; 3.01, s, NMe; 3.20, t, J 7 
Hz, NCH2CH2; 4.30, s, ArCH2N; 7.22, s, H3,5.
The above crude phenol (0.149 g) and 4-chloro-7-trifluoromethylquinazoline (0.113 
g) [under similar reaction conditions to those described above but refluxed for 10 h and the 
crude product purified by PTLC (alumina; ethyl acetate/hexane, 1:3, developed twice] gave 
the title compound (0.102 g) (Found: C, 64.3; H, 7.5. C27H36F3N5O requires C, 64.4, 
H, 7.2%. *H n.m.r. 5 0.93, complex, CH2Me; 1.50, complex, NCH2CH2CH2; 2.29, s, 
NMe; 2.51, complex, NCH2CH2; 3.62, s, ArCH2N; 7.42, s, H3,5; 7.57, br, OH, NH; 
7.70, dd, J5',6' 8.5 Hz, J6-,8- 1.5 Hz, H6’; 7.99, d, J5'>6' 8.5 Hz, H5’; 8.16, s, H8’; 8.75, 
s, H2\
2 .6 -  B is (p yrro l id in - l  ,- y lm e th y l ) -4 - (7 ,,- t r i f lu orom eth y lqu in azo l in -4”-yl- 
am in o)pheno l  (III.16f)
A similar reaction of 4-amino-2,6-bis(pyrrolidin-r-ylmethyl)phenol172 (0.139 g) 
and 4-chloro-7-trifluoromethylquinazoline (0.118 g), but refluxed for 6 h, gave a crude 
product which was purified by PTLC (alumina; chloroform) to give the title compound as a 
yellow oil (0.083 g) (Found: C, 63.7; H, 6.2, F, 11.9; N, 14.5. C25H28F3N5O requires 
C, 63.7; H, 6.0; F, 12.1; N, 14.8%). *H n.m.r. 8 1.79, complex, H3',4'; 2.60, complex, 
H2',5'; 3.74, s, ArCH2N; 7.37, s, H3,5; 7.64, br d, J5",6» 9 Hz, H6"; 8.10, br d, J5">6" 9
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Hz, H5"; 8.14, br s, H8"; 8.36, br, OH, NH; 8.72, s, H2M. I.r. vmax 3320 (br) (OH st 
and NH st), 2970 (m) (CH2 st), 1580 (s), 1480 (s), 1320 (s), 1130 (s) cm-1.
2 .6 -  B i s (d im e th y la m in o m eth y l ) -4 - (7 ,- t r i f lu o ro m eth y lq u in a zo l in -4 ,-yl-  
am in o)pheno l  (III.16a)
A mixture of 4-amino-2,6-bis(dimethylaminomethyl)phenol172 (0.214 g), 4-chloro- 
7-trifluoromethylquinazoline (0.223 g), methanol (1.5 ml), water (0.4 ml) and concentrated 
hydrochloric acid (2 drops) was refluxed at 90° for 5 h. The solvent was evaporated under 
reduced pressure, the residue diluted with water and neutralised with dilute ammonium 
hydroxide. The product was extracted into chloroform, the extract dried (Na2S04) and the 
solvent evaporated. The cmde product was purified by PTLC (alumina; 0.5% methanol in 
chloroform) to give 2,6-bis(dimethylaminomethyl)-4-(7,-trifluoromethylquinazolin-4'-yl- 
amino)phenol (0.262 g) as an oil (Found, for a sample dried at 120°/0.2 mmHg for 5 h: C, 
60.4; H, 6.1; N, 16.8. C2iH24F3N50  requires C, 60.1; H, 5.8; N, 16.7%). n.m.r. 5 
2.28, s, Me; 3.55, s, CH2N; 7.36, s, H3,5; 7.64, br d, J5->6' 8.5 Hz, H6’; 8.11, br s, H8’; 
8.16, br d, J5-,6' 8.5 Hz, H5’; 8.73, s, H2\ I.r. vmax 3700-2400 (br) (OH st and NH st), 
1580 (s), 1485 (s), 1465 (s), 1320 (s), 1145 (s) cm’1.
2 .6 -  B is (d ie th y la m in o m e th y l ) -4 - (7 ,- t r i f lu orom eth y lqu in azo l in -4 ,-y lamino)- 
p h e n o l  (III.16b)
4-Amino-2,6-bis(diethylaminomethyl)phenol172 (0.117 g) and 4-chloro-7-trifluoro- 
methylquinazoline (0.097 g) were allowed to react as for the analogue above. The crude 
product was purified by PTLC (alumina; 7% methanol in methylene chloride) and the 
product (0.154 g) was crystallised from a mixture of methylene chloride and light petroleum 
(b.p. 60-80°) to give the title compound m.p. 75-85°. (Found, for a sample dried at 
20°/0.2 mmHg for 24 h: C, 62.3; H, 7.0, N, 14.4. C25H32F3N5O.0.3H2O requires C, 
62.4; H, 6.8; N, 14.5%). !H n.m.r. 5 1.07, t, J 7 Hz, Me; 2.61, q, J 7 Hz, CH2Me; 
3.69, s, ArCH2N; 7.40, s, H3,5; 7.65, br d, J5-i6' 8.5 Hz, H6’; 8.09, br d, J5',6’ 8.5 Hz, 
H5'; 8.13, br s, H8'; 8.73, s, H2’. U.v. Xmax (pH 6.7) 206 nm (log 8 4.73), 246-248
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nm (log e 4.12), 316 nm (log e 3.98). MS m/z 475 (M+), 446 (2.4%), 403 (1.4%), 373 
(9.3%), 331 (11.0%), 197 (3.9%), 170 (2.8%).
2 .6 -  Bis( d ip ro p y la m in o m e th y l ) -4 - (7 ,- t r i f lu orom eth y lqu in azo l in -4 ,-y lamino )- 
p h e n o l  (III.16c)
4-Amino-2,6-bis(dipropylaminomethyl)phenol172 (0.123 g) and 4-chloro-7-tri- 
fluoromethylquinazoline (0.086 g) were allowed to react as above. The crude product was 
purified by PTLC (alumina; chloroform, developed twice and then alumina; 1% methanol in 
chloroform) to give the title compound (0.156 g) (Found: C, 64.3; H, 7.8; N, 12.8. 
C29H40F3N5O.O.5 H20  requires C, 64.4; H, 7.6; N, 12.9%). n.m.r. 5 0.87, t, J 7 
Hz, Me; 1.49, complex, CH2Me; 2.48, complex, NCH2CH2; 3.69, s, AJCH2N; 7.42, s, 
H3,5; 7.66, br d, J5 >6’ 8.5 Hz, H6 '; 7.84, br s, NH; 8.07, br d, J5-,6' 8.5 Hz, H5'; 8.14, 
br s, H8 ', OH; 8.74, s, H2'. I.r. vmax 3500 (br) (H20), 2970 (w) (CH aliph st); 1580 
(m), 1480 (s), 1130 (s) cm-1.
2 .6- B is (p ip e r id in - l  ,- y lm e th y l ) -4 - (7 ,,- t r i f lu orom eth y lqu in azo l in -4”-yl- 
am in o)pheno l  (III.16g)
The product from 4-amino-2,6-bis(piperidin-l'-ylmethyl)phenol172 (0.240 g) and 
4-chloro-7-trifluoromethylquinazoline (0.184 g) when refluxed as above (but for 5 h) and 
purified by PTLC (alumina; chloroform and alumina; 0.5% methanol in chloroform) gave 
as an oil the title compound (0.197 g) (Found: C, 62.9; H, 6 .8; N, 13.3. C27H32F3N5O. 
H2O requires C, 62.6; H, 6 .6 ; N, 13.5%). *H n.m.r. 8 1.51, complex, H3',4',5'; 2.49, 
complex, H2',6'; 3.60, s, ArCH2N; 7.37, s, H3,5; 7.67, br d, J5">6" 8.5 Hz, H6"; 7.79, 
br s, OH, NH; 8.03, br d, J5">6" 8.5 Hz, H5"; 8.15, br s, H8"; 8.74, s, H2". I.r. vmax 
3360 (br) (OH st and NH st), 2940 (m) (CH2 st), 1580 (s), 1480 (s), 1320 (s), 1130 
(s), cm-1.
2 .6 -  B is(3 '~m ethy lp iper id in- l  ,- y lm e th y l ) -4 - (7 ”- tr i f luorom ethylqu inazo l in -  
4"-y lam ino)phenol  (III.16h)
This compound was prepared similarly from 4-amino-2,6-bis(3'-methylpiperidin- 
l'-ylmethyl)phenol172 (0.227 g) and 4-chloro-7-trifluoromethylquinazoline (0.159 g) and
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the crude yellow solid was subjected to PTLC (alumina; 0.3% methanol in chloroform) to 
give the title compound (0.318 g) (Found, for a sample dried at 120°/0.2 mmHg for 5 h: C, 
64.7; H, 7.0; N, 12.8. C29H36F3N 5O.O.65 H20  requires C, 64.6; H, 7.0; N, 13.0%) 
!H n.m.r. 5 0.86, d, J 5.5 Hz, Me; 1.65, complex, H3',4',5'; 2.85, complex, H2',6'; 
3.62, s, ArCH2N; 7.38, s, H3,5; 7.67, br d, J5”>6" 9 Hz, H6"; 7.67, br, OH, NH; 8.02, 
br d, J5",6" 9 Hz, H5M; 8.15, br s, H8”; 8.75, s, H2". I.r. v max 3400 (br) (H20 ), 2940 
(w) (CH aliph st), 1580 (s), 1480 (s), 1320 (m), 1130 (m) cm-1.
4 .6 -  B i s ( 3 f, 5 f-d im e th y lp ip e r id in - l  ,- y lm e th y l ) - 4 - (7 ”- tr i f luorom ethylqu inazo-  
l in - 4 ”-y lam ino)phenol  (III. 16i)
The 3',5'-dimethyl analogue was prepared from 4-amino-2,6-bis(3',5'-dimethyl- 
piperidin-l'-ylmethyl)phenol172 (0.290 g) and 4-chloro-7-trifluoromethylquinazoline 
(0.188 g). The product was subjected to PTLC (alumina; 20% ethyl acetate in hexane) to 
give the title compound (0.223 g) (Found: C, 66 .8; H, 7.6; N, 12.5. C31H40F3N 5O 
requires C, 67.0; H, 7.3; N, 12.6%). *H n.m.r. 5 0.85, complex, Me; 1.65, complex, 
H3',4',5'; 2.90, complex, H 2\6’; 3.60, s, ArCH2N; 7.36, s, H3,5; 7.65, br d, J5»>6» 8.5 
Hz, H6"; 8.09, br d, J5»,6" 8.5 Hz, H5”; 8.14, br s, H8”; 8.72, s, H2". I.r. v max 2960 
(w) (CH aliph st), 1580 (m), 1475 (m), 1320 (m), 1130 (m) cnr1.
2 .6 -  B is (4 ' -m e th y lp ip e r id in - l  ,- y lm e th y l ) -4 - (7 f,- t r i f luorom ethylqu inazo l in -  
4 " -y lamino)phenol  (III.16j)
The 4-methyl isomer was prepared similarly from 4-amino-2,6-bis(4'-methyl- 
piperidin-r-ylmethyl)phenol172 (0.309 g) and 4-chloro-7-trifluoromethylquinoline (0.217 
g), it precipitated as a yellow solid, and purified by PTLC (alumina; 25% ethyl acetate in 
hexane) to give the title compound (0.182 g) (Found: C, 65.9; H, 7.1; F, 10.4; N, 13.0. 
C29H36F3N 5O requires C, 66.0; H, 6.9; F, 10.8; N, 13.3%). A sample of this product 
was dissolved in dilute hydrochloric acid and reprecipitated by addition of ammonium 
hydroxide to pH 9. The solid was filtered off, washed with water and dried in the air. It 
melted at ca 130° (Found: C, 64.0; H, 7.4; N, 12.7. C29H36F3N5 0 .H20  requires C, 63.8; 
H, 7.0; N, 12.8%). *H n.m.r. 5 0.91, br s, Me; 1.47, complex, 2.04, br t, J 11 Hz,
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2.93, br d, J 11 Hz, H2,,3,,4,,5’,6’; 3.59, s, ArCH2N; 7.35, s, H3,5; 7.64, br d, J5",6" 
8.5 Hz, H6M; 8.08, br d, J5")6» 8.5 Hz, H5M; 8.04, br s, OH, NH; 8.13, br s, H8"; 8.72, 
s, H2". I.r. vmax 2980 (w) and 2950 (w) (CH aliph st), 1590 (m), 1485 (m), 1330 (m),
1140 (m) cm-1.
4,6-Bis(4’-benzylpiperidin-l ,-ylmethyl)-4-(7"-trifluoromethylquinazolin- 
4 ,,-ylamino)phenol (III.16k)
2,6-Bis(4'-benzylpiperidin-r-ylmethyl)-4-nitrophenol (0.260 g) in ethanolic 
ammonia was reduced as described above to give the corresponding amino compound 
(0.127 g). *H n.m.r. 6 1.16-2.37, complex, 2.95, m, H2',3',4',5',6'; 2.52 br s, 
CH2Ph; 3.53, s, ArCH2N; 6.46, s, H3,5; 7.21, complex, Ph.
The above crude phenol (0.127 g) and 4-chloro-7-trifluoromethylquinazoline (0.061 
g) were allowed to react under conditions similar to those described above and the crude 
product was purified by PTLC (alumina, dichloromethane) to give the title compound 
(0.085 g), m.p. 98-1020 (Found: C, 72.2; H, 6.8, N, 10.1. C41H44F3N5O. 0.2H2O 
requires C, 72.1; H, 6.6; N, 10.2%). *H n.m.r. 5 1.12-2.23, complex, 2.98, m, 
H2',3',4',5',6'; 2.54, br s, CH2Ph; 3.64, s, ArCH2N; 7.22, complex CH2Ph; 7.40, s, 
H3.5; 7.68, br d, J5",6» 8.5 Hz, H6M; 8.00, br d, J5»>6» 8.5 Hz, H5"; 8.16, br s, H8M; 
8.74, s, H2".
N*-(4’-Diethylamino-1'-methylbutyl)-7-trifluoromethylquinazolin-4-amine 
(III.18)
A mixture of 4-chloro-7-trifluoromethylquinazoline (0.070 g), A ^^-diethyl- 
pentane-1,4-diamine (0.6 ml; 0.490 g) and heptane (1.4 ml) was heated in a teflon lined 
screw-top reaction vessel at 140° for 20 h. The solvent was evaporated and the product 
subjected to PTLC (alumina; 30% ethyl acetate in hexane, developed twice) to give the title 
compound (0.082 g), m.p. 89-91° (Found: C, 60.8.; H, 7.1; N, 15.6. C isH25F3N4 
requires C, 61.0; H, 7.1; N, 15.8%). *H n.m.r. 5 1.03, t, J 7 Hz, MeCH2; 1.34, d, J 6.5 
Hz, MeCH; 1.68, complex, CH2CH2CH2N; 2.47, complex, CH2CH2CH2N; 2.55, q, J 7
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compound (0.082 g), m.p. 89-91° (Found: C, 60.8.; H, 7.1; N, 15.6. C18H25F3N4 
requires C, 61.0; H, 7.1; N, 15.8%). *H n.m.r. 5 1.03, t, J 7 Hz, MeCH2; 1.34, d, J 6.5 
Hz, MeCH; 1.68, complex, CH2CH2CH2N; 2.47, complex, CH2CH2CH2N; 2.55, q, J 7 
Hz, MeCH2; 4.50, complex, MeCH; 6.75, br d, NH; 7.59, dd, 15,6 9 Hz, J6,8 1-5 Hz; 
H6; 7.93, br d, J5)6 9 Hz, H5; 8.09, br s, H8; 8.69, s, H2.
III-8.2 Determination of the basic ionization constant of 7-trifluoro- 
methylquinazolin-4-ol (III.13)
Substance: 7-Trifluoromethylquinazolin-4-ol 
C9H5F3N20; MW 214.146
Concentration: 1.0 x 10'4 M. Recrystallised compound, m.p. 227-228°, was dried at 
20° and 0.2 mmHg overnight and 0.0107 g was dissolved in warm ethanol (5.0 ml) then 
made up to 500.0 ml with water. This stock solution (3.0 ml) was diluted with relevant 
buffer (1.0 ml).
Analytical wavelength: 316 nm; cell, 1 cm
Buffer: Hydrochloric acid and sulphuric acid buffer (1=0.1)
Species: Neutral and cationic species
Temperature: 20°
Result:
Hq value: 2.0 1.8 1.6 1.4 1.2 0.98 0.8 0.6
pKa calc.: 1.51 1.48 1.42 1.39 1.41 1.36 1.46 1.4
pKa =1.43 ± 0.08
CHAPTER IV
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CHAPTER IV 4’-ChIoro-3-(substituted amino)methyl-5-[7-substituted 
quinolin (quinazolin and l,5-naphthyridin)-4-ylamino]biphenyl-2-ols
IV -1 Introduction
Werbel e ta /.,101 in 1986, described the syntheses, antimalarial activity (against 
P. berghei infections in mice) and semi-quantitative structure-activity relationships of 3-(f- 
butylaminomethyl)-4’-chloro-5-(7-chloroquinolin-4-ylamino)biphenyl-2-ol, "Tebuquine" 
(IV. 1), a series of analogues, and their /V-oxides.
The high antimalarial activities shown by "Tebuquine" and the 
antimalarial amodiaquine86 (IV.2) both of which contain mono-Mannich base side chains, 
and the antimalarial activity of the di-Mannich bases recently reported by Barlin and 
coworkers,95’97’98 prompted the present work to prepare analogues of "Tebuquine", such 
as compounds IV.3, IV.4, IV.5 and IV.6, which incorporated different heterocyclic 
nuclei.
The syntheses and physical properties of these compounds are discussed in this 
chapter, and the results of testing for antimalarial activity in in vitro tests against 
P . falciparum and in vivo tests against P. vinckei vinckei in mice are presented in Chapter 
VIII.
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IV.3 Y=CH IV.5 X=Br
IV.4 Y=N IV.6 X=CF3
IV-2 Literature Preparations of 4'-Chloro-5-nitrobiphenyI-2-ol, iV-(4'- 
Chloro-4-hydroxybiphenyl-3-yl)acetamides and "Tebuquine".
Werbel et a/.101 in their synthesis of "Tebuquine" and its analogues, used as 
intermediates the V-(4-hydroxybiphenyl-3-yl)acetamides such as V-(4'-chloro-4- 
hydroxybiphenyl-3-yl)acetamide (IV.12), and its preparation was described by two routes 
(Scheme IV-1).
Route A, (Scheme IV-1) involved the nitrosation209 of 4'-chlorobiphenyl-2-ol 
(IV.7) (prepared by an Ullmann reaction between l-chloro-4-iodobenzene and l-iodo-2- 
methoxybenzene to give 4'-chloro-2-methoxybiphenyl,101’210 followed by 
hydrolysis101»211 of the methoxy group) with sodium nitrite in aqueous acetic acid to give 
2-(4-chlorophenyl)-2,5-cyclohexadiene-l,4-dione 4-oxime (IV.8). Reduction of 
compound IV.8 with sodium dithionite gave the amino compound IV. 11 which was 
acetylated with acetic anhydride to afford the acetamide (IV.12).
The alternative, route B (Scheme IV-1), was superior to route A,101 in terms of 
yield, availability of starting materials, and wide applicability to the syntheses of 
multisubstituted aromatic ring systems from aliphatic components. It was first reported by 
Hill and Hale in 1905.212 Thus condensation of l-(4-chlorophenyl)-2-propanone (IV.9) 
with sodium nitromalonaldehyde hydrate in the presence of sodium hydroxide gave the 
nitrobiphenyl (IV.10). Catalytic hydrogeneration of the nitro compound (IV.10) gave the
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corresponding amino compound (IV. 11) which with acetic anhydride, afforded the 
acetamide (IV.12).
Route A : Route B :
+ Na+
CHO
<Sno2
CHO
NaN02/aq. AcOH aq. NaOH
N-OH
IV.8 IV .10
IV .11
Ac20
NHCOMe
IV .12
Scheme IV-1
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The N-(4'-chloro-6-hydroxybiphenyl-3-yl)acetamide (IV.12) was then subjected to 
the Mannich reaction with r-butylamine and formaldehyde to give the mono-Mannich base 
(IV.13; NR1R2=NHCMe3). Hydrolysis of this compound gave the free amine (IV.14; 
NR1R2=NHCMe3) which was then condensed with 4,7-dichloroquinoline to afford 
"Tebuquine" (IV.l).
IV.13 X=COMe 
IV.14 X=H
IV-3 Syntheses of 4'-Chloro-3-(substituted amino)methyl-5-[7-substi- 
tuted quinolin (quinazolin and l,5-naphthyridin)-4-ylamino]biphenyl-2-oIs
In the present work, the 5-amino-4'-chloro-3-(substituted aminomethyl)biphenyl-2- 
ols (IV. 14) required for the synthesis of "Tebuquine" analogues were prepared from 4- 
chlorobenzyl cyanide (IV. 15) through a-acetyl-a-(4-chlorophenyl)acetonitrile (IV.16)213 
and l-(4-chlorophenyl)propan-2-one (IV.9) (Scheme IV-2) and 4'-chloro-5-nitrobiphenyl- 
2-ol (IV. 10) by literature procedures.101 The last compound (IV. 10) was then subjected 
to the Mannich reaction to give compounds IV. 17 which were subsequently reduced to 
compounds IV.14. This differs from the procedure used by Werbel and coworkers,101 
(and described above) in which the Mannich reactions were conducted on the acetamido 
compounds (IV.12).
The amino compounds (IV.14) were then condensed with the relevant 4-chloro 
heterocycles to give the "Tebuquine" analogues.
Cl
n, EtOAc/NaOEt V cone. H2S 0 4
K c h 2cn " ^ C H C O M e
CN
U 1
I V . 15 I V . 16 I V .9
CH2COMe
(CH20 ) n
h n r ! r 2
CHO
Na+ (!:-n o 2
^HO
I V . 10
IV.3, IV.4, IV.5 and IV.6
IV.3, IV.4, IV.5, IV.6, IV.14 and IV.17
N R XR2 N R XR2
a NEt2 e 3-methyl piperidin-l-yl
b NHBu* f 4-methylpiperidin-l-yl
C pyrrolidin-l-yl g 4-benzyIpiperidin-l-yl
d piperidin-l-yl h 4-benzylpiperazin-l-yl
Scheme IV-2
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Thus compound IV. 15 with ethyl acetate in the presence of sodium ethoxide in 
ethanol at reflux for 3 h,214 gave compound IV.16, which in concentrated sulphuric 
acid214 was hydrolysed and decarboxylated to compound IV.9.
The ketone compound IV.9 with sodium a-nitromalonaldehyde hydrate215 in a 
mixture of ethanol and N sodium hydroxide at room temperature for 24 h, gave 4'-chloro-5- 
nitrobiphenyl-2-ol (IV.10). Under the conditions of the Mannich reaction,172 the nitro 
compound (IV.10) underwent reaction with paraformaldehyde and amines (such as 
diethylamine, r-butylamine, pyrrolidine, piperidine, 3- and 4-methylpiperidine, 4-benzyl- 
piperidine and 4-benzylpiperazine) in refluxing ethanol for 15-20 h to afford good yields of 
4'-chloro-5-nitro-3-(substituted amino)methylbiphenyl-2-ols (IV.17).
The nitro compounds (IV.17) dissolved easily in ethanolic ammonia, and were 
reduced therein with hydrogen in the presence of Raney nickel to give the corresponding 
amines (IV. 14) by the general procedures described by Barlin and Ireland.172 These 
amines (IV. 14) were condensed subsequently with 4-chloro-7-trifluoromethylquinoline, 4- 
chloro-7-trifluoromethylquinazoline or 7-bromo (or 7-trifluoromethyl)-4-chloro-l,5-naph- 
thyridine in refluxing aqueous methanol (containing a little hydrochloric acid) for 5-8 h, to 
give the mono-Mannich base derivatives (IV.3, IV.4, IV.5 and IV.6) of 4'-chloro-5-[7- 
trifluoromethylquinolin (and quinazolin)-4-ylamino]biphenyl-2-ols and 4'-chloro-5-[7- 
bromo (and 7-trifluoromethyl)-l,5-naphthyridin-4-ylamino]biphenyl-2-ols, respectively.
IV-4 Physical Properties
IV-4.1 XH Nuclear magnetic resonance spectra
The iH n.m.r. spectra of nitro compounds (IV.17a and b) and amino compounds 
(IV.14a and b) are given in Table IV-1. Inspection of the data revealed that the protons 
(H4 and H6) of the phenolic ring of the nitro compounds (IV. 17a and b) appeared at 
lower field by ca 0.5 ppm relative to those of the corresponding amino compounds 
(IV. 14a and b), due to the strong electron-withdrawing power of the nitro group 
compared to the electron-donating properties of the amino group. Similarly, the methylene 
protons of the Mannich side chain in these nitro compounds (IV.17a and b) were at lower
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field by 0.22 ppm; the reduced effect reflected the greater spacial separation of the 
interacting groups.
Table IV-1 Chemical shifts (8)a of some mono-Mannich base derivatives of 
4'-chloro-5-nitro (and 5-amino)biphenyl-2-ols
3 '
Compound Z N R ! r 2 A lkyl Group CH2 N H4 H6
I V . 1 7 a N O 2 N Et2 1.16, Me; 2 .73 , M eC H 2 3.94 7 .40 , 7 .58 7 .92 8.18
I V . 1 7 b N O 2 NH Bu1 1.27, M e 4 .0 9 7 .42 , 7 .57 7.98 8 .16
I V . 1 4 a n h 2 NEt2 1.09, 1 .17 ,Me; 3 .72 7 .34 , 7 .54 6 .40 6 .60
2 .62 , M eC H 2
I V . 1 4 b N H 2 N H Bu1 1.19, M e 3 .87 7 .3 4 ,.7 .5 2 6 .42 6 .59
a Reported as parts per million (5) downfield from tetramethylsilane (TMS) as 
internal standard in deutrochloroform (CDCI3) solution.
As expected the signals due to the protons H2\3',5,,6' (and the alkyl groups in the 
Mannich side chain) did not show large differences between the nitro and amino 
compounds, and the H2',3',5', and 6' protons revealed an AA'BB' pattern.
Inspection of the *H n.m.r. spectra of the "Tebuquine" analogues (IV.6) reported 
in the Experimental section revealed that, like the di-Mannich base derivatives of 4-(7-tri- 
fluoromethyl-l,5-naphthyridin-4-ylamino)phenol described in Chapter II, the proton at 
position 6 of the naphthyridine ring was the most deshielded (8 8.93-8.95) whereas the 
most shielded proton was that at position 3 (8 6.98-7.01). The signal due to H8 (8 8.54- 
8.58) was also slightly upfield of that due to H2 (8 8.57-8.61). The methylene protons of 
the Mannich side chains appeared in the range 8 3.77-4.05.
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The lH  n.m.r. spectra of the compounds IV.3, IV.4 and IV.5 are also reported 
in the Experimental section.
IV-4.2 Ultraviolet, infrared and mass spectra
The ultraviolet spectrum of a-acetyl-a-(4-chlorophenyl)acetonitrile (IV.16) was 
measured at pH 3.42 (The spectrum did not change in the range pH 3.0-3.5). At this pH, 
the compound was assumed to be the neutral molecule, and the spectrum consisted of two 
absorption maxima at 221 nm (log e 4.18) and 266 nm (log e 4.39).
The infrared spectrum of compound IV.16 displayed a strong absorption at 2133 
cm'1 due to C=N stretching and a medium absorption at 1632 cm-1, probably due to C=C 
stretching rather than C=0 stretching (which is normally a much stronged absorption band). 
Absorption peaks at 3130 (br) and 700 (br) cm-1, were probably due to the O-H stretching 
and O-H out of plane stretching, which may imply that compound IV. 16 exists as a 
mixture of keto and enol forms.
The nitro compound IV.17f (IV.17, NR1R2=4-methylpiperidin-l-yl), a 
representative of the Mannich nitro derivatives, displayed infrared absorptions due to O-H 
stretching at 3465 cm-1 and two absorption peaks due to NO2 stretching at 1495 and 1338 
cm'1. Likewise the quinazoline and naphthyridine; compounds IV.4f (IV.4; MUR2 = 4- 
methylpiperidin-l-yl) and IV.5f (IV.5; N R ^ 2 = 4-methylpiperidin-l-yl) showed 
absorptions due to O-H stretching at 3450 and 3470 cm'1, respectively.
The mass spectra of compounds IV.6a and IV.6f (IV.6 , NR1R2=NEt2 and 
4-methylpiperidin-l-yl; respectively) were examined. Each spectrum showed two 
molecular ion peaks associated with an M+l peak, the molecular ion peaks appeared at m/z 
500 (and 502) and 526 (and 528), for compounds IV.6a and IV.6f, respectively; with 
relative intensities of the lines in the ratio 3:1. As mentioned in Chapter II-6.3, this is 
characteristic of ions from chlorine containing compounds. Similar fragmentation of the 
Mannich N to C (benzylic) bond also occurred in these two compounds giving the same 
fragmentation peaks at m/z 427 for both compounds IV.6a and IV.6f.
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IV-5 Experimental
a-Acety l -a-(4-chlor ophenyl)ace to nitrile (IV. 16)
This compound was prepared213 from 4-chlorobenzyl cyanide. It had m.p. 120- 
122° (from toluene) (lit.213 124-125°) (Found, for a sample dried at 20°/0.2 mmHg for 20 
h: C, 62.4; H, 4.4; Cl, 18.1; N, 7.2. Calc, for C i0H8C1NO: C, 62.2, H, 4.2; Cl, 18.3; N 
7.2%). !H n.m.r. 5 2.30, s, Me; 4.65, s, CH; 7.31, d, 7.43, d, J 9 Hz, H2,,3,,5',6'. 
I.r. v max 3130 (br) (OH st ?), 2133 (s) (CEN st), 1632 (s) (C=C, C=0, st), 1499 (s), 
1356 (s) (OH st), 1091 (m), 1011 (w), 918 (w), 831 (s), 700 (br) (OH out of plane st). 
U.v. (pH 3.42) >.max 221 nm (log e 4.18), 266 nm (log e 4.39).
4 ,-Chloro-5-nitrobiphenyl-2-ol  (IV.10)
This compound was prepared from a-acetyl-a-(4-chlorophenyl)acetonitrile through 
l-(4-chlorophenyl)propan-2-one.101 It was purified by column chromatography (silica; 
benzene/methylene chloride) and by distillation: b.p. 78-80°/0.3 mmHg (lit.216 110-112°/6 
mmHg) (Found, for the distillate: C, 64.4; H, 5.5; Cl, 20.4. Calc, for C9H9CIO: C, 64.1;
H, 5.4; Cl, 21.0%). n.m.r. 5 2.18, s, Me; 3.68, s, CH2; 7.12, d, 7.31, d, J 9 Hz, 
H 2',3 ',5 ',6 '.
This last named compound and sodium a-nitromalonaldehyde hydrate,215 by a 
method similar to that described in detail for 5-nitro-3'-trifluoromethylbiphenyl-2-ol by 
Werbel et a /. ,101 gave the title compound, m.p. 163-165° (lit.101 161-163°) (Found: C, 
57.6; H, 3.0; N, 5.4. Calc, for C i2H8ClN0 3: C, 57.7; H, 3.2; N, 5.6%). JH n.m.r. 6
I. 56, s, OH; 7.08, d, J 9 Hz, H3; 7.42, d, 7.55, d, J 9 Hz, H2,,3’,5,,6’; 8.17, d, J 3 Hz, 
H6 ; 8.19, d, J 9 Hz, H4.
4*-Chloro-3-(diethylaminomethyl)-5-nitrobiphenyl-2-ol  (IV. 17a)
A mixture of paraformaldehyde (0.054 g), diethylamine (0.19 ml) and ethanol (2.0 
ml) was heated until it formed a clear solution. This mixture was chilled and 4'-chloro-5- 
nitrobiphenyl-2-ol (0.150 g) was added and the mixture refluxed at 95° for 16 h. After 
cooling, the yellow solid (0.261 g) was filtered off. The filtrate was subjected to PTLC 
(alumina; 26% ethyl acetate in hexane) to give a further 0.026 g of product. It was
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recrystallised from ethanol to give the yellow crystals of the title compound, m.p. 149-150° 
(Found: C, 60.7; H, 6.0; Cl, 10.4; N, 8.2. C17H19CIN2O3 requires C, 61.0; H, 5.7; Cl, 
10.6; N, 8.4%). *H n.m.r. 5 1.16, t, J 7.0 Hz, Me; 2.73, q, J 7 Hz, MeCH2; 3.94, s, 
CH2N; 7.40, d, 7.58, d, J 9 Hz, H2',3,,5',6'; 7.92, d, J 3 Hz, H4; 8.18, d, J 3 Hz, H6.
3- ( t -B uty lam inom eth yl ) -4 ' -ch loro-5 -n i t rob ipheny l -2 -o l  (IV. 17b)
Paraformaldehyde (0.144 g), r-butylamine (0.51 ml), ethanol (3.0 ml) and 4'- 
chloro-5-nitrobiphenyl-2-ol (0.40 g) were refluxed for 15 h and the precipitate (0.421 g) 
was filtered off. It was purified by PTLC (alumina; 40% ethyl acetate in hexane) and 
recrystallised from ethanol to give the title compound , m.p. 211-213°. The filtrate gave a 
further quantity (0.070 g) after PTLC (Found: C, 61.1; H, 5.9; N, 8.4. Ci7Hi9ClN203 
requires C, 61.0; H, 5.7; N, 8.4%). *H n.m.r. 5 1.27, s, Me; 3.06, br s, NH; 4.09, s, 
CH2; 7.42, d, 7.57, d, J 9 Hz, H2,,3,,5',6’; 7.98, d, J 3 Hz, H4; 8.16, d, J 3 Hz, H6.
4 f-C hloro -5 -n i t ro -3 - (pyrro l id in - l  ”-y lmethyl)biphenyl-2~ol  (IV. 17c)
In a similar manner from paraformaldehyde (0.144 g), pyrrolidine (0.39 ml), 
ethanol (4.0 ml) and 4'-chloro-5-nitrobiphenyl-2-ol (0.40 g) there was obtained after PTLC 
(alumina; 40% ethyl acetate in hexane) and recrystallisation from chloroform/methanol, 
yellow needles of the title compound (0.494 g), m.p. 155-156° (Found: C, 59.7; H, 5.3; 
N, 8.0. Ci7H i7C1N2O3.0.5 H20  requires C, 59.7; H, 5.3; N, 8.2%). JH n.m.r. 5 1.91, 
complex, H3",4"; 2.78, complex, H2",5"; 4.01, s, CH2; 5.24, br s, OH; 7.40, d, 7.58, d, 
J 9 Hz, H2',3,,5,,6'; 7.94, d, J 3 Hz, H4; 8.19, J 3 Hz, H6.
4 ,-C hloro-5 -n i t ro -3 - (p iper id in - l  ,f-y lm ethy l)b iphenyl -2-o l  (IV.17d)
This compound (0.478 g) was prepared from paraformaldehyde (0.086 g), 
piperidine (0.28 ml), ethanol (4.0 ml) and 4'-chloro-5-nitrobiphenyl-2-ol (0.40 g) by 
refluxing for 20 h. The crystalline solid (0.478 g) was purified by recrystallisation from 
ethanol and had m.p. 199-200° (Found: C, 62.0; H, 5.8; N, 8.1. Ci8Hi9ClN2C>3 requires 
C, 62.3; H, 5.5; N, 8.1%). *H n.m.r. 5 1.65, complex, 2.65, complex, H2",3",4",5",6"; 
3.84, s, ArCH2N; 7.41, d, 7.57, d, J 9 Hz, H2,,3',5,,6'; 7.91, d, J 3 Hz, H4; 8.17, d, J 
3 Hz, H6.
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4'-Chloro-3-(3”-methylpiperidin-1 ”-ylmethyl)-5-nitrobiphenyl-2-ol (IV.17e)
This compound was prepared similarly from paraformaldehyde (0.082 g), 
3-methylpiperidine (0.32 ml), ethanol (2.3 ml) and 4'-chloro-5-nitrobiphenyl-2-ol (0.40 g). 
The reaction mixture was evaporated and the viscous liquid purified by PTLC (alumina; 
30% ethyl acetate in hexane) to give the title compound (0.570 g) as a thick oil (Found: C, 
63.6; H, 6.0; N, 7.5. C19H21CIN2O3 requires C, 63.2; H, 5.9; N, 7.8%). *H n.m.r. 5 
0.91, d, J 6 Hz, Me; 1.72, complex, 3.00, complex, H2",3",4",5",6M; 3.84, s, ArCH2N; 
7.41, d, 7.59, d, J 9 Hz, H2',3,,5,,6'; 7.92, d, J 3 Hz, H4; 8.18, d, J 3 Hz, H6.
4 ,-Chloro-3-(4”-methylpiperidin-1 ”-ylmethyl)-5-nitrobiphenyl-2-ol (IV.17f) 
Paraformaldehyde (0.086 g), 4-methylpiperidine (0.34 ml), ethanol (4.0 ml) and 
4'-chloro-5-nitrobiphenyl-2-ol (0.40 g) refluxed for 20 h gave yellow crystals (0.504 g) 
which were recrystallised from ethanol/water to give the title compound, m.p. 135-137° 
(Found: C, 63.0; H, 6.1; N, 7.5. C19H21CIN2O3 requires C, 63.2; H, 5.9; N, 7.8%). *H 
n.m.r. 5 0.95, d, J 5 Hz, Me; 1.5, complex, 2.25, complex, 3.01, complex, H2",3",4", 
5",6”; 3.84, s, ArCH2N; 7.40, d, 7.58, d, J 9 Hz, H2,,3,,5',6'; 7.92, d, J 3 Hz, H4; 
8.16, d, J 3 Hz, H6. I.r. vmax 3465 (br w) (OH st), 2970 (w) (CH aliphatic st), 1597 (m) 
(aromatic st), 1495 (s) (NO2 st), 1460 (aromatic st), 1338 (s) (NO2 st), 1310 (br m), 838 
(m), 750 (m) cm-1.
3-(4 ,f-Benzylpiperidin-l ,,-ylmethyl)-4,-chloro-5-nitrobiphenyl-2-ol (IV.17g) 
Paraformaldehyde (0.062 g), 4-benzylpiperidine (0.37 ml), ethanol (2.0 ml) and 4'- 
chloro-5-nitrobiphenyl-2-ol (0.177 g) refluxed for 16 h and chilled gave a crystalline solid. 
This solid was filtered off, washed with light petroleum (b.p. 60-80°) and recrystallised 
from a mixture of methylene chloride and light petroleum to give the title compound (0.257 
g), m.p. 132-134° (Found: C, 68.7; H, 5.9; N, 6.4. C25H25CIN2O3 requires C, 68.7; H, 
5.8; N, 6.4%). *H n.m.r. 5 1.66, complex, 2.25, complex, 3.07, complex, H2",3",4", 
5”,6"; 2.54, d, J 6.5 Hz, CH2Ph; 3.86, s, ArCH2N; 7.23, m, Ph; 7.41, d, 7.57, d, J 9 
Hz, H2',3',5',6'; 7.92, d, J 3 Hz, H4; 8.18, d, J 3 Hz, H6 .
3 - ( 4 " -B enzylp iper  azin-1 " -y lmethy l) -4 ’-chloro-5-ni trob iphenyl-2-o l  
(IV.17h)
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Paraformaldehyde (0.097 g), /V-benzylpiperazine (0.56 ml), ethanol (3.5 ml) and 
4'-chloro-5-nitrobiphenyl-2-ol (0.30 g) were refluxed as above and gave, after 
concentration and dilution with chloroform, a yellow solid (0.458 g) which was filtered off 
and washed with ethanol. It was recrystallised from ethanol to give light yellow needles of 
the title compound, m.p. 135-136° (Found: C, 65.3; H, 5.9; N, 9.6. C24H24CIN3O3 0.2 
H20  requires C, 65.3; H, 5.6; N, 9.5%). *H n.m.r. 5 2.67, br, H2",3",5",6"; 3.57, s, 
CH2Ph; 3.87, s, ArCH2N; 7.41, d, 7.55, d, J 9 Hz, H2',3,,5,,6'; 7.31, s, Ph 7.94, d, J 3 
Hz, H4; 8.18, d, J 3 Hz, H6.
4 ,-Chloro-3 - (d ie thy lam inom ethyl ) -5 - (7 ,,- tr if luoromethylquinolin-4"-yl-  
amino)b ipheny l -2 -o l  (IV.3a)
4’-Chloro-3-(diethylaminomethyl)-5-nitrobiphenyl-2-ol (0.122 g) was dissolved in 
ethanolic ammonia (5.0 ml) and ethanol (5.0 ml) and shaken with hydrogen over Raney 
nickel until the yellow colour was discharged and hydrogen uptake ceased. The catalyst 
was filtered on Celite and the filtrate evaporated to give the crude amino compound (0.085 
g). *H n.m.r. 5 1.09, t, 1.17, t, J 7 Hz, Me; 2.62, q, 2xMeCH2; 3.72, s, ArCH2N; 5.29, 
br s, NH2; 6.40, d, J 3 Hz, H4; 6.60, d, J 3 Hz, H6; 7.34, d, 7.54, d, J 9 Hz, 
H 2',3 ',5 ',6 '.
This amine (0.10 g) and 4-chloro-7-trifluoromethylquinoline (0.076 g) in methanol 
(1.7 ml) and water (0.7 ml) with two drops of concentrated hydrochloric acid were refluxed 
for 8 h. The solvent was evaporated and the residue dissolved in water and adjusted by 
addition of ammonium hydroxide to pH 10, to give a yellow precipitate. This was the 
extracted into chloroform, the extract dried (Na2SC>4) and the solvent evaporated to give the 
crude product (0.162 g). It was purified by PTLC (alumina; 30% ethyl acetate in hexane), 
and recrystallised from acetonitrile to give yellow needles of the title compound, m.p. 213- 
215° (Found: C, 64.6; H, 5.4; N, 8.3. C27H25CIF3N3O requires C, 64.9; H, 5.0; N, 
8.4%). *H n.m.r. 5 1.16, t, J 7 Hz, Me; 2.70, q, J 7 Hz; MeCH2; 3.86, s, ArCH2N; 
6.79, d, J 5.5 Hz, H3M; 6.98, d, J 2.5 Hz, 7.20, d, J 2.5 Hz, H4,6; 7.38, d, 7.59, d, J 9
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Hz, H2',3',5',6'; 7.59, d, J 9 Hz, H6"; 8.08, d, J 9 Hz, H5"; 8.33, br s, H8”; 8.55, d, J
5.5 Hz, H2".
3-( t -B u ty lam inom eth y l ) -4 ,-ch loro -5 - (7”- tr i f luorom ethylqu ino l in -4 ,,-yl- 
amino)b ipheny l -2 -o l  (IV.3b)
3- (r-Butylaminomethyl)-4'-chloro-5-nitrobiphenyl-2-ol (0.230 g) in ethanolic 
ammonia (30.0 ml) and ethanol (10.0 ml) was reduced with hydrogen over Raney nickel as 
above to give the amine (0.190 g). *H n.m.r. 8 1.19, s, Me; 3.87, s, ArCH2N; 4.60, br s, 
NH2; 6.42, d, J 3 Hz, H4; 6.59, d, J 3 Hz, H6; 7.34, d, 7.52, d, J 9 Hz, H2’,3,,5,,6’.
4- Chloro-7-trifluoromethylquinoline (0.071 g) and the above amine (0.094 g) were 
allowed to react as described in the previous preparation. The crude product was purified 
by PTLC (alumina; 40% ethyl acetate in hexane, developed twice) to give the title 
compound (0.147 g), m.p. 92-98° (Found: C, 64.8; H, 4.8; N, 8.1. C27H25CIF3N3O 
requires C, 64.8; H, 5.0; N, 8.4%). lH n.m.r. 5 1.27, s, Me; 4.04, s, ArCH2N; 6.78, d, 
J 5.5 Hz, H3"; 7.03, d, 7.18, d, J 3 Hz, H4,6; 7.38, d, 7.57, d, J 9 Hz, H2,,3,,5,,6’; 
7.66; d, J 9 Hz, H6M; 8.10, d, J 9 Hz, H5"; 8.33, br s, H8"; 8.53, d, J 5.5 Hz, H2".
4 ’-C h lo ro -3 - (p yrro l id in - l  ”-y lm e thy l ) -5 - (7 ' '* - t r i f luorom ethy lqu in o l in -4 ’,f- 
y lam in o )b ip h en y l -2 -o l  (IV.3c)
4,-Chloro-5-nitro-3-(pyrrolidin-r,-ylmethyl)biphenyl-2-ol (0.250 g) in ethanolic 
ammonia (12.5 ml) and ethanol (12.5 ml) was reduced with hydrogen over Raney nickel to 
give the corresponding amine (0.187 g).
The above amine (0.101 g) and 4-chloro-7-trifluoromethylquinoline (0.077 g) were 
allowed to react as described earlier. The yellow precipitate (0.151 g) obtained after 
adjustment to pH 9 was subjected to PTLC (alumina; 30% ethyl acetate in hexane) and 
recrystallised from heptane to give the title compound, m.p. 210-214° (Found: C, 65.2; H, 
4.8; N, 8.3. C27H23CIF3N3O requires C, 65.1; H, 4.7; N, 8.4%). *H n.m.r. 8 1.87, 
complex, H3",4"; 2.71, complex, H2",5"; 3.92, s, ArCH2N; 6.79, d, J 5.5 Hz, H3M; 
6.98, d, J 3 Hz, 7.19, d, J 3 Hz, H4,6; 7.38, d, 7.58, d, J 9 Hz, H2,,3’,5,,6'; 7.66, d, J
8.5 Hz, H6 '"; 8.07, J 8.5 Hz, H5m; 8.32, br s, H8m; 8.56, d, J 5.5 Hz, H2"\
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4 ,-C h lo ro -3 - (p ip e r id in - l  ,,- y lm e th y l ) -5 - (7 , , , - t r i f lu o ro m eth y lq u in o l in -4 , , ,~ 
y lam in o)b iph en y l -2 -o l  (IV.3d)
4'-Chloro-5-nitro-3-(piperidin-l"-ylmethyl)biphenyl-2-ol (0.2 g) in ethanolic 
ammonia was reduced with hydrogen over Raney nickel as described above to give the 
corresponding amine (0.107 g).
This amine (0.076 g) and 4-chloro-7-trifluoromethylquinoline (0.056 g) as above 
gave a crude product which was purified by PTLC (alumina; 30% ethyl acetate in hexane) 
to give the title compound (0.112 g), m.p. 203-205° (Found: C, 65.9; H, 5.0; N, 8.0%. 
C28H25CIF3N3O requires C, 65.7; H, 4.9; N, 8.2%). *H n.m.r. 5 1.62, br, 2.60, br, 
H2",3",4",5",6"; 3.75, s, ArCH2N; 6.77, d, J 5.5 Hz, H3,M; 6.98, d, J 3 Hz, 7.19, d, J 
3 Hz, H4,6; 7.38, d, 7.58, d, J 9 Hz, H2,,3’,5,,6'; 7.67, d, J 5.5 Hz, H6 ,M; 8.17, d, J
5.5 Hz, H5"'; 8.33, br s, H8m; 8.53, d, J 5.5 Hz, H2m.
4 ,-C h lo ro -3 - (3 ”- m e t h y l p i p e r i d i n - l y l m e t h y l ) - 5 - ( 7 , , , - t r i f luorom eth y l - 
q u in o l in - 4 , , , -y lam in o)b ipheny l -2 -o l  (IV.3e)
4,-Chloro-3-(3"-methylpiperidin-l"-ylmethyl)-5-nitrobiphenyl-2-ol (0.2 g) was 
reduced as described above to give the amine (0.16 g).
This amine (0.080 g) and 4-chloro-7-trifluoromethylquinoline (0.056 g) as for the 
piperidino analogue gave the title compound (0.135 g), m.p. 197-200° (Found: C, 66.4; H, 
5.5; N, 7.9. C29H27CIF3N3O requires C, 66.2; H, 5.2; N, 8.0%). *H n.m.r. 5 0.90, d, J 
5 Hz, Me; 1.71, complex, 2.90, complex, H2",3",4",5",6"; 3.75, s, ArCH2N; 6.79, d, J
5.5 Hz, H3'"; 6.96, d, J 3 Hz, 7.19, d, J 3 Hz, H4,6; 7.38, d, 7.58, d, J 9 Hz, 
H2',3',5',6'; 7.77, d, J 9 Hz, H6"'; 8.06, d, J 9 Hz, H5’"; 8.32, br s, H8m; 8.56, d, J
5.5 Hz, H2"\
4 ' -C h lo ro -3 - (4 ”-m e th y lp ipe r id in - l  ”- y lm e th y l ) -5 - (7 , , , - t r i f luoromethyl-  
q u i n o l i n - 4 " ,-y la m in o)b iph en y l -2 -o l  (IV.3f)
4'-Chloro-3-(4"-methylpiperidin-l"-ylmethyl)-5-nitrobiphenyl-2-ol (0.04 g) was 
reduced as above to give the corresponding amine (0.038 g). *H n.m.r. 5 0.90, d, J 3 Hz,
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Me; 1.56, complex, 2.07, complex, 2.96, complex, H2",3",4",5",6"; 3.34, br s, 
ArCH2N; 5.80, br, NH2; 7.38, complex, H4,6,2’,3,,5,,6'.
This amine (0.11 g) and 4-chloro-7-trifluoromethylquinoline (0.077 g) as above 
gave the title compound (0.100 g), m.p. 175-178° (Found: C, 66.4; H, 5.5; N, 7.8. 
C29H27C1F3N30  requires C, 66.2; H, 5.2; N, 8.0%). *H n.m.r. 5 0.94, d, J 5 Hz, Me;
1.53, complex, 2.17, complex, 3.03, complex, H2",3",4",5",6"; 3.76, s, CH2N; 6.78, d,
J 5.5 Hz, H3’"; 6.95, d, J 3 Hz, 7.18, d, J 3 Hz, H4,6; 7.38, d, 7.58, d, J 9 Hz, 
H2',3',5',6'; 7.67, d, J 9 Hz, H6,M; 8.08, d, J 9 Hz, H5’"; 8.32, br, H8m; 8.56, d, J 
5.5 Hz, H2"\
3 - ( 4 n-B en zy lp iper id in - l  "-y lm e th y l ) -4 ’-ch lo ro -5 - (7 , n -tr i f luoromethyl-  
q u in o l in - 4 , , , -y lam in o)b ipheny l -2 -o l  (IV.3g)
3-(4"-Benzylpiperidin-l"-ylmethyl)-4'-chloro-5-nitrobiphenyl-2-ol (0.2 g) was 
reduced in a manner similar to that described above to give the corresponding amine. 
*H n.m.r. 6 1.58, complex, 2.04, complex, 2.98, complex, H2",3",4",5",6"; 2.50, d, J 6 
Hz, CH2Ph; 3.62, s, CH2N; 4.42, br, NH2; 6.37, d, J 3 Hz, H4; 6.59, d, J 3 Hz, H6; 
7.15, complex, Ph; 7.35, d, 7.53, d, J 9 Hz, H2,,3',5,,6'.
This amine (0.116 g) and 4-chloro-7-trifluoromethylquinoline (0.066 g) gave, as 
above, and after PTLC (alumina; methylene chloride), the title compound (0.161 g), m.p. 
112-115° (Found: C, 69.8; H, 5.3; N, 6.9. C35H3i C1F3N30  requires C, 69.8; H, 5.2; N, 
7.0%). *H n.m.r. 5 1.65, complex, 2.11, complex, 3.05, complex, H2",3",4",5",6";
2.53, d, J 6 Hz; CH2Ph; 3.74, s, CH2N; 6.77, d, J 5.5 Hz, H3'"; 6.96, d, J 3 Hz, 7.18, 
d, J 3 Hz, H4,6; 7.23, m, Ph; 7.38, d, 7.58, d, J 9 Hz, H2,,3,,5,,6'; 7.66, d, J 9 Hz, 
H6"'; 8.10, d, J 9 Hz, H5m; 8.32, br s, H8m; 8.52, d, J 5.5 Hz, H2,M.
3 - ( 4 n-B en zy lp ip era z in - l  ”-y lm e th y l ) -4 ' -ch loro -5 - (7 , , ' - t ri f luoromethyl-  
q u in o l in - 4 ,,f-y lam in o)b ipheny l -2 -o l  (IV.3h)
3-(4"-Benzylpiperazin-l"-ylmethyl)-4’-chloro-5-nitrobiphenyl-2-ol (0.281 g) was 
reduced as described above to the corresponding amine (0.252 g). *H n.m.r. 8 2.56, br,
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H2",3",5",6"; 3.51, s, CH2Ph; 3.66, s, ArCH2N; 4.59, br s, NH2; 6.40, d, J 3 Hz, H4; 
6.60, d, J 3 Hz, H6; 7.29, s, Ph, 7.35, d, 7.54, d, J 9 Hz, H2',3,,5,,6'.
This amine (0.140 g) and 4-chloro-7-trifluoromethylquinoline (0.080 g), as above, 
and the product purified by PTLC (alumina, methylene chloride) and recrystallised from a 
mixture of methylene chloride and hexane, gave pale orange crystals of the title compound 
(0.124 g), m.p. 188-1890 (Found: C, 67.5; H, 4.9; N, 9.1. C34H30CIF3N4O requires C, 
67.7; H, 5.0; N, 9.3%). *H n.m.r. 5 2.62, br, H2",3",5”,6"; 3.54, s, CH2Ph; 3.78, s, 
ArCH2N; 6.76, d, J 5.5 Hz, H3m; 7.00, d, J 3 Hz, 7.21, d, J 3 Hz, H4,6; 7.30, s, Ph, 
7.38, d, 7.55, d, J 9 Hz, H2',3,,5,,6’; 7.64, d, J 8.5 Hz, H6m; 8.22, d, J 8.5 Hz, H5m; 
8.33, br s, H8m; 8.47, d, J 5.5 Hz, H2m.
3-(t-Butylaminomethyl)‘4 ,-chloro-5-(7,,-trifluoromethylquinazolin-4"-yl- 
amino)biphenyl-2-ol (IV.4b)
Crude 5-amino-3-(r-butylaminomethyl)-4'-chlorobiphenyl-2-ol (0.102 g; prepared 
by reduction of the corresponding nitro compound) and 4-chloro-7-trifluoromethyl- 
quinazoline (0.078 g) in a mixture of methanol (1.8 ml), water (0.8 ml) and concentrated 
hydrochloric acid (2 drops) were refluxed at 100° for 8 h. The crude product (0.153 g) 
was subjected to PTLC (alumina; 35% ethyl acetate in hexane) and then reprecipitated from 
dilute acetic acid solution by addition of 0.9 N ammonium hydroxide to give the title 
compound, m.p. 180° (dec) (Found: C, 59.6; H, 4.9; N, 10.5. C26H24C1F3N4 0 .1.3 H20  
requires C, 59.6; H, 5.1; N, 10.7%). *H n.m.r. 5 1.30, s, Me; 4.01, s, CH2N; 7.46, 
complex, H4,6,2',3',5',6'; 7.66, d, J 9 Hz, H6"; 8.11, s, H8"; 8.14, d, J 9 Hz, H5"; 
8.68, s, H2".
In a similar manner the following compounds were prepared from 4-chloro-7- 
trifluoromethylquinazoline and 3-substituted-5-amino-4'-chlorobiphenyl-2-ols.
4'-Chloro-3-diethylaminomethyl-5-(7”-trifluoromethylquinazolin-4',-yl- 
amino)biphenyl-2-ol  (IV.4a)
The title compound (73%) had m.p. ca 110° [after PTLC (alumina; 34% ethyl 
acetate in hexane)] (Found: C, 62.4; H, 5.0; N, 11.2. C26H24C1F3N4 0  requires C, 62.3;
99
H, 4.8; N, 11.2%). *H n.m.r. 5 1.14, t, J 7 Hz, Me; 2.70, q, J 7 Hz, MeCH2; 3.87, s, 
CH2N; 7.42, s, H4,6; 7.36, d, 7.58, d, J 9 Hz, H2',3,,5,,6’; 7.57, d, J 9 Hz, H6"; 8.00, 
d, J 9 Hz, H5M; 8.17, br s, H8"; 8.76, s, H2".
4 f- C h l o r o - 3 - ( p y r r o l i d i n - l y l m e t h y l ) - 5 - ( 7 ' ” - t r i f luorom eth y lqu inazo l in - 
4 , , , - y la m in o )b ip h en y l -2 -o l  (IV.4c)
This compound (72%) had m.p. 115-120° [after PTLC (alumina; methylene 
chloride)] (Found: C, 62.8; H, 4.5; N, 10.9. C2oH22C1F3N4 0  requires C, 62.6; H, 4.4; 
N, 11.2%). *H n.m.r. 8 1.86, complex, 2.72, complex, H2",3",4",5"; 3.93, s, CH2N; 
5.53, br, NH; 7.42, s, H4,6; 7.37, d, 7.57, d, J 9 Hz, H2,,3,,5’,6’; 7.69, d, J 9 Hz, 
H6m; 8.02, d, J 9 Hz, H5"’; 8.17, br s, H8m; 8.76, s, H2,M
4 ' -C h lo ro -3 - (p ip e r id in - l  ,,- y lm e th y l ) - 5 - (7 " ,- t r i f luorom eth y lqu inazo l in -4 '" -  
y lam in o )b ip h en y l -2 -o l  (IV.4d)
The title compound (81%) had m.p. ca 135° with sublimation [after PTLC (alumina; 
30% ethyl acetate in hexane; then alumina; methylene chloride)] (Found: C, 63.0; H, 4.6; 
N, 10.6. C27H24C1F3N40  requires C, 63.3; H, 4.7; N, 10.9%). lH n.m.r. 5 1.59, 
complex, 2.60, complex, H2",3",4",5",6"; 3.78, s, CH2N; 4.42, br s, NH; 7.43, s, H4,6; 
7.38, d, 7.57, d, J 9 Hz, H2,,3,,5,,6’; 7.70, d, J 9 Hz, H6m; 8.03, d, J 9 Hz, H5m; 
8.17, br s, H8,M; 8.72, s, H2m.
4 ,-C h lo r o -3 - (3 ”-m e th y lp ip e r id in - l  ”- y lm e th y l ) -5 - (7 ,n - tr i f luorom eth y l - 
qu inazo l in~4 , , , -y lam in o)b ipheny l -2 -o l  (IV.4e)
The title compound (69%) had m.p. 118-122° [after PTLC (alumina; 30% ethyl 
acetate in hexane)] (Found: C, 63.8; H, 5.2; N, 10.3. C28H2öC1F3N40  requires C, 63.8; 
H, 5.0; N, 10.6%). *H n.m.r. 5 0.87, d, J 5.5 Hz, Me; 1.72, complex, 3.02, complex, 
H2",3",4",5",6"; 3.75, s, CH2N; 7.43, s, H4,6; 7.38, d, 7.59, d, J 9 Hz, H2,,3,,5’,6’; 
7.68, d, J 9 Hz, H6’"; 8.01, d, J 9 Hz, H5m; 8.19, br s, H8"’; 8.77, s, H2m.
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4 T-Chlor  o -3 - ( 4 ”-me thy lp iperidin-1  ”-y lm e th y l ) -5 - (7 , , , - t r i f luorom eth y l - 
q u in a zo l in -4 , , , -y lam in o)b ipheny l -2 -o l  (IV.4f)
This compound (56%) had m.p. 119-123° [after PTLC (alumina; 36% ethyl acetate 
in hexane)] (Found: C, 63.8; H, 5.0; N, 10.3. C28H26CIF3N4O requires C, 63.8; H, 5.0; 
N, 10.6%). *H n.m.r. 8 0.93, d, J 3.5 Hz, Me; 1.51, complex, 2.20, complex, 3.06, 
complex, H2",3",4",5",6"; 3.80, s, CH2N; 7.42, s, H4,6; 7.39, d, 7.58, d, J 9 Hz, 
H2',3',5',6'; 7.68, d, J 9 Hz, H6m; 8.01, d, J 9 Hz, H5’M; 8.19, br s, H8,M; 8.77, s, 
H2m. I.r. v max 3450 (br) (OH st), 2945 (w) (aliphatic CH st), 1584 (s), 1472 (m), 1184 
(ms), 1140 (s) (CF3 st), 1084 (m) cm-1.
3-(4 "-Benzy lp iperid in-1  ”-y lm e th y l ) -4 ,- c h lo ro -5 - (7 , , , - t r i f luoromethyl-  
q u in a z o l in - 4 " ,-y lam in o)b ipheny l -2 -o l  (IV.4g)
The title compound (78%) after PTLC (alumina; methylene chloride then alumina; 
80% methylene chloride in hexane, developed twice) had m.p. ca 140° (after filtration from 
dilute hydrochloric acid) (Found: C, 67.9; H, 5.3; N, 9.0. C34H30CIF3N4O requires C, 
67.7; H, 5.0; N, 9.2%). *H n.m.r. 8 1.62, complex, 2.14, complex, 3.07, complex, 
H2",3",4",5",6"; 2.52, d, J 5.5 Hz, CH2Ph; 3.78, s, CH2N; 7.41, s, H4,6; 7.39, d, 
7.58, d, J 9 Hz, H2',3',5,,6'; 7.69, d, J 9 Hz, H6m; 8.01, d, J 9 Hz, H5'"; 8.16, s, 
H8m; 8.75, s, H2m.
3 - ( 4 ,f-B en zy lp iperaz in - l  "-y lm e th y l ) -4 f-ch loro - 5 - (7 n , -t r i f luoromethyl-  
q u in a zo l in -4 ,,f-y lam ino)b ipheny l -2 -o l  (IV.4h)
This compound was obtained in 64% yield [after PTLC (alumina; 40% ethyl acetate 
in hexane)]. It was dissolved in dilute hydrochloric acid and reprecipitated with aqueous 
ammonium hydroxide to give a yellow solid, m.p. 144-150° (Found: C, 63.2; H, 4.7; N, 
10.9. C33H29CIF3N5O .I.4 H20  requires C, 63.0; H, 5.1; N, 11.1%). *H n.m.r. 8 2.71, 
complex, H2",3",5",6"; 3.63, s, CH2Ph; 3.83, s, CH2N; 7.44, complex, H4,6,2",3", 
5",6"; 7.73, d, J 9 Hz, H6'"; 8.06, d, J 9 Hz, H5”'; 8.19, br s, H8M'; 8.78, s, H2,M.
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3 - (4" -B en zy lp ipe r id in -1  ,- y l m e th y l ) - 5 - (7 , , , - b r o m o - l , 5 " ’-naphthyr id in-  
4 " ,-y l )am in o-4 ' -ch lorob iph en y l -2 -o l  (IV.5g)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine110 (0.059 g) and crude 5-amino- 
3-(4"-benzylpiperidin-l"-ylmethyl)-4’-chlorobiphenyl-2-ol [0.100 g, prepared by 
reduction, as above, of 3-(4"-benzylpiperidin-l"-ylmethyl)-4'-chloro-5-nitrobiphenyl-2-ol] 
in a mixture of methanol (1.8 ml), water (0.6 ml) and concentrated hydrochloric acid (2 
drops) was refluxed at 100° for 8 h. The product was isolated as above and purified by 
PTLC (alumina, methylene chloride) and recrystallised from a mixture of methylene 
chloride and hexane with concentration to give as a pale yellow solid the title compound 
(0.10 g), m.p. 169-170.5° (Found: C, 64.7; H, 4.8; N, 9.0. C33H3oBrClN4 0  requires C, 
64.6; H, 4.9; N, 9.1%). *H n.m.r. 6 1.63, complex, 2.09, complex, 3.04, complex, 
H2",3",4",5",6"; 2.49, d, J 5.5 Hz, CH2Ph; 3.73, s, CH2N; 6.90, d, J 5.5 Hz, H3m; 
6.96, d, 7.17, d, J 3 Hz, H4,6; 7.38, d, 7.58, d, J 9 Hz, H2,,3,,5,,6’; 8.21, br, NH; 
8.41, d, J 2 Hz, H8'"; 8.48, d, J 5.5 Hz, H2m; 8.72, d, J 2 Hz, H6,M.
In a similar manner the following compounds were prepared from the 
corresponding 3-bromo-8-chloro-l,5-naphthyridine110 and 3-substituted 5-amino-4'- 
chlorobiphenyl-2-ols.
5 - ( 7 ”-B rom o- l  ,,, 5 ”-naphthyr id in-4”-y lamino)’4 ' -chloro-3-die thylamino-  
m ethy lb ipheny l -2 -o l  (IV.5a)
The title compound was obtained in 96% yield after PTLC (alumina; 20% ethyl 
acetate in hexane). Recrystallisation from a mixture of ether and light petroleum (b.p. 60- 
80°) gave a pale yellow solid, m.p. 171-173° (Found: C, 59.0; H, 4.8; N, 11.1. 
C25H24BrClN4 0  requires C, 58.7; H, 4.7; N, 11.0%. *H n.m.r. 5 1.14, t, J 7 Hz, Me; 
2.68, q, J 7 Hz, MeCH2; 3.85, s, CH2N; 6.92, d, J 5.5 Hz, H3"; 7.00, d, 7.24, d, J 3 
Hz, H4,6; 7.38, d, 7.59, d, J 9 Hz, H2',y95\6'; 8.24, br, NH; 8.44, d, J 2 Hz, H8M; 
8.50, d, J 5.5 Hz, H2"; 8.75, d, J 2 Hz, H6M.
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5-(7  n-Bromo-1 u, 5 ”- t iaphthyr idin-4"-y lamino)-3-( t-buty laminomethyl)-4 '-  
ch lorob ipheny l-2-o l  (IV.5b)
The title compound (66%) had m.p. ca 97° [after PTLC (alumina; methylene 
chloride)] (Found: C, 58.7; H, 4.8; N, 10.8. C25H24BrClN40  requires C, 58.7; H, 4.7; 
N, 10.9%). 1H n.m.r. 8 1.23, s, Me; 3.98, s, CH2N; 6.87, d, J 5.5 Hz, H3"; 6.96, d, J 2 
Hz, 7.18, d, J 2 Hz, H4,6; 7.35, d, 7.56, d, J 9 Hz, H2,,3',5,,6'; 8.20, br, NH; 8.38, d,
J 2 Hz, H8"; 8.47, d, J 5.5 Hz, H2"; 8.70, d, J 2 Hz, H6".
5 - ( 7 ”-B rom o- l  ” , 5 ”-n aph th yr id in -4" -y lam in o) -4 ,-ch loro-3- (pyrro l id in- l  
y lm e th y l )b ip h en y l -2 -o l  (IV.5c)
This compound (68%) had m.p. 198-201° [from PTLC (alumina; 20% ethyl acetate 
in hexane)] (Found: C, 58.5; H, 4.3; N, 10.7. C25H22BrClN40  requires C, 58.9; H, 4.3; 
N,11.0%). !H n.m.r. 5 1.90, complex, H3M,,4m; 2.76, complex, H2,",5m; 3.96, s, 
CH2N; 6.95, d, J 5.5 Hz, H3"; 7.05, d, 7.27, d, J 3 Hz, H4,6; 7.40, d, 7.60, d, J 9 Hz, 
H2',3',5,,6'; 8.30, br, NH; 8.49, br s, H8"; 8.53, d, J 5.5 Hz, H2".
5 - ( 7 ”-B r o m o -1 ">5 ”-n aph th yr id in -4 ,,- y la m in o ) -4 ,-ch loro-3 - (p iper id in - l  
y lm e th y l )b ip h en y l -2 -o l  (IV.5d)
This title compound (91%) had m.p.173-1750 [after PTLC (alumina; 30% ethyl 
acetate in hexane, developed twice)] (Found: C, 59.5; H, 4.7: N, 10.4. C2öH24BrClN40  
requires C, 59.6; H, 4.6; N, 10.7%). *H n.m.r. 5 1.59, complex, 2.60, complex, 
H2"’,3’",4m,,5",,6"'; 3.75, s, CH2N; 6.92, d, J 5.5 Hz, H3"; 6.99, d, 7.24, d, J 3 Hz, 
H4,6; 7.37, d, 7.59, d, J 9 Hz, H2',3,,5,,6'; 8.24, br, NH; 8.47, s, H8"; 8.48, d, J 5.5 
Hz, H2M; 8.75, d, J 2 Hz, H6".
5 - ( 7 ,f-Bromo-1 ,,,5 " -n aph th yr id in -4 ,,- y la m in o ) -4 ,-ch lo ro -3 - (3 , , , -methyl-  
p i p e r i d i n - l , , , - y lm e th y l )b iph en y l -2 -o l  (IV.5e)
The title compound (78%) was obtained after PTLC (alumina; 30% ethyl acetate in 
hexane; then alumina; methylene chloride). It had m.p. 86-88° (Found: C, 60.3; H, 4.7; N, 
10.3. C27H26BrClN40  requires C, 60.3; H, 4.9; N, 10.4%). *H n.m.r. 8 0.90, d, J 5.5
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Hz, Me; 1.69, complex, 2.92, complex, H2m,3m,4m,5m,6,H; 3.75, s, C H 2N; 6.93, d,
J 5.5 Hz, H3"; 7.00, d, 7.24, d, J 3 Hz, H4,6; 7.39, d, 7.59, d, J 9 Hz, H2',3,,5',6'; 
8.24, br s, NH; 8.44, d, J 2 Hz, H8"; 8.51, d, J 5.5 Hz, H2”; 8.74, d, J 2 Hz, H6".
5- (7 " -B ro m o - l  ", 5 ”-n aph thyr id in -4"-y lam ino) -4 ' -ch loro-3 - (4 ’"-methyl-  
p i p e r i d i n - 1 ~ y l m e t h y l ) b i p h e n y l - 2 - o l  (IV.5f)
The title compound (95%) had m.p.207-209° [after PTLC (alumina; 33% ethyl 
acetate in hexane)] (Found: C, 60.5; H, 5.0; N, 10.3. C27H26BrClN40 requires C, 60.3; 
H, 4.9; N, 10.4%). !H n.m.r. 5 0.93, d, J 4.5 Hz, Me; 1.25, complex, 3.04, complex, 
H2,",3,",4",,5,",6,,,; 3.77, s, CH2N; 6.92, d, J 5.5 Hz, H3"; 7.00, d, 7.26, d, J 3 Hz, 
H4,6; 7.39, d, 7.58, d, J 9 Hz, H2,,3,,5',6’; 8.33, br, NH; 8.48, br s, H8"; 8.51, d, J 
5.5 Hz, H2"; 8.76, br s, H6". I.r. vmax 3470 (br) (OH st), 3390 (w) (NH st), 2964 (w) 
(aliphatic CH st), 1598 (m), 1570 (s), 1530 (m), 1502 (m), 1470 (s), 1370 (ms), 842 (m) 
cm*1.
3 - ( 4 ”-B e n zy lp ip e ra z in - l  y lm e th y l ) - 5 - ( 7 , , t - b r o m o - 1 f" , 5 ,r,-naphthyr id in-  
1 ,,r-y lam ino)~4'-ch lorob ipheny l-2-o l  (IV.5h)
This compound (81%) had m.p. ca 107-110° [after PTLC (alumina; methylene 
chloride; and alumina; 25% ethyl acetate in hexane, developed twice)] (Found: C, 62.5; H, 
4.8; N, 11.2. C32H29BrClN50  requires C, 62.5; H, 4.8; N, 11.4%). !H n.m.r. 6 2.66, 
complex, H2",3",5",6"; 3.56, s, PhCH2N; 3.80, s, ArCH2N; 6.92, d, J 5.5 Hz, H3m; 
7.02, d, 7.26, d, J 3 Hz, H4,6; 7.39, d, 7.58, d, J 9 Hz, H2,,3',5’,6’; 8.26, br, NH; 
8.46, d, J 2 Hz, H8"'; 8.50, d, J 5.5 Hz, H2m; 8.75, d, J 2 Hz, H6"\
4 ,-Chloro-3-d ie thy laminomethyl-5 - (7"‘tr i f luorom ethy l - l  "f5 ,f-naphthyridin-  
4 n-y lam ino)b ipheny l-2-o l  (IV.6a)
4'-Chloro-3-diethylaminomethyl-5-nitrobiphenyl-2-ol (0.122 g) was dissolved in 
half-saturated ethanolic ammonia (10.0 ml), and shaken with hydrogen over Raney nickel at 
room temperature until uptake ceased. The catalyst was filtered off on Celite, and the filtrate 
evaporated to give crude 5-amino-4'-chloro-3-diethylaminomethylbiphenyl-2-ol (0.085 g).
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This amine (0.085 g) and 4-chloro-7-trifluoromethyl-l,5-naphthyridine (0.061 g) in 
a mixture of methanol (1.5 ml), water (0.5 ml) and concentrated hydrochloric acid (3 drops) 
at pH 2.5 was refluxed at 95-100° for 5 h. The solvent was evaporated, the residue diluted 
with water (5.0 ml) and adjusted with 0.9 N sodium hydroxide to give a yellow precipitate. 
The product was extracted into chloroform, the extract washed with water, dried (Na2SÜ4), 
and the solvent evaporated to give a yellow oil. It was purified by PTLC (alumina; 20% 
ethyl acetate in hexane) to give the title compound (0.118 g), m.p. 140-142° (Found: C, 
62.6; H, 5.0; N, 11.1. C26H24CIF3N4O requires C, 62.3; H, 4.8; N, 11.3%). *H n.m.r. 
6 1.16, t, J 7 Hz, Me; 2.73, q, J 7 Hz, MeCH2; 3.88, s, CH2N; 7.01, d, J 5.5 Hz, H3M; 
7.04, 7.26, br s, H4,6; 7.38, d, 7.59, d, J 9 Hz, H2,,3',5,,6’; 8.36, br s, NH; 8.58, br s, 
H8"; 8.61, d, J 5.5 Hz, H2"; 8.95, d, J 2 Hz, H6". MS m/z 500 (9.4%), 502 (3.4%), 
501 (2.6%), 503 (0.9%), 427 (17.7%).
In a similar manner the following compounds were prepared from 4-chloro-7- 
trifluoromethyl-l,5-naphthyridine and the corresponding 3-substituted-5-amino-4’- 
chlorobiphenyl-2-ols.
3 - ( t ’B u ty lam in om eth y l ) -4 ,-ch loro-5 - (7”- tr i f luorom ethyl- l  ”, 5 ”-naphthy-  
r id in-4" -y lamino)b iphenyl-2-o l  (IV.6b)
The title compound (68%) after PTLC (alumina; 30% ethyl acetate/hexane) and 
reprecipitation from aqueous acid by neutralisation with ammonium hydroxide gave a 
yellow solid, had m.p.l89-192° (Found: C, 61.6; H, 4.6; N, 10.8. C26H24CIF3N4O. 
0.25 H20  requires C, 61.8; H, 4.9; N, 11.1%). *H n.m.r. 5 1.25, s, Me; 4.05, s, CH2N; 
7.14, d, J 5.5 Hz, H3"; 7.18, br s, 7.24, d, J 2 Hz, H4,6; 7.40, d, 7.59, d, J 9 Hz, 
H2',3',5',6’; 8.34, br s, NH; 8.54, d, J 2 Hz, H8"; 8.64, d, J 5.5 Hz, H2"; 8.95, d, J 2 
Hz, H6".
4 ' - C h l o r o - 3 - ( p y r r o l i d i n - l " - y l m e t h y l ) - 5 - ( T " - t r i f l u o r o m e t h y l - l " ' , 5 " ' -  
n a p h th y r id in -4 , , , -y lam in o)b ipheny l -2 -o l  (IV.6c)
The title compound (78%) [after PTLC (alumina; 20% ethyl acetate in hexane)] had 
m.p. 125-127° (Found: C,. 62.5; H, 4.3; N, 11.2. C26H22CIF3N4O requires C, 62.6; H,
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4.4; N, 11.2%). *H n.m.r. 5 1.89, complex, 2.73, complex, H2",3",4",5"; 3.93, s, 
CH2N; 7.01, d, J 5.5 Hz, H3m; 7.04, br s, 7.27, br s, H4,6; 7.38, d, 7.59, d, J 9 Hz, 
H2',3',5',6'; 8.32, br s, NH; 8.54, br s, H8m; 8.61, d, J 5.5 Hz, H2m; 8.93, br s, 
H 6 ,M.
4'-Chloro-3-(piperidin-1 ”-ylmethyl)-5-(7,, ,-trifluoromethyl-l fff,5 '” -naph- 
thyridin-4"'-ylamino)biphenyl-2-ol  (IV.6d)
This compound {11%) had m.p.165-1660 [after PTLC (alumina; 25% ethyl acetate 
in hexane)] (Found: C, 62.3; H, 4.8; N, 10.6. C27H24CIF3N4O requires C, 63.3; H, 4.7; 
N, 10.9%). *H n.m.r. 6 1.64, complex, 2.63, complex, H2",3",4",5",6"; 3.77, s, 
CH2N; 7.01, d, J 5.5 Hz, H3m; 7.00, br s, 7.27, br s, H4,6; 7.40, d, 7.60, d, J 9 Hz, 
H2',3,,5',6'; 8.32, br s, NH; 8.55, br s, H8m; 8.59, d, J 5.5 Hz, H2m; 8.94, br s, 
H 6 " \
4'-Chloro-3’( 3 ”-methylpiperidin-l ylmethyl)-5~(7,,f-trifluoromethyl- 
1 , 5 ’"-naphthyridin-4,n-ylamino)biphenyl~2-ol (IV.6e)
It was obtained after PTLC (alumina; 25% ethyl acetate in hexane) as a yellow oil 
(87%) (Found: C, 63.9; h, 5.1, N, 10.3. C28H26CIF3N4O requires C, 63.8; H, 5.0; N, 
10.6%). *H n.m.r. 5 0.90, d, J 5.5 Hz, Me; 1.73, complex, 2.35, complex, 2.98, 
complex, H2",3",4",5",6"; 3.79, s, CH2N; 7.01, J 5.5 Hz, H3m; 7.04, br s, 7.26, br s, 
H4,6; 7.38, d, 7.58, d, J 9 Hz, H2,,3,,5,,6'; 8.36, br s, NH; 8.57, br s, H8m; 8.60, d, J 
5.5 Hz, H2"'; 8.93, br s, H6m.
4'-Chlor o-3-(4”-methylpiperidin-1 ”-ylmethyl)-5-(7,, ,-trifluoromethyl-
l ,  5 " ' -naphthyridin-4'"-ylamino)biphenyl-2-ol  (IV.6f)
The title compound (84%) after PTLC (alumina; 20% ethyl acetate in hexane), had
m. p.164-1670 (Found: C, 64.0; H, 5.2; N, 10.5. C28H26CIF3N4O requires C, 63.8; H, 
5.0; N, 10.6%). *H n.m.r. 8 0.94, d, J 4.5 Hz, Me; 1.54, complex, 2.19, complex, 3.05, 
complex, H2",3",4",5",6"; 3.78, s, CH2N; 6.99, d, J 5.5 Hz, H3"’; 7.03, br s, 7.24, br 
s, H4,6; 7.38, d, 7.58, d, J 9 Hz, H2,,3,,5',6’; 8.32, br s, NH; 8.55, br s, H8m; 8.60,
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d, J 5.5 Hz, H2"'; 8.93, br s, H6"\ MS m/z 526 (66.8%), 528 (26.4%), 527 (21.8%), 
529 (7.1%), 427 (63.5%).
3-(4"-Benzylpiperidin-1 "-ylmethyl)-4'-chloro-5-(7’"-trifluoromethyl-
l ,  5 f,,-naphthyridin~4,,,-ylamino)biphenyl-2-ol  (IV.6g)
This compound (82%) after reprecipitation and PTLC (alumina; methylene 
chloride), had m.p. ca 95° (Found: C, 68.0; H, 5.3; N, 9.2. C34H30CIF3N4O requires C, 
67.7; H, 5.0; N, 9.3%). n.m.r. 5 1.64, complex, 2.13, complex, 3.05, complex, 
H2",3",4",5",6"; 2.53, d, J 5.5 Hz, CH2Ph; 3.76, s, CH2N; 6.98, d, J 3 Hz, H3m; 
7.02, br s, 7.16, br s, H4,6; 7.39, d, 7.59, d, J 9 Hz, H2’,3,,5,,6’; 8.32, br s, NH; 8.54, 
br s, H8m; 8.57, d, J 5.5 Hz, H2m; 8.93, br s, H6"\
3-(4”-Benzylpiper azin-1 ,,-ylmethyl)-4'-chloro-5-(7,,,-trifluoromethyl-
1 , ,, ,5 ,"-naphthyridin-4",-ylamino)biphenyl-2-ol  (IV.6h)
The title compound (%1%) after PTLC (alumina; 30% ethyl acetate in hexane) 
crystallised as a yellow solid from a mixture of methylene chloride and hexane and had
m. p. 181-183° (Found: C, 63.8; H, 4.8; N, 11.0. C33H29C1F3N50.H20  requires, C, 
63.7; H, 5.0; N, 11.3%). !H n.m.r. 5 2.67, complex, H2",3",5”,6"; 3.60, s, PhCH2N; 
3.82, s, ArCH2N; 7.00, d, J 7 Hz, H3"’; 7.04, br s, 7.28, br s, H4,6; 7.39, d, 7.58, d, J 
9 Hz, H2,,3,,5\6’; 8.32, br s, NH; 8.54, br s, H8m; 8.60, d, J 5.5 Hz, H2,M; 8.94, d, J
2 Hz, H6"\
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CHAPTER V Mono-Mannich Bases of 4-[7-Bromo (and 7-Trifluoro- 
methyl)-l,5-naphthyridin-4-ylamino]-5,6,7,8-tetrahydronaphth-l-ols
V -l  Introduction
Nabih et a /.104 were the first to synthesise mono-Mannich bases of 4-(7-chloro- 
quinolin-4-ylamino and 6-chloro-2-methoxy-9-acridin-4-ylamino)-5,6,7,8-tetrahydro- 
naphth-l-ols for evaluation for antimalarial activity.217
Recent publications by Kesten et a/.105 and Shen et al.93 have reported the synthesis 
and antimalarial activity against/5, berghei in mice of Mannich base derivatives of 4-[7- 
chloro (and 7-trifluoromethyl)quinolin-4-ylamino]-5,6,7,8-tetrahydronaphth-l-ols (V.l; 
X=C1 and CF3, respectively). Kesten et a/ .105 found that the compound V.l (X=C1, 
NR1R2=NEt2) exhibited antimalarial activity (as measured by increased mean survival time) 
when administered in a single dose of 10 mg/kg and that it effected partial cures at 40 
mg/kg.
V.l X=CI, cf3 V.2 X=Br 
V.3 X=CF3
In an attempt to discover other compounds which may have good antimalarial 
activity, mono-Mannich bases of 4-[7-bromo (and 7-trifluoromethyl)-l,5-naphthyridin-4- 
ylamino]-5,6,7,8-tetrahydronaphth-l-ols (V.2 and V.3) have been synthesised in the 
present work for testing for antimalarial activity. The synthesis of the starting material, N- 
(4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide (V.10) is mentioned first in this
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Chapter, and then the Mannich base derivatives (V.2 and V.3) are described. Their 
physical properties are also discussed briefly. The results of testing for antimalarial activity 
against P . falciparum in vitro, and the results of in vivo tests of two selected compounds 
against P. vinckei vinckei are discussed in Chapter VIII.
V-2 Syntheses of W -(4-Hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide
iV-(4-Hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide (V.10) was the necessary 
precursor for the present work. Two syntheses of compound V.10 have been reported. 
The first (Method A; Scheme V-l) was described by Kesten et a/.105 and commenced from 
the commercially available 4-nitronaphthyl-l-amine (V.4). It involved the hydrolysis of 
compound V.4 in refluxing 10% sodium hydroxide to afford 4-nitronaphth-l-ol (V.5) in 
good yields. Catalytic hydrogenation of compound V.5 over Raney nickel at 51 psi and 
subsequent acetylation with acetic anhydride provided N-(4-hydroxynaphth-l-yl)acetamide 
(V.6) in excellent yields. A further hydrogenation under high pressure (1500 psi) in the 
presence of Raney nickel gave V-(4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide 
(V.10) in high yields.
The second approach, Method B (Scheme V-l), involved the nitrosation218-220 0f 
the commercially available 5,6,7,8-tetrahydronaphth-l-ol (V.7) with sodium nitrite in 
sodium hydroxide solution in an ice-bath for 15 minutes then in 10% sulphuric acid at 0° 
for 1.5 h to afford 4-nitroso-5,6,7,8-tetrahydronaphth-l-ol (V.8). The reduction of 
compound V.8 with stannous chloride and hydrochloric acid218 or with aqueous 
ammonium sulphide221 has been described to give the amino analogue (V.9) which was 
then V-acetylated with a mixture of acetic anhydride and acetic acid (1:5) at 40° for 5 h to 
the compound V.10.
In the present work, Method B was chosen (in preference to Method A) to avoid the 
high pressure hydrogenation of a naphthalene to a tetrahydronaphthalene. It was also found 
preferable to reduce compound V.8 (dissolved in ethanolic ammonia) with hydrogen over 
Raney nickel.
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Method A
Method B 
OH
V .7
H 2/Ni (ISOOpsi)
OH
NHCOMe
V .10
V .8 V .9
Scheme V-l
V-3 Syntheses of Mono-Mannich Bases of 4-[7-Bromo (and 7-Trifluoro- 
methyl)-l,5-naphthyridin-4-yIamino]-5,6,7,8-tetrahydronaphth-l-ols
Compound V.10 underwent the Mannich reaction (as has been reported 
previously104 for the amines, diethylamine or piperidine and formaldehyde) to give mono- 
Mannich compounds (V.ll). In this work, further amines; namely, dipropylamine, 
f-butylamine, pyrrolidine, 3-methylpiperidine, 4-methylpiperidine, 4-benzylpiperidine and
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4-benzylpiperazine, and paraformaldehyde reacted with N-(4-hydroxy-5,6,7,8-tetrahy- 
dronaphth-l-yl)acetamide (V.10) in refluxing ethanol for 12 h and gave the mono-Mannich 
compounds (V .ll) (Scheme V-2).
OH
NHCOMe
OH
(CH20 ) n, HNFTR
EtOH
NHCOMe
V.10 V . l l
V.2 X=Br
V.3 x =c f 3 V .12
V.2, V.3, and V . l l
NR*R2 NR*R2
a NEt2 e piperidin-l-yl
b NPr2 f 3-methylpiperidin-l-yl
C NHBu1 g 4-methylpiperidin-l-yl
d pyrrolidin-l-yl h 4-benzylpiperidin-l-yl
[ 4-benzylpiperazin-l-yl
Scheme V-2
I l l
These compounds V .l l  were readily V-deacetylated on hydrolysis with 
concentrated hydrochloric acid in ethanol at 95° for 5-10 h to give the amino analogues 
(V.12). The reaction solution was then adjusted pH ca 3 with sodium hydroxide solution, 
and used directly for condensation with 7-bromo (and 7-trifluoromethyl)-4-chloro-l,5- 
naphthyridine at 100° for 8-10 h, to give the mono-Mannich bases of 4-[7-bromo (and 7- 
trifluoromethyl)-1,5-naphthyridin-4-ylamino]-5,6,7,8-tetrahydronaphth- 1-ols (V.2 and 
V.3, respectively).
V-4 Physical Properties
The !H n.m.r. spectra of compounds V.2, V.3 and V .l l  are recorded in the 
Experimental section. The 2-D COSY spectrum and the *H n.m.r. spectrum of compound 
V.3g were also measured on a XL-300 spectrometer. The latter spectrum is shown in 
Figure V-l. The assignment of the methylene protons in this compound (V.3g) was 
confirmed by the 2-D COSY spectrum (Figure V-2).
The 13C n.m.r. spectrum of compound V.3g has also been determined and the 
results are shown in Figure V-3. The assignments of the 13C n.m.r. chemical shifts were 
carried out by running a decoupled l3C n.m.r. spectrum, and 2-D HETCOR and HMBC 
spectra.
The assignments made using the HETCOR spectrum for aromatic carbons 
(C2",3",6”,8",3); methyl, methylene and methine carbons; and the other carbons, such as 
quaternary carbons (not connected with any protons) were assigned from the HMBC 
spectrum. For example carbon C-T was assigned on the basis of the cross peak between 
the resonance at 8 154.7 and the hydrogen atom peaks assigned to H3 and 2 -CH2N. These 
cross peaks are due to three-bond coupling.
Comparison of the 13C chemical shifts of the 1,5-naphthyridine nucleus in 
compound V.3g (Figure V-3) with the 1,5-naphthyridine nucleus in the di-Mannich base 
II.48a (see Figure II-1) revealed that the signals for C7" and C4" in compound V.3g 
(5 125.2 and 149.4) showed the biggest downfield shift from those in compound II.48a 
(5 121.5 and 148.5); whereas at other positions the differences were slight (0.0-0.2 ppm).
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Figure V-2 2-D COSY spectrum of 2-(4'-methyIpiperidin-l'-
ylmethyl)-4-(7"-trifluoromethyl-r,,5"-naphthyridin- 
4"-ylamino)-5,6,7,8-trtrahydronaphth-l-ol (V.3g) 
in CDCI3
4'-Me
S 8
Figure V-2.1 Expansion of Figure V-2 at region A
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22.4 23.3
23.3 ( S
126.9 ' 134.2
118.4
142.6 102.3
125.2
153.3
135.0
125.2
Figure V-3 The chemical shifts (ppm) of the carbon atoms in
2-(4-methylpiperidin-l-ylmethyI)-4-(7-trifluoromethyl- 
l,5-naphthyridin-4-ylamino)-5,6,7,8-tetrahydronaphth- 
l-ol (V.3g)
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V-5 Experimental
N-(4-Hydroxy-5,6,7,8-tetrahy dr onaphth-l-y  l) acetamide (V.10)
This compound was prepared from 5,6,7,8-tetrahydronaphth-l-ol by nitro- 
sation218' 220 to give 4-nitroso-5,6,7,8-tetrahydronaphth-l-ol [m.p. 157-159° (from 
aqueous ethanol) (lit.218 161-163° (dec.) (Found: C, 67.6; H, 6.3; N, 7.8. Calc, for 
C10H 11NO2 : C, 67.8; H, 6.3; N, 7.9%). n.m.r. 8 1.71, complex, 2.51, complex, 
H5,6,7,8; 6.41, d, J2,3 10 Hz, H2; 7.72, d, J23  10 Hz, H3] which was then reduced as 
follows.
4-Nitroso-5,6,7,8-tetrahydronaphth-l-ol (2.0 g) was dissolved in half-saturated 
ethanolic ammonia (200 ml) and shaken with hydrogen gas over Raney nickel until uptake 
ceased. The mixture was filtered through Celite and the filtrate evaporated to give 4-amino- 
5,6,7,8-tetrahydronaphth-l-ol (1.843 g), m.p. 145-146° (lit.221 144-146°). ^  n.m.r. 
5 1.81, complex, 2.50, complex, H5,6,7,8; 6.43, d, 6.54, d, J23  9 Hz, H2,3.
This amino compound (1.950 g), acetic acid (59.0 ml) and acetic anhydride (12.0 
ml) were heated at 40° for 5 h. The mixture was then evaporated to dryness under reduced 
pressure and the residue recrystallised from a mixture of acetone and light petroleum (b.p. 
60-80°) to give theiV-(4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide (1.752 g), m.p. 
192-194° (lit.221 188-189°) (Found, for a sample dried at 120°/0.2 mmHg for 2 h: C, 
69.9; H, 7.6; N, 6 .8. Calc, for C i 2H i 5N 0 2: C, 70.2; H, 7.4; N, 6 .8%). n.m.r. 
(CD3OD) 5 1.72, complex, 2.58, complex, H5,6,7,8; 2.08, s, Me; 6.55, d, 6.83, d, J 9 
Hz, H2,3.
N-(3-Diethylaminomethyl-4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)-  
acetamide (V .lla)
This compound was prepared from Ar-(4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)- 
acetamide, paraformaldehyde and diethylamine as described by Nabih et a/.104 It had m.p. 
154-155° (from aqueous ethanol and aqueous acetone) (lit.105 156-157°). JH n.m.r. 8 
1.11, t, J 7 Hz, MeCH2; 1.80, complex, 2.59, complex, H5,6,7,8; 2.15, s, MeCO; 2.63, 
q, J 7 Hz, MeCH2; 3.72, s, CH2N; 6.63, br s, 6.75, br s, NH, OH; 7.10, s, H3.
N -(3 -D ip ro p y la m in o m eth y l -4 -h yd ro x y -5 ,6 ,7 ,8 -te trahy d ro n a p h th -1 -yl)- 
acetamide  (V.llb)
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A mixture of A-(4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide (0.603 g), 
paraformaldehyde (0.167 g), dipropylamine (0.76 ml) and ethanol (7.2 ml) was refluxed at 
ca 95° for 12 h. The solvent was evaporated under reduced pressure and the yellow oily 
residue was washed with water and then extracted into chloroform. The product was 
subjected to column chromatography in methylene chloride over alumina and then PTLC 
(alumina; chloroform) to give the title compound (0.648 g), m.p. 80-83° (Found C: 72.0; 
H, 9.8; N, 8.8. C19H30N 2O2 requires C, 72.0; H, 9.5; N, 8.8%). *H n.m.r. 8 0.89, t, J 
7 Hz, M eCH2; 1.56, complex, MeCH2CH2; 1.76, complex, 2.56 complex, H5,6,7,8; 
2.14, s, MeCO; 2.48, t, J 7 Hz, MeCH2CH2; 3.70, s, CH2N; 6.62, br s, 6.77; br s, NH, 
OH; 7.08, H3.
N -(3 - t -B u ty la m in o m eth y l -4 -h yd ro x y -5 ,6 ,7 ,8 - te t ra h yd ro n a p h th - l -y l ) -  
acetamide  (V.llc)
A mixture of paraformaldehyde (0.223 g) and r-butylamine (0.77 ml) in ethanol (6.0 
ml) was refluxed to give a clear solution, chilled, N-(4-hydroxy-5,6,7,8-tetrahydronaphth- 
l-yl)acetamide (0.504 g) added and the refluxing continued for 12 h. The solvent was 
evaporated and the residue washed with water to give a brown solid (0.643 g). It was 
recrystallised from aqueous acetone with charcoal filtration to give white crystals of the title 
compound, m.p. 190-191° (Found, for a sample dried at 20°/0.2 mmHg for 24 h: C, 70.3; 
H, 9.3; N, 9.3. C17H26N2O2 requires C, 70.3; H, 9.0; N, 9.6%). *H n.m.r. 8 1.19, s, 
Me3C; 1.73, complex, 2.56, complex, H5,6,7,8; 2.16, s, MeCO; 4.06, s, CH2N; 6.66, 
br, 6.74, br, 2xNH; 7.18, br s, H3.
N - [ 4 -H y d ro x y -3-(pyrro l id in-1  f-y lm e th y l ) -5 f6f7y8 - t e t r a h y d r o n a p h th - l - y l ]-  
acetamide  (V.l ld)
This compound (73%) as white needles had m.p. 191-193° (from aqueous acetone) 
(Found: C, 70.4; H, 8.5 N, 9.7. C17H24N 2O2 requires, C, 70.8; H, 8.4; N, 9.7%).
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!H n.m.r. 5 1.81, complex, 2.66, complex, H2',3',4',5'; 1.81, complex, 2.66, complex, 
H5,6,7,8; 2.16, s, MeCO; 3.78, s, CH2N; 6.64, br s, NH; 7.11, s, H3.
N -[4-Hy droxy -3 -(piperidin-1'-ylmethyl)-5,6,7,8-tetrahydronaphth-l-yl]- 
acetamide (V.lle)
This compound was prepared in an analogous manner by the method of Nabih et 
al.104 It had m.p. 164-166° (lit.105 164-166°). l H n.m.r. 5 1.70, complex, 2.58, 
complex, H2,,3',4',5',6' and H5,6,7,8; 2.16, s, Me; 3.62, s, CH2; 6.62, br s, 6.73, br s, 
NH, OH; 7.09, s, H3. I.r. vmax 3285 (br) (NH st), 2950 (s) (CH aliph st), 1668 + 1648 
(s) (C=0 st), 1556 (s) (ar skeleton st), 1470 (s), 1232 (m), 879 (m), 790 (m) cm-1.
The following compounds were prepared by similar procedures to those described 
or referred to above.
N -[4-Hydroxy-3-(3,-methylpiperidin-l '-ylmethyl)-5,6,7,8-tetrahydro- 
naphth-l-yl]acetamide (V.llf)
The title compound (72%) had m.p. 122-125° (after chromatography in methylene 
chloride over alumina, and triturated with cyclohexane) (Found: C, 72.8; H, 9.3; N, 8.5. 
C i9H28N2O2.0.2C6H i 2: C, 72.8; H, 9.2; N, 8.4%). !H n.m.r. 5 0.86, d, J 5.5 Hz, 
MeC; 1.74, complex, 2.59, complex, 2.85, complex, H2',3',4,,5',6' and H5,6,7,8; 2.12, 
s, MeCO; 3.57, s, CH2N; 6.98, s, H3; 7.08, br s, NH.
N-[4-Hydroxy-3-(4f-methylpiperidin-l ’-ylmethyl)-5,6y7,8-tetrahydro- 
naphth-l-yl]acetamide (V.llg)
The title compound was obtained by extraction with chloroform and it was purified 
by chromatography in chloroform over alumina. After triturated with light petroleum (b.p. 
60-80°) it was obtained as white crystals (79%), m.p. 143-145° (Found: C, 72.0; H, 9.0; 
N, 8.8. C i9H28N20 2 requires C, 72.1; H, 8.9; N, 8.8%). n.m.r. 5 0.93, d, MeC; 
1.37, complex, 1.76, complex, 2.61, complex, 2.98, complex, H2',3',4',5,,6' and H5,6, 
7,8; 2.15, s, MeCO; 3.64, s, CH2N; 6.62, br s, 6.72, br s, NH, OH; 7.09, s, H3.
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N - [ 3 - ( 4 r-B enzy lp iper id in-1  '-ylm e th y l ) - 4 - h yd r o x y -5 ,6 ,7 ,8 - te trahydro-  
na p h th - l -y l ]a ce ta m id e  (V . l lh )
This compound (73%) had m.p. 193-194° (after crystallisation from methylene 
chloride/acetone) (Found: C, 76.0; H, 8.9; N, 6.8. C25H32N2O2 requires C, 75.9; H, 8.9; 
N, 7.0%). *H n.m.r. 6 1.76, complex, 2.58, complex, 2.95, complex, H2',3',4',5',6' 
and H5,6,7,8; 2.55, d, CH2Ph; 3.63, s, CH2N; 6.62, br s, 6.72, br s, NH, OH; 7.09, s, 
H3; 7.20, complex, Ph.
N - [ 3 - ( 4 ' -B e n zy lp ip e r  azin-1 ' - y lm e th y l ) -4 -h yd ro x y -5 ,6 ,7 ,8 - te trahydro -  
n a p h th - l -y l ]a c e ta m id e  (V . l l i )
The title compound (70%) had m.p. 221-222° (from aqueous acetone) (Found: C, 
73.4; H, 8.2: N, 10.3. C24H31N3O2 requires C, 73.3; H, 7.9; N, 10.7%). *H n.m.r. 5 
1.76, complex, 2.58, complex, H2',3',4,,5',6' and H5,6,7,8; 2.16, s, MeCO; 3.54, s, 
CH2Ph; 3.66, s, CH2N; 6.67, br, NHCO; 7.08, s, H3; 7.31, s, Ph.
4 - ( 7 f-Bromo-1  ' , 5 ,- n a p h th y r id in - 4 ,-y lam in o) -2 -d ie th y lam inom ethy l -  
5 ,6 ,7 ,8 - t e t r a h y d r o n a p h t h - l -ol  (V.2a)
Ar-[3-Diethylaminomethyl-4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide 
(0.063 g), ethanol (2.0 ml) and concentrated hydrochloric acid (0.28 ml) were refluxed for 
10 h. The mixture was cooled, adjusted to pH 4.5 with aqueous sodium hydroxide, 3- 
bromo-8-chloro-l,5-naphthyridine (0.042 g) and a little ethanol added and the mixture 
refluxed for 10 h. It was then evaporated to dryness, the residue diluted with water, and 
some undissolved solid removed by filtration. The filtrate (pH 3) was adjusted with 
aqueous ammonia to pH 8.5-9 to give a yellow precipitate (0.045 g). It was recrystallised 
from aqueous ethanol to give the title compound, m.p. 167-169° (Found: C, 60.5; H, 6.0; 
N, 12.0. C23H27BrN40  requires C, 60.7; H, 6.0; N, 12.3%). *H n.m.r. 5 1.15, t, J 7 
Hz, Me; 1.75, complex, 2.67, complex, H5,6,7,8; 2.67, q, J 7 Hz, MeCH2; 3.76, s, 
CH2N; 6.53, d, J2\3’ 5.5 Hz, H3'; 6.85, s, H3; 7.96, br s, NH; 8.43, d, J2-,3' 5.5 Hz, 
H2'; 8.48, d, J6',8’ 2 Hz, H8’; 8.76, d, J6',8' 2 Hz, H6'.
4-(7 '-Bromo~l ,;5 ,-n aph th yr id in -4 ,-y lam in o) -2 - ( t -bu ty lam inom ethy l ) -  
5 ,6 ,7 ,8 - t e t r a h y d ro n a p h th - l -o l  (V.2c)
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A mixture of iV-(3-f-butylaminomethyl-4-hydroxy-5,6,7,8-tetrahydronaphth-l- 
yl)acetamide (0.097 g), concentrated hydrochloric acid (0.43 ml) and ethanol (3.2 ml) was 
refluxed for 5 h; cooled, adjusted to pH 3, 3-bromo-8-chloro-l,5-naphthyridine (0.092 g) 
added and then refluxed for a further 8 h. It was diluted with aqueous ethanol and adjusted 
to pH 9 to give a precipitate (0.14 g). This was purified by PTLC (alumina; methylene 
chloride) and reprecipitated from methylene chlorideAight petroleum (b.p. 60-80°)/hexane 
to give the yellow title compound (0.066 g), m.p. 181-183° (Found: C, 60.7; H, 6.2; N, 
12.2. C23H27BrN40  requires C, 60.7; H, 6.0; N, 12.3%). *H n.m.r. 5 1.23, s, Me3C; 
1.75, complex, 2.67, complex, H5,6,7,8; 3.93, s, CH2N; 6.60, d, J 5.5 Hz, H3'; 6.92, s, 
H3; 7.92, br s, NH; 8.45, d, J 2 Hz, H8'; 8.45, d, J 5.5 Hz, H2'; 8.75, d, J 2 Hz, H6'.
4 - ( 7 ,- B r o m o - l r ,5 ' -n a p h th yr id in - 4 ,-y la m in o ) -2 - (p yrro l id in - l  "-y lmethyl) -  
5 ,6 ,7 ,8 - te t r a h y d ro n a p h th - l -o l  (V.2d)
N-[2-Hydroxy-3-(pyrrolidin-r-ylmethyl)-5,6,7,8-tetrahydronaphth-l-yl]acetamide 
(0.044 g), ethanol (1.5 ml), and concentrated hydrochloric acid (0.2 ml; 37%) were 
refluxed for 5 h. The mixture was then adjusted to pH 4.7 with dilute sodium hydroxide. 
3-Bromo-8-chloro-l,5-naphthyridine (0.037 g) and a little ethanol were added and the 
mixture refluxed for 5 h, and then evaporated under reduced pressure. The residue was 
dissolved in water, the solution filtered, and the filtrate adjusted to pH 8.5 with aqueous 
ammonia. The yellow precipitate was collected, washed with water, and recrystallised from 
aqueous ethanol to give the title compound (0.013 g), m.p. 167-169° (Found, for a sample 
dried at 110°/0.2 mmHg for 5 h: C, 61.3; H, 5.9; N, 12.2. C23H25BrN40  requires C, 
60.9; H, 5.6; N, 12.4%). *H n.m.r. 5 1.76, complex, 2,67, complex, H2",3",4",5" and 
H5,6,7,8; 3.86, s, NCH2; 6.53, d, J2->3- 5.5 Hz, H3'; 6.88, s, H3; 7.97, br s, NH; 8.44, 
d, J2-j3- 5.5 Hz, H2'; 8.48, d, J6->8- 2.5 Hz, H8’; 8.75, d, J6',8- 2.5 Hz, H6’.
In a similar manner the following compounds were prepared.
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4 - ( 7 * -B ro m o - l ', 5 f-n a p h th yr id in -4 ,-y la m in o ) -2 - (p ip er id in - l  ”-y lm e th y l )- 
5 ,6 ,7 ,8 - t e t r a h y d r o n a p h t h - l - o l  (V.2e)
The title compound (75%) had m.p. 180-182° (from acetone) (Found, for a sample 
dried at 110°/0.2 mmHg for 5 h: C, 61.9; H, 6.1; N, 12.0. C24H27BrN40  requires C, 
61.7; H, 5.8; N, 12.0%). *H n.m.r. 5 1.68, complex, 2.65, complex, H2",3",4",5",6" 
and H5,6,7,8; 3.69, s, CH2N; 6.52, d, J2-,3- 5.5 Hz, H3’; 6.85, s, H3; 8.02, br s, NH; 
8.43, d, J2->3- 5.5 Hz, H2’; 8.53, d, J6\8’ 2 Hz, H8’; 8.77, d, 2 Hz, H6’.
4-(7 ' -Bromo-1  f ,5 ' -n a p h th yr id in -4 ,-y la m in o ) -2 - (3 n-methylp iper id in-1  ”-yl- 
m eth y l ) -5 ,6 ,7 ,8 - te t r a h y d ro n a p h th - l -o l  (V.2f)
The title compound (70%) had m.p. 210-212° [after PTLC (alumina; methylene 
chloride) and recrystallisation from methylene chloride/hexane) (Found: C, 60.3; H, 6.3; 
N, 10.9. C25H29BrN40 .H 20  requires C, 60.1; H, 6.3; N, 11.2%). n.m.r. 5 0.91, d, 
MeC; 1.77, complex, 2.63, complex, 2.89, complex, H2",3",4",5",6" and H5,6,7,8; 
3.65, s, CH2N; 6.52, d, J 5.5 Hz, H3’; 6.84, s, H3; 7.89, br s, NH; 8.43, d, J 2 Hz, 
H8'; 8.45, d, J 5.5 Hz, H2’; 8.74, d, J 2 Hz, H6\
4 - ( 7 f-Bromo-1 ,, 5 ,-n aph th yr id in -4 ' -y la m in o ) -2 - (4 ,,-m e th y lp ipe r id in - l  "-y l­
m e th y l ) -5 ,6 ,7 ,8 - te t r a h y d ro n a p h th - l -o l  (V.2g)
The title compound (47%) had m.p. 201-203° [after PTLC (alumina; 25% ethyl 
acetate in methylene chloride, then methylene chloride) and trituration with hexane] (Found: 
C, 62.1; H, 6.2; N, 11.5. C25H29BrN40  requires C, 62.4; H, 6.1; N, 11.6%). *H n.m.r. 
5 0.97, d, MeC; 1.40, complex, 1.77, complex, 2.13, complex, 2.66, complex, 3.03, 
complex, H2",3”,4",5",6" and H5,6,7,8; 3.67, s, CH2N; 6.51, d, J 5.5 Hz, H3'; 6.84, s, 
H3; 6.90, br s, NH; 8.43, d, J 2 Hz, H8'; 8.45, d, J 5.5 Hz, H2'; 8.75, d, J 2 Hz, H6’.
2-(4*-B e n zy lp iper id in -1 '-y Ime thy l ) -4 - (7 ”-bromo-1 ,,, 5 ”-n a p h th yr id in -4 ,,-yl- 
am in o ) -5 ,6 ,7 ,8 - te t ra h y d ro n a p h th - l -o l  (V.2h)
This compound (51%) had m.p. ca 120° (with prior softening) [after PTLC 
(alumina; methylene chloride)] (Found: C, 66.9; H, 6.2; N, 9.8. C3iH33BrN40  requires 
C, 66.8; H, 6.0; N, 10.0%). *H n.m.r. 8 1.76, complex, 2.09, complex, 2.63, complex,
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3.05, complex, H2,,3,,4,,5,,6, and H5,6,7,8; 2.58, d, J 5 Hz, CH2Ph; 3.67, s, CH2N; 
6.50, d, J 5.5 Hz, H3"; 6.84, s, H3; 7.22, complex, Ph; 7.92, br s, NH; 8.43, d, J 5.5 
Hz, H2"; 8.45, d, J 2 Hz, H8"; 8.75, d, J 2 Hz, H6".
2 - ( 4 ' - B e n z y lp ip e r a z in - l '-y lmethyl)~4-(7"-bromo-1  ",5 n a p h th yr id in -4 ”-y l- 
a m in o ) -5 ,6 ,7 ,8 - te t r a h y d ro n a p h th - l -o l  (V.2i)
The title compound (65%) had m.p. 141-143° [after PTLC (alumina; 30% ethyl 
acetate in hexane) and recrystallisation from methylene chloride/hexane)] (Found: C, 64.5; 
H, 6.0; N, 12.5. C3oH32BrN5 0  requires C, 64.5; H, 5.8; N, 12.4%). *H n.m.r. 8 1.76, 
complex, 2.60, complex, H2',3',5,,6' and H5,6,7,8; 3.54, s, CH2Ph; 3.68, s, CH2N; 
6.49, d, J 5.5 Hz, H3"; 6.85, s, H3; 7.30, complex, Ph; 7.88, br s, NH; 8.43, d, J 2 Hz, 
H8M; 8.43, d, J 5.5 Hz, H2"; 8.73, d, J 2 Hz, H6”.
2 - ( 4 ' -Methylp iperid in -1  ,- y lm e th y l ) -4 - (7”- tr i f luorom eth y l - l  f,, 5 ”-naphthy-  
ridin-4" -ylamino) -5,6 ,7,8 - te trahydronaphth- l -o l  (V .3g)
N-[2-Hydroxy-3-(4'-methylpiperidin-r-ylmethyl)-5,6,7,8-tetrahydronaphth-l-yl] 
acetamide (0.1 g) with concentrated hydrochloric acid (0.4 ml) in ethanol (3.2 ml) was 
refluxed for 6 h, and evaporated to dryness under reduced pressure. The residue was 
dissolved in a mixture of methanol (1.8 ml) and water (0.8 ml) and 2.5 N sodium 
hydroxide added until a test sample had pH 2. 4-Chloro-7-trifluoromethyl-l,5-naphthy- 
ridine (0.074 g) was added and the mixture was refluxed for 10 h. After cooling a little 
white solid was removed and the filtrate adjusted to pH ca 9 and the yellow product 
extracted into chloroform to give an oil. This was subjected to PTLC (alumina; 25% ethyl 
acetate in hexane) and the product (0.092 g) triturated with hexane to give the title 
compound, m.p. 192-194° (Found: C, 66.7; H, 6.5; N, 11.9. C2öH29F3N4 0  requires C, 
66.4; H, 6.2; N, 11.9%). l H n.m.r. 5 0.97, d, MeC; 1.34, complex, 1.77, complex, 
2.13, complex, 2.68, complex, 3.02, complex, H2',3',4',5',6' and H5,6,7,8; 3.67, s, 
CH2N; 6.59, d, J 5.5 Hz, H3"; 6.85, s, H3; 7.98, br s, NH; 8.52, s, H8"; 8.55, d, J 5.5 
Hz, H2"; 8.93, J 2 Hz, H6".
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In a similar manner to the preparations described above were prepared the following 
compounds.
2-Diethylamino-4-(7'-trifliioromethyl-l ’ ,5*-naphthyridin-4’ -ylamino)- 
5,6,7,8-tetrahydronaphth-l -ol (V.3a)
A-(3-Diethylaminomethyl-4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide 
(0.080 g), ethanol (2.4 ml) and concentrated hydrochloric acid (0.32 ml) were refluxed for 
10 h, and then evaporated under reduced pressure. The residue was dissolved in a mixture 
of methanol (1.5 ml) and water (0.7 ml), adjusted with 2.5 N sodium hydroxide to pH 2, 
4-chloro-7-trifluoromethyl-l,5-naphthyridine (0.064 g) added and the mixture refluxed for 
8 h. After cooling a white solid (0.015 g) was filtered and rejected and the filtrate adjusted 
to pH 8.5 to give a yellow solid (0.079 g). It was subjected to PTLC (alumina; 30% ethyl 
acetate in hexane) to give the title compound, m.p. 147-148° (Found: C, 64.7; H, 6.3; N, 
12.4. C24H27F3N4O requires C, 64.8; H, 6.1; N, 12.6%). *H n.m.r. 5 1.16, t, J 7 Hz, 
MeCH2; 1.76, complex, 2.65, complex, H5,6,7,8; 2.69, q, J 7 Hz, MeCH2; 3.78, s, 
CH2N; 6.60, d, J 5.5 Hz, H3'; 6.87, s, H3; 8.01, br s, NH; 8.51, s, H8'; 8.54, d, J 5.5 
Hz, H2'; 8.95, d, J 2 Hz, H6’.
2-Dipropylaminomethyl-4-(7'-trifluoromethyl-l',5*-naphthyridin-4* -ylami- 
no)-5,6,7,8-tetrahydronaphth-l-ol  (V.3b)
This compound (46%) had m.p. 115-117° [after PTLC (alumina; 30% ethyl acetate 
in hexane)] (Found: C, 66.3; H, 7.0; N, 11.6. C26H31F3N4O requires C, 66.1; H, 6.6; 
N, 11.9%). *H n.m.r. 6 0.93, t, J 7 Hz, Me; 1.65, complex, MeCH2CH2; 1.75, 
complex, 2.55, complex, H5,6,7,8; 2.53, t, J 7 Hz, MeCH2CH2; 3.75, s, CH2N; 6.60, d, 
J 5.5 Hz, H3’; 6.86, s, H3; 8.0, s, NH; 8.52, s, H8’; 8.55, d, J 5.5 Hz, H2’; 8.94, d, J 2 
Hz, H6'. MS m/z 472 (1.3%) (M+), 371 (6.8%).
2-(t-Butylaminomethyl)-4-(7f-trifluoromethyl-1 f,5'-naphthyridin-4f-ylami- 
no)-5,6,7,8-tetrahydronaphth-l-ol  (V.3c)
The title compound (53%) had m.p. 178-180° [after PTLC (alumina; 30% ethyl 
acetate in cyclohexane, and crystallisation from methylene chloride/hexane)] (Found: C,
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64.9; H, 6.2; N, 12.5. C24H27F3N4O requires C, 64.9; H, 6.1; N, 12.6%). *H n.m.r. 5 
1.22, s, Me3C; 1.75, complex, 2.67, complex, H5,6,7,8; 3.93, s, CH2N; 6.64, d, J 5.5 
Hz, H3'; 6.91, s, H3; 7.97, br s, NH; 8.52, s, H8’; 8.55, d, J 5.5 Hz, H2’; 8.85, d, J 2 
Hz, H6 '. MS m/z 444 (8.9%) (M+), 371 (48.7%).
2 - ( P y r r o l i d i n - l '-y lm e thy l ) -4 - (7"-tr if luoromethyl-1  ” , 5 ”-n aph th yr id in -4” -yl- 
amino)-5 ,6 ,7 ,8 - te trahydronaphth- l-o l  (V.3d)
This compound (56%) had m.p. 154-157° [after PTLC (alumina; 30% ethyl acetate 
in cyclohexane)] (Found, for a sample dried at 20°/0.2 mmHg for 3 days: C, 65.1; H, 6.0; 
N, 12.4. C24H25F3N4O requires C, 65.1; H, 5.7; N, 12.7%). *H n.m.r. 5 1.81, complex, 
2.66, complex, H2,,3',4,,5' and H5,6,7,8; 3.83, s, CH2N; 6.59, d, J 5.5 Hz, H3"; 6.87, 
s, H3; 7.99, br s, NH; 8.53, s, H8"; 8.55, d, J 5.5 Hz, H2"; 8.94, d, J 2 Hz, H6M.
2 - ( P ip e r id i n - l '-y lm e thy l ) -4 - (7"- tr if luoromethyl-1 }\ 5 ”-n aph thyr id in -4” -yl- 
a m in o ) -5 ,6 ,7 ,8 - te t ra h y d ro n a p h th - l -o l  (V.3e)
The title compound (50%) had m.p. 169-171° [after PTLC (alumina; 20% ethyl 
acetate in hexane)] (Found: C, 65.1; H, 6.3; N, 11.8. C25H27F3N4O.O.3H2O requires C, 
65.0; H, 6.0; N, 12.1%). *H n.m.r. 5 1.67, complex, 2.60, complex, H2',3',4',5',6' 
and H5,6,7,8; 3.66, s, CH2N; 6.58, d, J 5.5 Hz, H3"; 6.84, s, H3; 8.00, br s, NH; 8.50, 
s, H8 "; 8.53, d, J 5.5 Hz, H2"; 8.93, d, J 2 Hz, H6 ". I.r. vmax 3320 (br) (NH st), 
2960+2945 (m) (CH2 aliph. st), 1600 (m), 1576 (m), 1540 (s), 1375 (ms), 1164 (s), 1140 
(s) (CF3 st), 744 (w), 690 (w) cm-1.
2 - (3 ' -M eth y lp iper id in -1r -y lmethyl) -4-(7  "- tr if luoromethyl-1  ”, 5 f,-naphthyri-  
d i n - 4 ,,-y lam in o ) -5 ,6 ,7 ,8 - t e t ra h yd ro n a p h th - l -o l  (V.3f)
This compound (15%) had m.p. 154-156° [after PTLC (alumina; 26% ethyl acetate 
in hexane then alumina; methylene chloride)] (Found: C, 65.1; H, 6.3; N, 11.5. 
C26H29F3N4O requires C, 65.1; H, 6.3; N, 11.7%). *H n.m.r. 5 0.92, d, J 5 Hz, MeC; 
1.77, complex, 2.68, complex, 2.90, complex, H2',3',4',5,,6' and H5,6,7,8; 3.67, s, 
CH2N; 6.60, d, J 5.5 Hz, H3"; 6 .86 , s, H3; 7.99, br s, NH; 8.52, br s, H8"; 8.56, d, J 
5.5 Hz, H2"; 8.95, d, J 2 Hz, H6".
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2 -(4’-B enzylpiperidin-1 ,-ylmethyl)-4-(7”-trifluoromethyl-1 ”,5 ”-naphthyri- 
din-4n-ylamino)-5,6,7,8-tetrahydronaphth-l-ol  (V.3h)
The title compound (61%) had m.p. 166-169° [after PTLC (alumina; 26% ethyl 
acetate in hexane)] (Found: C, 70.2; H, 6.4; N, 9.9. C32H33F3N4O requires C, 70.3; H, 
6.1; N, 10.2%). *H n.m.r. 5 1.76, complex, 2.67, complex, 3.06, complex, H2',3',4', 
5’,6' and H5,6,7,8; 2.59, d, CH2Ph; 3.69, s, CH2N; 6.57, d, J 5.5 Hz, H3"; 6.85, s, 
H3; 7.22, complex, Ph; 8.00, br s, NH; 8.53, d, J 5.5 Hz, H2"; 8.56, s, H8"; 8.94, d, J 2 
Hz, H6".
2-(4’-Benzylpiperazin-l '-ylmethyl)-4-(7"-trifluoromethyl-1 ” , 5 ”-naphthyri- 
din-4"-ylamino)-5,6,7,8-tetrahydronaphth-l-ol  (V.3i)
The title compound (61%) had m.p. 193-195° [after PTLC (alumina; chloroform) 
and trituration with hexane] (Found: C, 67.6; H, 5.9; N, 12.4. C3iH32F3N5O.0.3H2O 
requires C, 67.6; H, 5.9; N, 12.4%). *H n.m.r. 8 1.75, complex, 2.60, complex, 
H2',3',5',6’ and H5,6,7,8; 3.56, s, CH2Ph; 3.70, s, ArCH2N; 6.57, d, J 5.5 Hz, H3"; 
6.86, s, H3; 7.25, complex, Ph; 7.97, br s, NH; 8.50, br s, H8"; 8.53, d, J 5.5 Hz, H2"; 
8.92, br s, H6".
CHAPTER VI
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Chapter VI Di-Mannich Bases of 4-[7-Chloro (and 7-Trifluoromethyl)- 
quinolin-4-ylamino]-3-methylphenols and 4-(7-Bromo-l,5-naphyridin-4-yl- 
amino)-3-methylphenols
V I-1 Introduction
In yet unpublished work, Barlin and coworkers have observed that the 3- and 5- 
methyl derivatives of 4,6-bis(pyrrolidin-l-ylmethyl)-2-(7-trifluoromethylquinolin-4-yl- 
amino)phenol exhibit higher solubility and antimalarial activity against P. falciparum in 
vitro than their demethyl analogues.
Accordingly, it was decided to examine the 3-methyl derivatives of some 4- 
aminophenols, such as the di-Mannich bases derived from 4-(7-trifluoromethylquinolin-4- 
ylamino)phenol and 4-(7-bromo-l,5-naphthyridin-4-ylamino)phenbl (parent compounds 
found previously to possess high antimalarial activity98) together with di-Mannich bases 
derived from 4-(7-chloroquinolin-4-ylamino)-3-methylphenol [cf. Amodiaquine (I.9a)].
In the first part of this chapter, the syntheses of di-Mannich bases of 3-methyl-4- 
nitrophenol and di-Mannich bases of some 4-[7-substituted quinolin (and 1,5- 
naphthyridin)-4-ylamino]-3-methylphenols are reported. Physical properties (such as the 
nuclear magnetic resonances and mass spectra) are then discussed. Test results for 
antimalarial activity against P. falciparum in vitro, using both the hypoxathine uptake 
method222 and a visual method223 are discussed in Chapter VUI.
VI-2 Syntheses of Di-Mannich Bases of 3-Methyl-4-nitrophenol
The nitro compounds required in this work, were prepared by standard procedures 
described by Barlin and coworkers to make di-Mannich base derivatives of 4-amino- 
phenol172 and 2-aminophenol.224
3-Methyl-4-nitrophenol with four to ten equivalents of paraformaldehyde and the 
appropriate amines, dimethylamine, diethylamine, r-butylamine, pyrrolidine and piperidine
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in refluxing ethanol for an extended period (ca 65 h) gave di-Mannich base (VI.1) of 3- 
methyl-4-nitrophenol. These di-Mannich compounds were readily purified by column and
OH
VI.1, X=N02 VI.2, NR1R2=pyrrolidin-l-yl
VI.3, X=NH2
VI.4, X=C1 VI.6
VI.l, VI.3, VI.4, VI.5 and VI.6
NR1R2
a NMe2
b NEt2
C NHBu1
d pyrrol idin-l -yl
e piperidin- l -y l
then preparative thin layer chromatography (PTLC) over alumina. Interestingly, when a 
lower proportion of paraformaldehyde and pyrrolidineP {ca 3 equivalents) was used and the
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reflux was conducted for 19 h only, more complex mixtures including mono-Mannich 
products such as compound VI.2 were obtained. Obviously under these conditions which 
favour mono-Mannich base formation, steric hindrance by the 3-methyl group in 3-methyl- 
4-nitrophenol hinders substitution at position 2 and the mono-Mannich side chain is inserted 
at position 6.
The separation of mixtures of mono- and di-Mannich bases such as compounds 
VI.2 and VI. 1 could not be achieved readily on alumina because they possessed similar 
Rf values. However separation was readily effected by PTLC over silica gel.
VI-3 Syntheses of Di-Mannich Bases of 4-[7-ChIoro (and 7-Trifluoro- 
methyl)quinolin-4-ylamino]-3-methylphenol and 4-(7-Bromo-l,5-naphthyri- 
din-4-ylamino)-3-methylphenol
The nitro compounds (VI.I) were subjected to catalytic reduction with hydrogen 
over Raney nickel in ethanolic ammonia at atmospheric pressure and room temperature to 
afford the corresponding amines (VI.3). These were then condensed with the appropriate 
4-halogenoheterocycles, namely 4,7-dichloroquinoline, 4-chloro-7-trifluoromethylquinoline 
and 3-bromo-8-chloro-l,5-naphthyridine,110 in aqueous methanol containing a few drops 
of concentrated hydrochloric acid (the mixture had pH ca 4.7) at reflux for 14-19 h. The 
product was precipitated by addition of dilute ammonium hydroxide and purified by PTLC. 
In this way di-Mannich bases of 4-[7-chloro (and 7-trifluoromethyl)quinolin-4-ylamino]-3- 
methylphenol (VI.4 and VI.5) and 4-(7-bromo-l,5-naphthyridin-4-ylamino)-3-methyl- 
phenol (VI.6) were prepared.
Di-Mannich bases of the demethyl analogues, 2,6-bis(dipentylaminomethyl)-4-(7- 
trifluoromethylquinolin-4-ylamino)phenol (VI.7d) and 2,6-bis(V-butyl-V-methylamino- 
methyl)-4-(7-trifluoromethylquinolin-4-ylamino)phenol (VI.7e) were also synthesised for 
comparative studies with quinazolines.
The testing of these compounds for antimalarial activity is reported in Chapter VIQ.
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HN----<C/—°H
c h 2n r 1r 2
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VI.7d, NR1R 2=NC sH 12 
VI.7e, NR1R2=NBuM e
HN— ß— OH
F , C ^ ^ N ^
. HCI
V I.8
V I-4  Physical P ro p erties
V I-4 .1  lH  N uclear m agnetic resonance sp ec tra
The structure of the mono-Mannich compound (VI.2) was established from its 
n.m.r. It showed singlets for H2 and H5 at 8 6.67 and 7.84, respectively, that due to 
H5 adjacent to the nitro group was downfield; and the methylene protons at C-6 appeared at 
5 3.87.
The corresponding di-Mannich compound V I.Id  gave signals for methylene 
protons at C-2 and C-6 at 5 3.73 and 3.88, respectively. The methylene protons in 4-nitro- 
2,6-bis(pyrrolidin-l-ylmethyl)phenol have been shown to occur at 5 3.80.172
The 1H n.m.r. spectra of compounds VI.4, VI.5 and V I.6 are given in the 
Experimental section. The assignments in the spectrum of compound VI.5e were checked 
by running 2-D COSY225 (see Appendix 1, Figure A3), in which coupling between the 3- 
methyl protons and the methylene protons at C-2 was observed.
V I-4 .2  13C N uclear m agnetic resonance spectra
The 13C n.m.r. spectral data for 2,6-bis(piperidin-l-ylmethyl)-4-(7-trifluoromethyl- 
quinolin-4-ylamino)-3-methylphenol (VI.5e) and quinoline (for comparison) are shown in 
Figures VI-1 and VI-2, respectively.
The assignments of the 13C chemical shifts were carried out by running a decoupled 
13C n.m.r. spectrum, and 2-D HETCOR and HMBC spectra. The chemical shifts of carbon
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atoms connecting-with one or more protons were assigned from the HETCOR spectrum, 
other carbons such as quaternary carbons (not-connected with any protons) were assigned 
from the HMBC spectrum.
Comparison of the 13C chemical shifts of the quinoline nucleus in compound VI.5e 
with those of quinoline itself revealed that C4" in VI.5e was downfield of that in quinoline 
by 13.9 ppm, but C3" was upfield by 19.5 ppm; presumably due to the 4-(substituted 
amino) group. All carbon atoms in the benzene ring of quinoline were downfield of the 
corresponding atoms in compound VI.5e by 1.3-8.5 ppm. The carbon of the trifluoro- 
methyl group (with the strong electron-withdrawing fluoro substituents) appeared as a 
quartet at 130.8 ppm, J 32 Hz. [compared with the carbon of the 3-methyl (phenolic) group 
at 13.7 ppm].
In contrast with the *H n.m.r. spectrum of compound VI.5e the signal in the 13C 
spectrum due to the carbon of the 2-CH2 group (attached to the phenol) was downfield of 
that due to the 6-CH2 group.
VI.5e
Figure VI-1 The chemical shifts (ppm) of the carbon atoms in
3-methyl-2,6-bis(piperidin-l-yImethyl)-4-(7-trifIuoro- 
methyIquinolin-4-ylamino)phenol (VI.5e)
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127.0
129.9
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Figure VI-2 The chemical shifts (ppm) of the carbon atoms 
in quinoline
VI-4.3 Ionization Constants
The basic ionization constant (pKa) of 4-(7-trifluoromethylquinolin-4-ylamino)- 
phenola (VI.8) (determined spectroscopically by methods described in Chapter II-6.2) was 
found to be 7.60±0.05.
901 99Ionization constants have been published for 4-aminoquinoline (pKa 9.17), 
4-amino-7-chloroquinoline (pKa 8.23)227 and 4-aminophenol (pKa 5.5 and 10.3).228 The 
pKa of compound VI.8 which is a weaker base by 0.63 units compared to 4-amino-7- 
chloroquinoline, obviously reflects the effects of the greater electron-withdrawing power of 
the trifluoromethyl group compared to the chloro substituent and the electronic effect of the 
A-(4-hydroxyphenyl) substituent in compound VI.8.
VI-4.4 Ultraviolet and mass spectra
Some ultraviolet spectra of compounds VI.5a, VI.6a and VI.8 are recorded in 
the Experimental section. At pH 8.8, compound VI.8 (pKa 7.6) existed as a neutral 
molecule, and had a long-wavelength absorption maximum at 342 nm (log e 3.98); which 
in the cation, at pH 4.47, was at 348 nm (log £ 4.14). This bathochromic shift on 
protonation at the ring nitrogen atom is consistent with similar effects in 2-, 3- and 4- 
aminopyridines.229
a Kindly prepared by S.J. Ireland
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The ultraviolet spectrum of compound VI.6a at pH 8.6 (it was constant in the range 
pH 8.5 to 9.5) was probably that of the mono-cation involving protonation of a Mannich 
side chain (the pKa values of dimethylamine and triethylamine at 20° are 10.9 and 9.9, 
respectively).230
The mass spectra of compound VI.2 showed high intensity peaks due to the 
molecular ion (at m/z 236) and also M++ l. The major fragmentations observed with this 
compound involved the loss of pyrrolidinyl group and then loss of the nitro group to give 
fragments of m/z 166 and 120.
In compounds VI.5 (a, b and e) and VI.6 (d and e), the major fragmentations 
involved the cleavage at the C-N benzylic bonds (loss of dimethylamine and diethylamine in 
compounds VI.5a and VI.5b gave m/z 387 and 415, respectively), and the loss of the 
CHO fragment (such as compound VI.5b; m/z 386).
The bromo compounds (VI.6d and VI.6e) showed two molecular ion peaks in the 
ratio 1:1 due to the two major isotopes of bromine.
VI-5 Experimental 
VI-5.1 Synthetic work
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3-Methyl-4-nitro-2,6-bis(piperidin-l ’-ylmethyl)phenol  (VI.le)
A mixture of paraformaldehyde (1.569 g), piperidine (5.16 ml) and ethanol (10.0 
ml) was heated until all dissolved. After cooling, 3-methyl-4-nitrophenol (2.01 g) was 
added and the mixture refluxed at 90-95° for 65 h. The solvent was evaporated under 
reduced pressure and the residue diluted with water and extracted with methylene chloride. 
The extract was washed with 10% aqueous sodium chloride, dried (Na2SC>4) and 
evaporated to leave an orange liquid. The product was purified by chromatography in 
methylene chloride over a column of alumina (25cm x 4cm) to give the oily title compound 
(4.4 g) which was purified further for analyses by PTLC (alumina; methylene chloride, 
developed twice) (Found C: 65.5; H, 8.5; N, 11.8. C19H29N3O3 requires C, 65.7; H, 
8.4; N, 12.1%). 1H n.m.r. 5 1.52, complex, 2.45, complex, H2',3',4',5',6'; 2.45, s, 
Me; 3.56, s, 2-CH2; 3.65, s, 6-CH2; 7.73, s, H5.
In a similar manner were prepared the following compounds.
2 ,6-Bis(dimethylaminomethyl)-3-methyl-4-nitrophenol  (Vl.la) (75%) [after 
chromatography over a column of alumina (20cm x 6cm) in methylene chloride and elution 
with methylene chloride-methanol, and PTLC (alumina; 3% methanol in chloroform)] 
(Found C: 58.1; H, 8.1; N, 15.5. C13H21N3O3 requires C, 58.4; H, 7.9; N, 15.7%). *H 
n.m.r. 5 2.33, s, MeN; 2.48, s, MeC; 3.55, s, 2-CH2; 3.66, s, 6-CH2; 7.73, s, H5.
2y6-Bis(diethylaminomethyl)-3-methyl-4-nitrophenol  (Vl.lb) (90%) [after 
chromatography over a column of alumina in methylene chloride and then 2% methanol in 
methylene chloride followed by PTLC (alumina; chloroform)] (Found C: 63.4; H, 9.2; N, 
13.3. C17H29N3O3 requires C, 63.1; H, 9.0; N, 13.0%). lH n.m.r. 5 1.06, t, 1.08, t, J 
7 Hz, MeCH2; 2.46, s, 3-Me; 2.60, q, J 7 Hz, MeCH2, 3.64, s, 2-CH2; 3.77, s, 6-CH2; 
7.80, s, H5. MS m/z 323 (0.3%) (M+), 221 (24.4%).
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2,6-Bis(t-butylaminomethyl)-3-methyl-4-nitrophenol (VI.lc) (70%) [after the 
crude product was extracted (with hexane) and chromatographed in chloroform over a 
column of alumina, and PTLC (alumina; chloroform, developed twice)] (Found C: 60.2; H, 
7.0; N, 13.7. C25H34BrN50  requires C, 60.0; H, 6.9; N, 14.0%). *H n.m.r. 5 1.20, s, 
Me3C; 2.37, s, 3-Me; 3.67, s, 2-CH2; 4.05, s, 6-CH2; 7.86, s, H5.
3‘Methyl-4-nitrO’2,6-bis(pyrrolidin-l,-ylmethyl)phenol (Vl.ld) (86%) [after 
column chromatography over alumina in methylene chloride with addition of methanol and 
PTLC (alumina; 1% methanol in chloroform)] (Found C: 63.7; H, 8.1; N, 13.3. 
Ci7H25N30 3 requires C, 63.9; H, 7.9; N, 13.2%). n.m.r. 5 1.84, complex, 2.65, 
complex, H2',3',4',5',; 2.47, s, Me; 3.73, s, 2-CH2; 3.88, s, 6-CH2; 7.78, s, H5.
3- Methyl-4-nitro-6-(pyrrolidin-l'-ylmethyl)phenol (VI.2)
This compound was obtained (14%), together with the di-Mannich compound, 
when a mixture of pyrrolidine (1.721 g), paraformaldehyde (0.782 g) and 3-methyl-4- 
nitrophenol (1.2 g) in ethanol (10.0 ml) was refluxed for 19 h. The crude product was 
obtained by extraction with chloroform and methylene chloride. It was subjected to PTLC 
(alumina; 1% methanol in chloroform) and then PTLC (silica; 6% methanol in chloroform) 
and the product at higher Rf was recrystallised from cyclohexane to give the title compound, 
m.p. 110-113° (Found C: 61.8; H, 6.9; N, 11.3. C i2HiöN2O3.0.1 C6H12 requires C, 
61.9; H, 7.1; N, 11.4%). lH n.m.r. 5 1.89, complex, 2.67, complex, H2',3',4',5'; 2.58, 
s, 3-Me; 3.87, s, 6-CH2; 6.67, s, H2; 7.84, H5. MS m/z 237 (M+l) (2.2%), 236 (M+) 
(12.2%), 166 (4.5%), 120 (3.7%), 84 (cyclohexane) (32.4%).
4- (7’-Chloroquinolin-4,-ylamino)-3-methyl-2,6-bis(piperidin-l ”-ylmethyl) 
phenol  (VI.4e)
3-Methyl-4-nitro-2,6-bis(piperidin-l-ylmethyl)phenol (0.6 g) in saturated ethanolic 
ammonia (30.0 ml), ethanol (20.0 ml) and Raney-nickel were shaken with hydrogen until 
uptake ceased and the yellow colour had discharged. The catalyst was removed on Celite 
and the solvent evaporated to give the crude amine (0.556 g). n.m.r. 8 1.14, complex,
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2.40, complex, 2.46, complex, H2',3,,4',5',6'; 2.10, s, Me; 3.50, s, 2-CH2; 3.58, s, 6- 
CH2; 5.69, br s, NH, OH; 6.47, s, H5.
4,7-Dichloroquinoline (0.121 g) and the above amine (0.194 g) with methanol (2.2 
ml), water (0.6 ml) and concentrated hydrochloric acid (3 drops) (pH mixture 4.7) were 
refluxed at 90-95° for 14.5 h. The mixture was diluted with water, made alkaline with 
ammonium hydroxide and the precipitate collected. It was subjected to PTLC (alumina; 
chloroform, developed twice) and the product (0.221 g) reprecipitated from dilute hydro­
chloric acid with ammonium hydroxide to give as a white solid the title compound, m.p. 
181-184° (Found C: 66.7; H, 7.4; N, 10.9. C28H35CIN4O.I.4H2O requires C, 66.7; H, 
7.6; N, 11.1%). *H n.m.r. 5 1.55, complex, 2.53, complex, H2",3",4",5",6"; 2.12, s, 
3-Me; 3.60, s, 2-CH2; 3.68, s, 6-CH2; 6.13, d, J 5.5 Hz, H3'; 6.50, br s, NH; 7.08, s, 
H5; 7.41, d, 7.43, d, J5-t6' 9 Hz, J6',8' 2 Hz, H6’; 7.85, d, J 9 Hz, H5; 8.00, d, J 2 Hz, 
H8'; 8.44, d, J2-,3' 5 Hz, H2'.
In a similar manner the following compounds were prepared.
3 - M ethyl-2 ,6 -b is(p ip  er idin-1 ,~y lmethyl) -4-(7”- t r i f lu orom eth y lqu in o l in -4n - 
y la m in o )p h en o l  (VI.5e) (73%) as yellow crystals m.p. 186-188° [after PTLC 
(alumina; 1% methanol in methylene chloride, developed twice) and recrystallisation from a 
mixture of ethanol and light petroleum (b.p. 60-80°)] (Found: C, 68.1; H, 7.1; N, 10.7. 
C29H35F3N4O requires C, 68.0; H, 6.9; N, 10.9%). *H n.m.r. 5 1.54, complex, 2.50, 
complex, H2',3',4',5',6'; 2.12, s, Me; 3.57, s, 2-CH2; 3.68, s, 6-CH2; 6.23, d, J 5.5 
Hz, H 3M; 6.58, br s, NH; 7.06, s, H5; 7.63, d, 7.65, d, J5",6» 9 Hz, J6»>8« 2 Hz, H6"; 
8.04, d, J 9 Hz, H5; 8.31, br s, H8"; 8.52, d, J 5.5 Hz, H2". MS m/z 512 (3.0%) (M+), 
427 (7.1%). 13c n.m.r. (CDCI3) 13.7, 24.0, 25.7, 53.9, 56.6, 102.2, 120.1, 120.4, 
121.3, 122.1, 122.5, 125.8, 127.5, 127.8, 130.8, 134.1, 148.0, 152.2, 156.4 ppm.
4 -  ( 7 f- B r o m o - l  ’ f5 r-naphthy  r id in-4 ' -y  lam in o) -3 -m e  thy 1-2,6-b is (p iper id in-  
l" -y lm ethy l)phenol  (VI.6e) (71%) as white crystals, m.p. 184-186° [after PTLC 
(alumina; 0.5% methanol in chloroform) and recrystallisation from a mixture of ethanol and 
light petroleum (b.p. 60-80°)] (Found, C, 61.7; H, 6.6; N, 12,9. C27H34BrN50 requires
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C, 61.8; H 6.5; N, 13.3%). 1H n.m.r. 8 1.55, complex, 2.51, complex, 
H2",3",4",5",6"; 2.17, s, Me; 3.57, s, 2-CH2; 3.68, s, 6-CH2; 6.39, d, J 5 Hz, H3’; 
7.10, s, H5; 7.96, br s, NH; 8.41, d, J 2 Hz, H8'; 8.44, d, 12\3' 5 Hz, H2’; 8.75, d, J 2 
Hz, H6*. MS m/z 523 (2.3%), 525 (2.3%) (M+) 438 (4.8%), 440 (5.8%), 354 (13.3%).
4-(7’-Chlor oquinolin-1f -ylamino)-2,6-bis( dime thy laminomethyl)-3-methyl- 
phenol  (VI.4a)
2,6-Bis(dimethylaminomethyl)-3-methyl-4-nitrophenol (0.712 g) was reduced as 
described above to give the amine (0.656 g). *H n.m.r. 8 2.14, s, 3-Me; 2.28, s, MeN; 
3.44, s, 2-CH2; 3.55, s, 6-CH2; 6.43, s, H5.
The above amine (0.299 g) and 4,7-dichloroquinoline (0.191 g) gave, after PTLC 
(alumina; 3% methanol in methylene chloride), the title compound (61%). It was recrys­
tallisation twice from a mixture of cyclohexane and ethanol and then from methylene 
chloride and light petroleum (b.p. 60-80°) to give yellow needles, m.p. 177-179° (Found, 
C, 66.1; H, 6.8; N, 13.5. C22H27C1N40  requires C, 66.2; H, 6.8; N, 14.0). *H n.m.r. 
8 2.17, s, 3-Me; 2.29, s, 2.33, s, MeN; 3.51, s, 2-CH2; 3.65, s, 6-CH2; 6.12, d, J 5.5 
Hz, H3'; 6.56, br s, NH; 6.97, s, H5; 7.39, d, 7.42, d, J5’,6- 9 Hz, J6->8- 2 Hz, H6'; 7.86, 
d, J 9 Hz, H5’; 7.99, d, J 2 Hz, H8’; 8.42, d, J 5.5 Hz, H2\
2,6-Bis( dime thy laminome thy l)-3-methy l-4-(7,-trifluorome thy lquinolin-4t- 
ylamino)phenol (VI.5a) (63%), as yellow needles, m.p. 183-186° [after PTLC 
(alumina; 2.3% methanol in methylene chloride) and recrystallisation from a mixture of 
ethanol and light petroleum (b.p. 60-80°)] (Found C: 64.1; H, 6.5; N, 13.0. 
C23H27F3N40  requires C, 63.9; H, 6.3; N, 13.0%). *H n.m.r. 8 2.15, s, 3-Me; 2.30, s, 
2.34, s, MeN; 3.52, s, 2-CH2; 3.66, s, 6-CH2; 6.22, d, J 5.5 Hz, H3’; 6.65, br s, NH; 
6.99, s, H5; 7.62, d, 7.64, d, J5',6' 9 Hz, J6-,8’ 2 Hz, H6'; 8.06, d, J 9 Hz, H5’; 8.30, br 
s, H8'; 8.51, d, J 5.5 Hz, H2’. I.r. v max 3480 (br) (OH st), 3200 (m) (NH st), 2975 + 
2954 (m) (aliph. CH st), 1598 (s), 1582 (s), 1535 (s), 1477 (s), 1390 (s), 1388 (s), 1156 
(s), 1131 (s) (CF3 st), 1079 (m), 828 (m), 743 (mw), 690 (ms) cm-1. U.v. Xmax (pH
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8.34) 212 nm (löge  4.77), 244 nm (log e 4.12) (as inflexion), 330 nm (log e 4.16). MS 
m/z 432 (2.0%) (M+), 387 (11.3%).
4-(7'-Bromo-1 ’ , 5 ’-naphthyridin-4'  -ylamino)-2,6-bis(dimethylamino-  
methyl)-3-methylphenol  (VI.6a) (48%) [after PTLC (alumina; 3% methanol in 
methylene chloride, developed twice)]. It was recrystallised from a mixture of cyclohexane 
and ethanol to give a white solid, m.p. 117-119° (Found C: 56.5; H, 5.7; N, 15.5. 
C2iH 2öBrN5 0  requires C, 56.8; H, 5.9; N, 15.8%). n.m.r. 6 2.19, s, 3-Me; 2.31, s, 
2.35, s, MeN; 3.54, s, 2-CH2; 3.66, s, 6-CH2; 6.37, d, J 5.5 Hz, H3’; 7.06, s, H5; 7.95, 
br s, NH; 8.42, d, J 2 Hz, H8'; 8.44, d, J 5.5 Hz, H2'; 8.75, d, J 2 Hz, H6'. I.r. v max 
3460 (br) (OH st), 3230 (br) (NH st), 2964 (mw), 1602 (m) (ar. CH skeleton st), 1575 
(s), 1528 (m), 1476 (multiplet), 1369 (s), 1476 (s) cm’1. U.v. Xm2LX (pH 8.6) 263 nm 
(log e 4.44), 314-316 nm (log e 3.89), 354 nm (log e 3.93).
4-(7 ’-Chloroqu inol in-4’-y lamino)-2,6-bis( die thy laminome thy l)-3-methyl- 
phenol  (VI.4b)
2,6-Bis(diethylaminomethyl)-3-methyl-4-nitrophenol (90.8 g) was reduced as 
above to give the corresponding amine (0.772 g). JH n.m.r. 5 1.05, t, J 7 Hz, MeCH2; 
2.10, s, 3-Me; 2.55, q, 2.57, q, J 7 Hz, MeCH2; 3.58, s, 2-CH2; 3.68, s, 6-CH2; 5.47, 
br s, NH, OH; 6.56, s, H5.
This amine (0.297 g) and 4,7-dichloroquinoline (0.202 g) as above gave, after 
PTLC (alumina; 3% methanol in methylene chloride) and recrystallisation from a mixture of 
ethanol and light petroleum (b.p. 60-80°), the title compound (52%), m.p. 137-139° 
(Found, C, 68.8; H, 7.8; N, 12.1. C26H35C1N4 requires C, 68.6; H, 7.8; N, 12.3%). 
!H n.m.r. 8 1.06, t, 1.11, t, J 7 Hz, MeCH2; 2.14, s, 3-Me; 2.59, q, 2.63, q, J 7 Hz, 
MeCH2; 3.64, s, 2-CH2; 3.78, s, 6-CH2; 6.14, d, J 5.5 Hz, H3'; 6.58, br s, NH; 7.08, s, 
H5; 7.40, d, 7.42, d, J5-,6' 9 Hz, J6-j8’ 2 Hz, H6’; 7.87, d, J 9 Hz, H5'; 7.99, d, J 2 Hz, 
H8’; 8.42, d, J 5.5 Hz, H2\ MS m/z, 454 (M+), 425 (M+- Et).
2 ,6-Bis(die thylaminomethyl)-3-methyl-4-(7 '-tr ifluoromethylquinolin-4’ - 
ylamino)phenol  (VI.5b) (69%) as white crystals, m.p. 155-157° [after PTLC
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(alumina; 2.5% methanol in methylene chloride, developed twice) and recrystallisation from 
a mixture of cyclohexane and methylene chloride] (Found, C, 66.6; H, 7.4; N, 11.3. 
C27H35F3N4O requires C, 66.4; H, 7.2; N, 11.5%). *H n.m.r. 5 1.10, t, 1.14, t, J 7 
Hz, M eCH 2; 2.15, s, 3-Me; 2.65, q, J 7 Hz, M eCH2; 3.70, s, 2-CH2; 3.81, s, 6-CH2; 
6.24, d, J 5.5 Hz, H3'; 6.54, br s, NH; 7.15, s, H5; 7.65, br d, J 9 Hz, H6'; 8.05, d, J 9 
Hz, H5'; 8.31, s, H8'; 8.53, d, J 5 Hz, H 2\ MS m/z, 488 (0.5%) (M+), 459 (2.4%) 
(M+-Et), 415 (3.5%), 386 (6.0%), 344 (17.6%).
4 - ( 7 ' - B r o m o - l ', 5 ,-n a p h th yr id in -4 ' -y lam in o) -2 ,6 -b i s (d ie th y lam in om eth y l )-
3-  methylphenol  (VI.6b) (80%) [after PTLC (alumina; 3% methanol in methylene 
chloride, developed twice) and reprecipitation from aqueous acid with ammonium 
hydroxide] (Found, C, 59.6; H, 6.6; N, 13.7. C2sH34BrN50 requires C, 60.0; H, 6.8; 
N, 14.0%). !H n.m.r. 5 1.08, t, 1.12, t, J 7 Hz, M eC H 2; 2.19, s, 3-Me; 2.62, q, 
2.64, q, J 7 Hz, M eCH 2; 3.68, s, 2-CH2; 3.79, s, 6-CH2; 6.40, d, J 5.5 Hz, H3'; 7.17, 
s, H5; 7.97, br s, NH; 8.42, d, J 2 Hz, H8'; 8.44, d, J 5 Hz, H2’; 8.75, d, J 2 Hz, H6\
4 -  ( 7 ,- B r o m o - l ', 5 ' -n a p h th yr id in -4 ,-y lam in o ) -2 ,6 -b i s ( t -b u ty la m in o m eth y l ) -  
3-m e th y lp h en o l  (VI.6c)
2,6-Bis(t-butylaminomethyl)-3-methyl-4-nitrophenol (0.602 g) was reduced as 
above to give the corresponding amine (0.523 g). *H n.m.r. 5 1.20, s, 1.23, s, Me3C; 
2.14, s, 3-Me; 2.95, br, NH; 3.75, s, 2-CH2; 3.83, s, 6-CH2; 6.42, s, H3.
This amine (0.152 g) and 3-bromo-8-chloro-l,5-naphthyridine (0.149 g) as above 
gave after PTLC (alumina; 3% methanol in chloroform) the title compound (0.054 g). It 
was recrystallised from light petroleum (b.p. 60-80°) and had m.p. 149-151° (Found: C, 
60.2; H, 7.0; N. 13.7. C25H34BrN50  requires C, 59.9; H, 6.9; N, 14.0%). *H n.m.r. 5 
1.22, s, 1.25, s, Me3C; 2.20, s, 3-Me; 3.84, s, 2-CH2; 3.91, s, 6-CH2; 6.39, d, J 5.5 Hz, 
H3'; 7.01, s, H5; 7.90, br s, NH; 8.42, d, J 2 Hz, H8'; 8.44, d, J 5.5 Hz, H2’; 8.75, d, J 
2 Hz, H6'.
4-(7 ,-Chloroquinolin-4,-ylamino)-3-methyl-2y6-bis(pyrrolidin-l ”-yl- 
methyl)phenol (VI.4d)
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3-Methyl-4-nitro-2,6-bis(pyrrolidin-r-ylmethyl)phenol (0.701 g) was reduced as 
above to the corresponding amine (0.578 g). *H n.m.r. 8 1.75, complex, 2.58, complex, 
H2',3',4',5'; 2.13, s, Me; 3.61, s, 2-CH2; 3.73, s, 6-CH2; 6.41, br s, H5.
This amine (0.175 g) and 4,7-dichloroquinoline (0.123 g) as above gave after 
precipitation, PTLC (alumina; 3% methanol in methylene chloride) and recrystallisation 
from a mixture of cyclohexane and ethanol, the title compound (0.144 g), m.p. 174-176° 
(Found: C, 67.2; H, 6.5; N, 11.5. Q7H31F3N4O requires C, 66.9; H, 6.5; N, 11.6%). 
' h  n.m.r. 6 1.79, 1.83, complex, 2.59, 2.65, complex H2",3",4",5"; 2.12, s, Me; 3.69, 
s, 2-CH2; 3.85, s, 2-CH2; 6.12, d, J 5.5 Hz, H3'; 6.56, br s, NH; 7.02, s, H5; 7.39, d, 
7.41, d, J5',6' 9 Hz, J6',8' 2 Hz, H6'; 7.85, d, 9 Hz, H5'; 7.99, d, 2 Hz, H8’; 8.41, d, J 
5.5 Hz, H2’.
3- M ethyl-2 f6-bis(pyrrolidin-l ' -ylmethyl)-4-(7 "-trifluoromethylquinolin-4n - 
ylamino)phenol (VI.5d) (49%), as a white solid, m.p. 178-180° [after PTLC (alumina; 
3% methanol in methylene chloride, developed twice) and recrystallisation from a mixture 
of cyclohexane and a little ethanol] (Found, C, 67.2; H, 6.5; N, 11.5. C27H3iF3N40 
requires C, 66.9; H, 6.5; N, 11.6%). *H n.m.r. 5 1.81, 1.85, complex, 2.62, 2.68, 
complex, H2',3',4',5'; 2.15, s, Me; 3.72, s, 2-CH2; 3.88, s, 6-CH2; 6.24, d, J 5.5 Hz, 
H3M; 6.59, br s, NH; 7.06, s, H3; 7.60, d, 7.69, d, J5",6» 9 Hz, J6»,8" 2 Hz, H6"; 8.04, d, 
J 9 Hz, H5"; 8.31, br s, H8"; 8.52, d, J 5.5 Hz, H2".
4- (7 '-Brom o-l ' ,5'-naphthyridin-4' -ylamino)-3-methyl-2,6-bis(pyrrolidin- 
l ”-ylmethyl)-phenol (VI.6d) (62%), m.p. 182-184° [after PTLC (alumina; 2.5% 
methanol in methylene chloride, developed twice) and recrystallisation from a mixture of 
methylene chloride and hexane] (Found, C, 60.7; H, 6.2; N, 14.0. C2sH3oBrN50 
requires C, 60.5; H, 6.1; N, 14.1%). lH n.m.r. 8 1.86, complex, H3",4"; 2.20, s, Me; 
2.70, complex, H2",5"; 3.76, s, 2-CH2; 3.90, s, 6-CH2; 6.40, d, J 5.5 Hz, H3'; 7.14, s,
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H5; 7.95, br s, NH; 8.42, br s, H8' 8.45, d, J 5.5 Hz, H2'; 8.75, d, J 2 Hz, H6\  MS 
m/z 495 (1.4%), 497 (1.4%) (M+), 426 (2.5%), 355 (7.3%).
2 .6 - Bis( d ipen ty lam in om eth y l ) -4 - (7 ,- t r i f lu orom eth y lqu in o l in -4 ,-y lamino)- 
ph en o l  (VI.7d)
4-Amino-2,6-bis(dipentylaminomethyl)phenol (0.371 g; see above), 4-chloro-7- 
trifluoromethylquinoline (0.151 g), methanol (3.0 ml), water (1.0 ml) and concentrated 
hydrochloric acid (0.1 ml) were refluxed at 90° for 18 h. The methanol was evaporated 
under reduced pressure, the residue diluted with water and adjusted with ammonium 
hydroxide to pH 7 and the mixture extracted with chloroform. The extract was dried 
(Na2SC>4) and evaporated to give an oil which was subjected to PTLC (alumina; 
dichloromethane) to give 2,6-bis(dipentylaminomethyl)-4-(T-trifluoromethylquinolin-4'- 
ylamino)phenol (0.243 g) (Found: C, 70.2; H, 9.1; F, 8.7; N, 8.5. C38H57F3N4O.O.5 
H20  requires C, 70.0; H, 9.0; F, 8.7; N, 8.6%). *H n.m.r. 5 0.87, t, J 7 Hz, Me; 1.26, 
complex, NCH2CH2CH2CH2; 2.5, t, J 7 Hz, NCH2CH2; 3.69, s, ArCH2N; 6.74, d, 
J2’,3' 5.5 Hz, H3'; 7.07, s, H3,5; 7.63, br d, J5'j6’ 9 Hz, H6 '; 8.04, d, J5'>6' 9 Hz, H5’; 
8.31, s, H8'; 8.54, d, J2\ 3’ 5.5 Hz, H2\
2 .6 -  B i s (N -b u ty l -N -m e th y la m in o m e th y l ) -4 - (7 f- tr i f luorom ethylqu ino l in -4 '  - 
y lam ino)pheno l  (VI.7e)
4-Amino-2,6-bis(V-butyl-V-methylaminomethyl)phenol (0.551 g; see above) and 
4-chloro-7-trifluoromethylquinoline (0.413 g) as for the analogue above gave a crude 
product which was purified by PTLC (alumina; ethyl acetate/hexane, 1:5) to yield the title 
compound (0.352 g). Found: C, 60.4; H, 6.1; N, 16.8. C21H24F3N 5O requires C, 60.1; 
H, 5.8; N, 16.7%). lH n.m.r. 5 0.90, t, J 7 Hz, MeCH2; 1.45, complex, NCH2(CH2)2; 
2.26, s, NMe; 2.46, t, J 7 Hz, NCH2CH2; 3.61, s, NCH2Ar; 6.74, d, J2',3’ 5 Hz, H3’; 
7.04, s, H3,5; 7.30, br s, NH; 7.58, br d, J5-,6’ 9 Hz, H6’; 8.12, br d, J5'>6' 9 Hz, H5'; 
8.28, br s, H8'; 8.54, d, J2,3 5 Hz, H2'. I.r. vmax 2960 (w), 1580 (m), 1480 (s), 1125 
(m) cm-1.
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VI-5.2 Determination of the basic ionization constant and ultraviolet
spectra of 4-(7-trifluoromethylquinolin-4-ylamino)phenol (VI.8)
Substance: 4-(7-Trifluoromethylquinolin-4-ylamino)phenol hydrochloride,a 
C 16H 11F3N2O. HC1; MW 340.729.
Concentration: 1:1 x 10_4 M. Recrystallised compound (m.p.315-3170) was dried at
20°/0.2 mmHg overnight and a sample (0.0094 g) was dissolved in ethanol (2.5 ml) added 
to hot water (200 ml), then cooled and made up to 250.0 ml with water. This stock solution 
(2.0 ml) was diluted with appropriate buffers (2.0 ml).
Analytical wavelength: 350 nm; cell, 1 cm
Buffer: Potassium dihydrogen orthophosphate and disodium hydrogen orthophos­
phate buffers (I = 0.1)
Species: Neutral and cationic species
Temperature: 20°
Result:
pH measured: 7 .6 9  7 .62  7.51 7 .42  7 .32  7 .13  6.91
pKa calc.: 7 .55  7 .59  7 .59  7 .63  7 .55  7 .65  7 .64
pKa = 7.60 ± 0.05
The ultraviolet spectra were recorded as follows:
u.v. ^max (pH 8.8) 342 nm (log 8 3.98)
(pH 4.47) 348 nm (log 8 4.14)
a Kindly prepared by SJ. Ireland
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CHAPTER VII a-(Piperidin-2-yl)-a-(7'-trifluoromethylquinolin-4'-yl)-  
methanol, its l'-Oxide and Related Compounds
VII-1 Introduction
A series of quinolinylmethanols (VII.l), which are structurally related to quinine 
(I.la), have been shown to possess high antimalarial activity; and mefloquine [oc-(2,8- 
bistrifluoromethylquinolin-4-yl)-a-(piperidin-2-yl)methanol] (VII.2) is now widely used 
as an antimalarial.
VII.l VII.2
Prior to the discovery of mefloquine, a number of a-(piperidin-2-yl)-a- 
(quinolin-4-yl)methanols231-233 was shown to possess high antimalarial activity. This 
activity was associated with a substituent in the 2-position of the quinoline nucleus, 
particularly the phenyl substituent, which prevented oxidation at that position (the cinchona 
alkaloids and related compounds were rapidly biotransformed in man to the inactive 
carbostyril derivatives234). Thus a-(6,8-dichloro-2-phenylquinolin-4-yl)-a-(piperidin-2- 
yl)m ethanol235 (SN 10,275) (VII.3) was 8 times more active than quinine against P. 
cathemerium in ducks;141 but this compound was also reported to cause photosensitisation 
in mice236 and man.237 Further evaluation of the phototoxicity of quinolinylmethanol 
derivatives (VII.l) has been reported by Rothe and Jacobus.236 Surprisingly, quinine 
(a well-known quinolinylm ethanol lacking a 2-substituent) does not cause any 
phototoxicity.
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A consideration of the above data and of the high antimalarial activity of a series of 
di-Mannich bases of 4-(7-trifluoromethylquinolin-4-ylamino)phenol97’98 and related 
compounds reported previously from this laboratory prompted the present work to 
synthesise the a-(piperidin-2-yl)-a-(2-unsubstituted-7-trifluoromethylquinolin-4-yl)- 
methanol (VII.4) and related compounds, such as compounds VII.5, VII.6 and VII.7.
VII.6 X=Br v n .8
VII.7 X=CF3
VII-2 Some Literature Preparations Relating to the Synthesis of a -  
(Quinolin-4-yI)methanols
Literature syntheses relating to two types of a-(substituted quinolin-4-yl)methanols 
are discussed in this Chapter: a-alkyl (and a-dialkyl)aminomethyl-a-(quinolin-4-yl)- 
methanols (VII.8) in Chapter VII-2.1; a-(piperidin-2-yl)-a-(quinolin-4-yl)methanols 
(VIL1 except mefloquine) in Chapter VII-2.2; and mefloquine in Chapter VII-4.
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VII-2.1 Preparations of a-alkyl (and a-dialkyI)aminomethyl-a-(2-phenyl- 
quinolin-4-y I) methanols
The general methods used to prepare a-alkyl (and a-dialkyl)aminomethyl-a-(2- 
phenylquinolin-4-yl)methanols have commenced from the relevant quinoline-4-carboxylic 
acid or ester and have involved two synthetic methods. The first method which was more 
generally used (Scheme VII-1) involved the reaction of the acid chloride to give the 
diazomethyl ketone (VII.9).231 Hydrobromination of compound VII.9 gave the a-bromo 
methyl ketone (VII.10),238 and then an aluminium isopropoxide reduction afforded the 
bromohydrin (VII.11).239 Epoxidation and subsequent condensation of compound 
VII. 11 with appropriate amines afforded the amino alcohols (VII.12).240
The other method, which has been used in a few cases, involved the Claisen 
condensation between the quinolin-4-carboxylic ester and ethyl acetate to give the ß-keto 
ester (VII.13),241-243 followed either by simultaneous bromination and hydrolysis241 to 
the bromomethyl ketone (VII.10) or by hydrolysis and then decarboxylation to the methyl
Q-COC1 ----------  Q-COCH2N2
VII.9
Q-CHCH2NR2
VII.12
q -c h c h 2 
\  /
when Q
Q-COCH2Br
VII.10
Q-CHCH2Br
(^H
V II.ll
Scheme VII-1
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ketone (VII. 14) with a subsequent bromination to compound VII. 10. Amination then 
afforded the desired compound VII.12 (Scheme VII-2).
Q-COzEt ----------  Q-C0CH2C02Et ----------Q-COMe
VII.13 VII.14
VII.12
when Q
Q-COCH2Br
VII.10
Scheme VII-2
V II-2.2 Preparations of a-(piperidin-2-yl)-a-(2-substituted quinolin-4-
yl)methanols
The a-(piperidin-2-yl)-a-(quinolin-4-yl)methanols [(VII.15), R=R1=H; R=OMe, 
R1=H; R=H or OMe, R*=alkyl, allyl or crotyl] were first synthesised and evaluated for 
antimalarial activity by Ainley and King in 1938.231 They found that only compound 
VII.15 (R=OMe, R ^H ) and its diastereoisomer were active against malaria parasites. 
Their synthetic procedures are summarised in Scheme VHI-3.
a-(7-Chloroquinolin-4-yl)-a-(piperidin-2-yl)methanol (VIII.16) was synthesised 
(in a similar manner to that described above) by Senear et al.244 from ethyl 7-chloro- 
quinoline-4-carboxylate using the improved245 procedure of Ainley and King.231 The 5- 
chloro isomer of compound VII. 16, however, could not be obtained by this method, 
presumably due to the steric effect of the 5-chloro substituent.
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C 0 2Et
+ E t0 2C(CH2)5NHCH2Ph
40% HBr/Br2
H2/P t 0 2
VII.15 R*= H
Schem e VII-3
V II.16
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In 1967, Boykin et a/.233 reported a new and more convenient two-step synthesis 
from the corresponding quinoline-4-carboxylic acids to give the a-(2-arylquinolin-4-yl)- 
a-(piperidin-2-yl)methanols (VII.19). The first step involved conversion of 6-methyl- 
2-(p-tolyl)quinoline-4-carboxylic acid (VII. 17) by 2-pyridinyllithium into the pyridin-2- 
yl ketone (VII.18). The second step was a selective reduction of compound VII.18: 
catalytic hydrogenation reduced both the carbonyl and pyridinyl groups and gave 
compound VII.19, whereas sodium borohydride reduced only the carbonyl group to 
afford the a-(pyridin-2-yl)methanols (VII.20) (Scheme VII-4).
V II.17
NC5H4Li
-60°
When Ar=p-toIyl
VII.19
VII.18
Scheme VII-4
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Pinder and Burger,141 have reported the syntheses (using the method described by 
Boykin et a l233) and antimalarial activity of a series of a-(piperidin-2-yl and pyridin-2-yl)- 
a-(2-trifluoromethylquinolin-4-yl)methanols (VII.21 and VII.22). They found that 
compound VII.21 showed moderate antimalarial activity but induced photosensitisation, 
the unsubstituted compound (VII.21, R=H) was inactive; and the a-(pyridin-2-yl) 
methanols (VII.22) were inactive and did not cause photosensitisation.
OilHCX J
N h °
H
R Ok 'C F ,
V I I .2 1 V I I .2 2
Patel and coworkers246 attempted the synthesis of compound VII.4 but were 
unsuccessful. In this 7-trifluoromethylquinoline-4-carboxylic acid (VII.23) with 2- 
pyridinyllithium gave low yields of the pyridin-2-yl ketone (VII.24), and compound 
VII.25; but the ester derivative of compound VII.23 with 2-pyridinyllithium in ether gave 
compound VII.24 in good yields. However the selective hydrogenation of compound 
VII.24 to compound VII.4 was unsuccessful (Scheme VIII-5).
The syntheses of a-(2,8-bistrifluoromethylquinolin-4-yl)-a-(piperidin-2-yl)- 
methanol (mefloquine) (VII.2) by Ohnmacht,133 using a procedure similar to that 
described above, is mentioned in Chapter VII-4.
VIII-3 Palladium-catalysed Vinylation of Organic Halides
The palladium-catalysed vinylation of organic halides provides a very convenient 
method for carbon-carbon bond formation at unsubstituted vinylic positions, and the 
reaction can be carried out in one step. The general reaction247 is shown in Scheme VII-6.
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The base needed for this type of reaction may be a secondary248 or tertiary 
amine,249’250 or sodium bicarbonate,251»252 and a variety of organophosphine palladium 
complexes have been used as catalysts in these vinylic hydrogen substitution reactions.247
VII.24 VII.25VII.23
VII.4
Scheme VII-5
C—C + R.X + Base 
/  \
PdL2X2
/  \
Base H+ X
R = Aryl, heteroaryl, benzyl or vinyl 
X = Bromide, iodide,or (rarely) chloride 
L = Ligand
Scheme VII-6
The detailed mechanism of the reaction has not been established. However, 
Heck247 has proposed a mechanism (Scheme VII-7) which is based on the large amount of 
information available from related studies with other organopalladium reactions.
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Catalyst formation :
H
PdX2 + \= C  + 2L
/  \
A  .
PdL, + HX + \ = C
/  \
Catalytic cycle :
PdL2 + RX --------► RPdL2X
H H
RPdL2X + XC-C --------► R-C"-C-PdL2X
/  \ 1 1
H R
R i  C PdL2X S+II
/
u
1 1 /  \
HPdL2X + Base ------ --------► PdL2 + Base
Scheme VII-7
Ziegler and Heck253 have reported reactions of iV-vinylamides such as W-vinyl- 
pyrrolidin-2-one and N-vinylphthalimide with bromobenzene (Scheme VH-8) and Frank et 
al.254 have described the synthesis of nornicotine (VII.26) in four steps from 3- 
bromopyridine and V-(but-3-enyl)phthalimide (Scheme VII-9).
Palladium-catalysed vinylations of organic halides have been reviewed by Heck 247
VII-4 Literature Preparations of a-(2,8-BistrifIuoromethy!quinolin-4-yl)- 
a-(piperidin-2-yl)methanol (Mefloquine)
Mefloquine, registered under the name Lariam (F. Hoffmann-La Roche), is a highly 
active blood schizontocide against multidrug-resistant P. fa lciparum .^  Three syntheses 
of this compound have been described.
The first synthesis was reported in 1971 by Ohnmacht et a/.133 and involved the 
conversion of 2,8-bistrifluoromethylquinolin-4-one (VII.27) (obtained by PPA 
condensation of 2-trifluoromethylaniline and ethyl 4,4,4-trifluoroacetoacetate using 
adaptations of previously described procedures141*255) by phosphoryl bromide into the 4-
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- Ph1
f phY^/N
r  + PhBr
EtjN .N .— cr N* o-
60% 40%
Scheme VII-8
AcOHg
NaBH4
O
Scheme VII-9
bromoquinoline (VII.28) and its conversion in the presence of butyllithium and carbon 
dioxide to the quinoline-4-carboxylic acid (VII.29). Addition of 2-pyridinyllithium to 
compound VII.29 afforded the pyridinyl ketone (VII.30). Reduction of VII.30 with 
hydrogen over platinum oxide gave good yeilds of compound VII.2 (Scheme VII-10).
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O
V II.27 V II.28
V II.29
V II.2 V II.30
Schem e V II-10
The second synthesis256 (Scheme VII-11) involved the reaction of 6-bromohex- 
1-ene with potassium phthalimide in V^V-dimethylacetamide to give the V-(hex-5-en-l-yl) 
compound (VII.31), which was subjected to a palladium-catalysed vinylation reaction. 
Compound VII.31 was condensed with 4-bromo-2,8-bistrifluoromethylquinoline in the 
presence of tri-o-tolylphosphine and palladium acetate to give compound V II.32. 
Epoxidation of V II.32  with m-chloroperoxybenzoic acid afforded V II.33 and then 
cyclisation by treatment with hydrazine hydrate gave mefloquine (VII.2).
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V II.33 VI1-32
V II.2
Scheme VII-11
A third synthesis of mefloquine has been reported257 and involved the 
application of the Wittig rearrangement of aryl ethers to arylcarbinols.258’259 The 
condensation of 2-chloromethylpyridine and 4-hydroxy-2,8-bistrifluoromethylquinoline133 
gave the ether (VII.34) in 90% yield. This ether (VII.34) was treated with butyllithium at 
-78° in THF and then subjected to silylation affording (after flash chromatography) 
compound VII.35 (Scheme VII-12). Treatment of compound VII.35 with a catalytic 
amounts of tetrabutylammonium fluoride (TBAF) (0.2-0.5 equivalents) in acetonitrile at 
room temperature generated green solutions and gave a mixture of the expected carbinol 
(VII.36) and the ketone (VII.30). Catalytic hydrogenation of compound VII.30 over 
platinum oxide gave the desired compound (VEL2).
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VII.34
SiRMe2
TB AF
acetonitrile
VII.36 VII.30 VII.35
VII.2
Scheme VII-12
Carrol and Blackwell260 tested various optically active isomers of mefloquine 
for antimalarial activity but found no significant differences between such isomers.
VII-5 Syntheses of a-(Piperidin-2-yl)-a-(7-trifluoromethylquinolin-4-yl)- 
methanol and Related Compounds
VII-5.1 a-(Piperidin-2-yl)-a-(7-trifluoromethy!quinolin-4-yl)methanol
The synthesis of the above compound employed in this work is illustrated in 
Scheme VII-13 and the details are discussed in sections (a) and (b) below.
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VII.39 VII.38
VII.5
Scheme VII-13
(a) Synthesis of a-(piper'id\n-2-y\)-a-(7,-trifluoromethylquinolin‘4 ,-yl)- 
methanol l ’-oxide (VII.5)
6-Bromohex-l-ene with potassium phthalimide261 in dry V//-dimethylacetamide at 
room temperature as described by Adam,256 gave the vinyl compound (VII.31). This 
compound (VII.3I) with 4-bromo-7-trifluoromethylquinoline (VII.37) [prepared by
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bromination of the 4-hydroxy analogue with phosphoryl bromide at 140° for 4 h]141 and a 
mixture of palladium acetate, tri-o-tolylphosphine, sodium iodide and tributylamine in DMF 
at 100° for 17 h (a modification of literature procedures249’252’256 described above) gave 
compound VII.38. Surprisingly, when this reaction was carried out at 160° for 8 h the 
saturated compound (VII.40) was obtained. This palladium-catalysed reaction did not 
proceed when 4-chloro-7-trifluoromethylquinoline was used in place of its bromo analogue 
(V II.37).
When compound VII.38 was treated with excess m-chloroperoxybenzoic acid (ca 
3 equivalents) in refluxing chloroform, it gave compound VII.39; but with 1.5-2.0 
equivalents of the peroxyacid at room temperature for 3 h, it gave the l'-oxide (VII.41). 
This differed from the oxidation of compound VII.32256 in which the 2-trifluoromethyl 
group apparently hindered V-oxidation.
Hydrolysis and cyclisation of compound VII.39 with hydrazine hydrate in 
methanol at reflux gave the a-(piperidin-2-yl)-a-(7'-trifluoromethylquinolin-4'-yl)methanol 
l'-oxide (VII.5).
(b) Attempted synthesis of a - (p ip er id in -2 -y l ) -a - (7 - t r i f lu o ro m e th y l -  
quinolin-4-yl)methanol  (VII.4)
In the limited time available, attempts were made to remove the V-oxide group from 
compound VII.5 by two methods. Compound VII.5 with phosphorus trichloride262 in 
chloroform at reflux for 4 h gave a product differing in physical properties from VII.5. It
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had different Rf values on tic (alumina; 5% methanol-chloroform), different *H n.m.r. 
spectrum and mass spectrum, and its analysis approached the calculated values for 
compound VII.4. Another attempt to remove the V-oxide group by hydrogenation263 of 
compound VII.5 in saturated methanolic hydrogen chloride gave mixtures of products.
VII-5.2 Attempted syntheses of a-[(7-bromo (and 7-trifluoromethyl)-l,5- 
naphthyridin-4-yl]-a-(piperidin-2-yl)methanols
In the limited time available, and with the difficulties encountered in the syntheses 
described in Chapter VII-5.1 and common to this Section (VII-5.2), it was not possible to 
complete the syntheses of the above named compounds. The synthetic approaches 
employed and envisaged are shown in Scheme VII-14; some of these are described in detail 
below.
(a) Syntheses of N-[6-(7-subst i tuted-l ,5-naphthyridin-4-yl)hex-5-en-l-  
yl]phthalimides
Palladium-catalysed vinylation of compound VII.31 with 4-bromo-7-trifluoro- 
methyl-l,5-naphthyridine (VII.42b) (prepared from the 4-hydroxy compound with 
phosphoryl bromide at 140° for 4 h) in the presence of a mixture of palladium acetate, tri-o- 
tolylphosphine and tributylamine in hexamethylphosphoramide (HMPA) at 100° for 12 h 
gave compound VII.43b.
However when the reaction was carried out at 150° for 15 h the hexylphthalimide 
derivative (VII.44) was obtained as the major product. Mixtures of compounds VII.43b 
and VII.44 proved difficult to separate by PTLC.
4,7-Dibromo-l,5-naphthyridine (VII.42a) (prepared from the 4-hydroxy 
compound with phosphoryl bromide) with compound VII.31, palladium acetate, tri-o- 
tolylphosphine, tributylamine and sodium iodide in dimethylformamide (DMF) at 100° for 
21.5 h afforded compound VII.43a.
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O
VII.42a, X=Br
VII.31
VII.43a, X=Br
VII.44
VII.46
VII.45
VII.6, X=Br 
VII.7, X=CF
Scheme VII-14
(b) Synthesis of N-[6-(l-oxido-7-trifluoromethyl-l,5-naphthyridin-4-yl)-  
hex-5-en~l-yljphthalimide (VII.45)
Compound VII.43b was treated with m-chloroperoxybenzoic acid (1.5 
equivalents) in chloroform at 65° for 2 h to give compound VII.45 by oxidation at the ring 
nitrogen atom. The required intermediate epoxide (VII.46, X=CF3) was not obtained.
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This difference in behavior of compound VII.43b relative to compound VII.32 (Scheme 
VII-11) is obviously related to the presence of the 2-trifluoromethyl group in the latter 
compound.
VII-6 Physical Properties
VII-6.1 Nuclear magnetic resonance spectra
The *H n.m.r. spectrum of V-(hex-5-en-l-yl)phthalimide (VII.31) is shown in 
Figure VII-1, A. The assignments of V-allylic side chain protons were confirmed by 
means of proton-proton decoupling (Figures VII-1 and VII-1.1; B-C and D, repectively). 
Spectrum B shows that irradiation of the protons at 5 2.1 (H4), the complex pattern of the 
peaks at 8 5.53-6.08 (H5) was changed to a doublet of doublets, and the signal at 5 1.50 
was also changed. Spectrum C revealed that irradiation at 5 5.53-6.08 (H5) causes the 
peaks at 8 2.06 (H4) and 4.97 (H6) to change; and spectrum D shows that irradiation of the 
triplet at 8 3.7 (HI) causes a change in the complex peak at 8 1.50 (H2,3).
The *H n.m.r. spectra of the V-(hex-5-en-l-yl)phthalimides (VII.38 and VII.43) 
(see the Experimental section) revealed that they existed as the trans-isomers with coupling 
constants of 16 Hz; and H6 was at lower field than H5. Cis-olefinic coupling constants 
have been reported to occur in the range 7-11 Hz and the rra/u-olefinic coupling constant in 
the range 12-18 Hz.264
Whereas the hex-5-en-l-ylphthalimides (VII.38 and VII.43) exhibited olefinic 
protons in the region 8 6.0-7.20 (olefinic protons are reported to occur in the range 8 4.5- 
6.5),264 as expected, the hexylphthalimides (VII.40 and VII.44) did not show any 
signals in this region. These spectral differences were of assistance in the identification of 
the epoxides and V-oxides in subsequent reactions.
The *H n.m.r. spectra of compound VII.4 and its l'-oxide (VII.5) revealed that, 
as expected from data in the pyridine series,265 the signal for F12' at 8 8.37 in the l'-oxide 
(VII.5) was upfield of that in VII.4 (8 8.99) whereas the signal of H8' in the l'-oxide 
(VII.5) at 8 8.98 was significantly downfield of that in compound VII.4 at 8 8.42.
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13VII-6.2 C Nuclear magnetic resonance spectra
The assignment of the 13C n.m.r. spectral data for a-(piperidin-2-yl)-a-(7'- 
trifluoromethylquinolin-4'-yl)methanol (VII.4) and its T-oxide (VII.5) are shown in 
Figures VII-2 and VII-3, respectively.
23.5
128.0
Figure VII-2 The chemical shifts (ppm) of the carbon atoms in 
a-(piperidin-2-yl)-a-(7'-trifluoromethyIquinoIin- 
4'-ylamino)methanol (VII.4)
118.6
Figure VII-3 The chemical shifts (ppm) of the carbon atoms in 
a-(piperidin-2-yl)-a-(7'-trifIuoromethyIquinolin- 
4'-ylamino)methanol I'-oxide (VII.5)
The assignments of the 13C chemical shifts for these two compounds were carried 
out by running decoupled 13C n.m.r. spectra and 2-D HECTOR spectra. The 13C chemical
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shifts of carbon atoms with attached hydrogen atoms (C2',3',5',6',8'; C2,3,4,5,6; and C- 
a) were assigned from the HETCOR spectrum; the carbon of the CF3 group of VII.5 
appeared as a quartet (carbon-fluorine coupling); and the remaining carbon atoms were 
assigned similarly to compound VI.5e.
VII-6.3 Mass spectra
The mass spectra of V-[6-(7'-trifluoromethylquinolin-4'-yl)hex-5-en-l-yl]- 
phthalimide (VII.38) and the 7-bromo-l,5-naphthyridine analogue (VII.43a) were 
recorded (see Experimental section). The spectra showed the molecular ion peaks at m/z 
424 and 435 (associated with a peak at m/z 437; ratio 1:1), respectively. Major 
fragmentations of these two compounds involved C-C bond cleavages between Cl and C4 
to give the fragments at m/z M-160, M-174, M-188 and M-202. The loss of fluorine (mass 
19) and bromine substituents (mass 79) were also observed for compounds VII.38 and 
VII.43a to give fragments at m/z 405 and 356.
Surprisingly, the pattern of fragmentations of the oxiran W-oxide (VII.39) are 
different from those mentioned above; the stable fragments were m/z 160 (100%) and 211 
(87%), which are probably due to the loss of N-methylenephthalimide (C9H6NO2) and 4- 
methyl-7-trifluoromethylquinoline (C11H8F3N) fragments. The spectrum of compound 
VII.39 showed the molecular ion peak at m/z 456, and the loss of oxygen (cleavage of the 
N-0 bond)182 and carbon dioxide (from the phthalimide group)266*267 at m/z 440 (12%) 
and 412 (2%), respectively (alternatively it may involve loss of oxygen followed by loss of 
carbon monoxide from the phthalimido group).
The molecular ion peaks for a-(piperidin-2-yl)-a-(7'-trifluoromethylquinolin-4'- 
yl)methanol (V.II.4) and its W-oxide (VII.5) were not observed in their electron impact 
mass spectra, but the chemical ionization spectra [CI(NH3)] showed peaks due to the 
addition of a proton (MH+ peak) at m/z 311 and 327, respectively. The simultaneous loss 
of oxygen and water from compound VII.4 gave peaks at m/z 295 (88%) and 293 (48%), 
and from compound VII.5 gave peaks at m/z 311 (50%) and 309 (13%).
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VII-7 Experimental
4 -Bromo-7-trifluoromethylquinoline (VII.37)
7-Trifluoromethylquinolin-4-ol (4.0 g) and phosphoryl bromide (8.0 g) were heated 
at 140° for 4 h, cooled, and the residue was treated with ice and then with saturated sodium 
bicarbonate solution until it was alkaline. The grey precipitate was filtered off, washed with 
water, air dried and then recrystallised from isopropyl alcohol-water to give colourless 
needles of 4-bromo-7-trifluoromethylquinoline (4.7 g), m.p. 72-73° (Found, for a sample 
dried at 20°/0.2 mmHg for 3 h: C, 43.6; H, 1.6; Br, 28.5; N, 4.8. CioH5BrF3 N requires 
C, 43.5; H, 1.8; Br, 28.9; N, 5.1%). *H n.m.r. 5 7.82, dd, J5>6 9 Hz; J6>8 2 Hz, H6; 
7.82, d, J2,3 4.5 Hz, H3; 8.34, d, J5)6 9 Hz, H5; 8.43, br s, H8; 8.77; d, J2,3 4.5 Hz, H2.
4,7-Dibromo-1,5-naphthyridine (VII.42a)
7-Bromo-l,5-naphthyridine-4-ol (5.0 g) and phosphoryl bromide (20.0 g) were 
allowed to react as above. After neutralisation with 0.9 N ammonium hydroxide, the 
resulting brown solid was filtered off and recrystallised from heptane; to give colourless 
needles of the title compound (4.48 g), m.p. 190-192° (Found: C, 33.6; H, 1.2; N, 9.6. 
C8H4Br2N 2 requires C, 33.4; H, 1.4; N, 9.7%). *H n.m.r. 6 7.99, d, J 4.5 Hz; H3; 
8.61, d, J 2 Hz, H8; 8.74, d, J 4.5 Hz, H2; 9.07, d, J 2 Hz, H6.
4-Bromo-7-trifluoromethyl-l ,5-naphthyridine (VII.42b)
7-Trifluoromethyl-1,5-naphthyridin-4-ol (1.0 g) and phosphoryl bromide (2.0 g) 
were allowed to react as above. The crude product was purified by column chromato­
graphy (alumina; benzene) and the product (0.916 g) was recrystallised from heptane to 
give colourless needles of 4-bromo-7-trifluoromethyl-l,5-naphthyridine, m.p. 139-141° 
(Found, for a sample dried at 20°/0.2 mmHg for 19 h: C, 39.0; H, 1.4; Br, 28.7; N, 10.1. 
C9H4BrF3N2 requires C, 39.0; H, 1.5; Br, 28.8; N, 10.1%). *H n.m.r. 6 8.11, d, J 4.5 
Hz, H3; 8.73, br s, H8; 8.86, d, J 4.5 Hz, H2; 9.27, d, J 2Hz, H6.
N -(Hex-5-en-l-yl)phthalimide256 (VII.31)
Potassium phthalimide261 (1.34 g) and 6-bromohex-l-ene (0.9 ml) in dry N,N-di- 
methylacetamide (9.0 ml; dried over BaO and then distilled) were stirred at room
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temperature for 20 h. The mixture was extracted with ether and the crude product (1.56 g) 
was subjected to column chromatography [alumina; 5% ethyl acetate in light petroleum 
(b.p. 60-80°)] and gave the title compound (1.320 g), m.p. 27-28° (Found, for a sample 
dried at 20°/0.2 mmHg for 18 h: C, 73.1; H, 6.9; N, 5.8. Calc, for C14H15NO2: C, 73.3; 
H, 6.6; N, 6.1%). *H n.m.r. 6 1.50, complex, H2,3; 2.06, complex, H4; 3.70, t, J 6 
Hz, HI; 4.95, d, J6 ,6 9 Hz; 4.99, d, J5,6 16 Hz, H6; 5.53-6.08, complex, H5; 7.78, 
complex, ArH.
N-[6-(7,-Trifluoromethylquinolin-4’-yl)hex-5-en-l-yl]phthalimide (VII.38)
4-Bromo-7-trifluoromethylquinoline (2.3 g), A-(hex-5-en-l-yl)phthalimide (2.1 g), 
palladium acetate (0.020 g), tri-o-tolylphosphine (0.053 g), sodium iodide (0.030 g) and 
tributylamine (2.0 ml) in dimethylformamide (3.0 ml) were heated at 100° under nitrogen 
for 17 h. The residue was diluted with water, extracted with ethyl acetate, and the extract 
washed with dilute hydrochloric acid, saturated sodium bicarbonate solution, water, and 
then dried (Na2SC>4). The solvent was evaporated and the product subjected to column 
chromatography (alumina; 10-15% ethyl acetate in hexane) and recrystallised from ethanol 
to give white crystals of the title compound (0.719 g), m.p. 103.5-105° (Found: C, 67.8; 
H, 4.7; N, 6.5. C24H 19F3N2O2 requires C, 67.9; H, 4.5; N, 6.6%). *H n.m.r. 5 1.70, 
complex, H2,3; 2.44, complex, H4; 3.76; t, J 7 Hz, HI; 6.47, dt, 15,6 16 Hz, 14,5 7 Hz, 
H5; 7.08, d, 15,6 16 Hz, H6; 7.51, d, J2',3' 5 Hz, H3'; 7.75, complex, phthalimido H and 
H6'; 8.23, d, J5’,6’ 9 Hz, H5’; 8.39, br s, H8'; 8.91, d, J2\3’ 5 Hz, H2’. MS m/z 424 
(M+) (60%), 405 (7%), 277 (12%), 264 (31%), 250 (100%), 236 (29%), 211 (77%), 160 
(81%), 147 (2%).
N ~{4-[3 '-(1 ,,-Oxido-7”-trifluoromethylquinolin-4,,-yl)oxiran-2,-yl]but-l- 
yljphthalimide  (VII.39)
To A-[6-(7-trifluoromethylquinolin-4-yl)hex-5-en-l-yljphthalimide (0.261 g) in 
chloroform (3.0 ml), m-chloroperoxybenzoic acid (m-CPBA) (80%; 0.422 g) was added; 
the mixture was refluxed at 70° for 5 h. A white precipitate (0.075 g) was filtered off, and 
the filtrate was washed with 10% sodium sulfite solution, saturated sodium bicarbonate,
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10% sodium chloride, and the chloroform evaporated to give the crude product. This 
product was subjected to PTLC (alumina; 2.5% methanol-chloroform) and recrystallised 
from methanol to afford white crystals of the title compound (0.135 g), m.p. 146-147.5° 
(Found: C, 63.1; H, 4.2; N, 5.9. C24H 19F3N2O4 requires C, 63.2; H, 4.2; N, 6.1%). 
l U n.m.r. 5 1.82, complex, H2,3,4; 2.97, dt, J2-3 - 2 Hz, J2\4 5 Hz, H2'; 3.77, t, J 6 Hz, 
HI; 4.18, d, J2’,3' 2 Hz, H3'; 7.35, d, J2",3" 6 Hz, H3"; 7.80, complex, phthalimido H and 
H6"; 8.23, d, J5")6" 9 Hz, H5"; 8.53, d, J2",3" 6 Hz, H2"; 9.13, br s, H8". MS m/z 457 
(M++1) (2%), 456 (M+) (7%), 440 (12%), 412 (2%), 211 (87%), 160 (100%).
a-(  P iperidin-2 -yl)- a - ( 7 '-trifluorome thy lquinolin-4'-yl) methanol 1 '-oxide 
(V II.5)
V-{4-[3'-(l"-Oxido-7"-trifluoromethylquinolin-4"-yl)oxiran-2'-yl]but-l-yl}phthali- 
mide (0.147 g) and hydrazine hydrate (0.10 ml) in methanol (1.5 ml) were refluxed at 90- 
95° for 6 h. The solvent was evaporated and the residue warmed with acetone and the 
white solid was filtered off. The filtrate was evaporated and the residue subjected to PTLC 
(alumina; 5% methanol-chloroform) and recrystallised from ethanol to afford white crystals 
of the title compound (0.045 g), m.p. 136-138° (Found: C, 58.8; H, 5.2; N, 8.2. 
C 16H 17F3N2O2 requires C, 58.9; H, 5.2; N, 8.6%). !H n.m.r. 5 1.27, 1.52, 1.82, 
complex, H3,4,5; 2.66, 3.04, complex, H2,6; 5.23, d, J 4.5 Hz, CHOH; 7.56, d, J2’,3’ 6 
Hz, H3'; 7.68, dd, J5-,6' 9 Hz, J6',8* 2 Hz, H6'; 8.12, d, J5-,6- 9 Hz, H5’; 8.37, d, J2*,3* 6 
Hz, H2'; 8.98, br s, H8\ MS mjz 327 (MH+) (33%), 311 (50%), 309 (13%), 242 
(17%), 226 (100%).
cc-(Piperidin-2-yl)-a-(7'-trifluoromethylquinolin-4'-yl)methanol (VII.4)
a-(Piperidin-2-yl)-a-(7'-trifluoromethylquinolin-4'-yl)methanol l'-oxide (0.025 g) 
and phosphorus trifluoride (0.1 ml) in chloroform (1.0 ml) were refluxed for 4 h and the 
solvent was evaporated. The residue was treated with ice and then 0.9 N ammonium 
hydroxide solution until it was neutral; the mixture was extracted with chloroform, the 
extract was washed with 10% sodium chloride solution, dried (Na2SC>4), and the solvent 
evaporated. The product was subjected to PTLC (alumina; 8% methanol-chloroform) and
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recrystallised from ethanol-cyclohexane to afford the off-white crystals of the title 
compound (0.009 g), m.p. 151-154° (Found: C, 61.3; H, 5.7; N, 8.5. C16H17F3N2O 
requires C, 61.9; H, 5.5; N, 9.0%). *H n.m.r. 5 1.15, 1.53, 1.77, complex, H3,4,5; 
2.70, t, 3.08, complex, H2,6; 3.59, br s, NH; 5.41, d, J 4 Hz, CH-OH; 7.66, d, J 9 Hz, 
H6'; 7.77, d, J 5 Hz, H3'; 8.11, d, J 9 Hz, H5'; 8.42, s, H8'; 8.99, d, J 5 Hz, H2’. MS 
m/z 311 (MH+) (53%), 295 (89%), 293 (48%), 288 (96%), 212 (100%).
N-[6-(7'-Trifluoromethyl-l ,y5 ,-naphthyridin-4'-yl)hex-5-en-l-yl]phthali- 
mide (VII.43b)
4-Bromo-7-trifluoromethyl-l,5-naphthyridine (0.174 g), W-(hex-5-en-l-yl)phthali- 
mide (0.144 g), tri-ö-tolylphosphine (0.050 g), palladium acetate (0.008 g) and 
tributylamine (0.15 ml) in hexamethylphosphoramide (HMPA) (1.0 ml) were heated in a 
Teflon-lined reaction vessel at 100° for 12 h. The mixture was then diluted with ethyl 
acetate and washed twice with water, dried (Na2SC>4) and the solvent evaporated. The 
product (0.393 g) was subjected to PTLC (alumina; 14% ethyl acetate-hexane) and 
recrystallised from ethanol to give the white crystals of the title compound (0.047 g), m.p. 
137-138° (Found: C, 64.7; H, 4.1; N, 9.6. C23H18F3N3O2 requires C, 64.9; H, 4.3; N, 
9.9%). *H n.m.r. 5 1.82, complex, H2,3; 2.49, q, H4; 3.75, t, J 6 Hz, HI; 6.80, dt, J 
16 Hz, H5; 7.58, d, J 16 Hz, H6; 7.78, complex, phthalimido H and H3'; 8.68, br s, H8'; 
8.97, d, J 5 Hz; H2’; 9.14, d J 2 Hz, H6'.
N ~ [ 6 - ( lO x id o - J ’- trif luoromethyl- l ' ,5 '-naphthyridin-4*-yl)hex-5-en-1 -yl]- 
phthalimide (VII.45)
V-[6-(7'-Trifluoromethyl-r,5'-naphthyridin-4'-yl)hex-5-en-l-yl]phthalimide 
(0.092 g) and m-chloroperoxybenzoic acid (80%; 0.050 g) in chloroform (1.5 ml) were 
heated at 65° for 2 h. The mixture was washed with 10% sodium sulfite solution, saturated 
sodium bicarbonate and 10% sodium chloride solution. The extract was dried (Na2SC>4), 
and the solvent evaporated. The crude product was subjected to PTLC [alumina; 64% 
chloroform-petroleum ether (b.p. 60-80°)] and recrystallised from methylene chloride- 
ethanol to give the title compound (0.055 g), m.p. 145-148° (Found: C, 62.5; H, 4.4; N,
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9.4. C23H 18F3N3O3 requires C, 62.6; H, 4.1; N, 9.5%). *H n.m.r. 5 1.75, complex, 
H2,3; 2.47, complex, H4; 3.76, t, J 6 Hz, HI; 6.64, dt, J 16 Hz, H5; 7.47, d, J 16 Hz, 
H6; 7.79, complex, phthalimido H and H3'; 8.54, d, J 7 Hz, H2'; 9.20, br s, H6'; 9.32, 
br s, H8'.
N - [ 6 - ( 7 f-B ro m o - l  ’,5 ' -n a p h th yr id in -4 ,- y l )h ex -5 -en - l -y l ]p h th a l im id e  
(VII.43a)
4,7-Dibromo-l,5-naphthyridine (0.187 g), N-(hex-5-en-l-yl)phthalimide (0.179 
g), palladium acetate (0.009 g), tri-o-tolylphosphine (0.050 g), sodium iodide (0.021 g) 
and tributylamine (0.3 ml) in V,V-dimethylformamide (1.5 ml) were heated at 100° under 
nitrogen for 21.5 h. The mixture was diluted with ethyl acetate, then washed with water, 
dried (Na2SC>4) and evaporated. The crude product was purified by PTLC (alumina; 20% 
ethyl acetate-hexane) and recrystallised from hot ethanol to give the white crystals of the title 
compound  (0.045 g), m.p. 119-121° (Found: C, 60.6; H, 3.9; Br, 18.3; N, 9.5. 
C22Hi8BrN302 requires C, 60.6; H, 4.2; Br, 18.3; N, 9.6%). ^ n .m .r .  5 1.75, 
complex, H2,3; 2.44, complex, H4; 3.75, t, J 6 Hz, HI; 6.78, dt, J 16 Hz, H5; 7.60, d, J 
16 Hz, H6; 7.78, complex, phthalimido H and H3'; 8.60, d, J 2 Hz, H8'; 8.86, d, J 5 Hz, 
H2'; 8.96, d, J 2 Hz, H6’. MS m/z 437, 435 (M+) (73, 75%), 356 (18%), 290 (13%), 
288 (15%), 277 (15%), 275 (19%), 263 (33%), 261 (36%), 249 (92%), 247 (100%), 235 
(56%), 233 (55%), 160 (46%).
N - [ 6 - ( 7 f-Tri f luorom ethy lqu ino l in -4 ' -y l )hexy l]ph tha l im ide  (VII.40)
4-Bromo-7-trifluoromethylquinoline (0.199 g), iV-(hex-5-en-l-yl)phthalimide 
(0.163 g), tri-<9-tolylphosphine (0.040 g), palladium acetate (0.007 g) and tributylamine 
(0.17 ml) in HMPA (1.0 ml) were heated in Teflon-lined vessel at 160° for 8 h. The 
mixture was diluted with ethyl acetate, then washed with water, 10% sodium chloride 
solution, dried (Na2SC>4) and the solvent evaporated. The crude product was subjected to 
PTLC (alumina; 10% ethyl acetate-hexane) and recrystallised from ethanol to give white 
crystals of N-[6-(7'-trifluoromethylquinolin-4'-y[)hexyl]phthalimide, m.p. 92-93° (Found, 
for a sample dried at 20°/0.2 mmHg for 19 h: C, 67.5; H, 5.0; N, 6.4. C24H21F3N2O2
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requires C, 67.6; H, 5.0; N, 6.6%). *H n.m.r. 8 1.50, complex, H3,4; 1.71, complex, 
H2,5; 3.10, t, J 9 Hz, H6; 3.70, t, J 9 Hz, HI; 7.35, d, J 4 Hz, H3'; 7.78, complex, 
phthalimido H and H6'; 8.16, d, J 9 Hz, H5'; 8.43, br s, H8'; 8.90, br d, J 4 Hz, H2\
N - [ 6 - ( 7 ’- T r i f lu o r o m e th y l - l ', 5 ' -n a p h th yr id in -4 ,-y l )hexy l ]ph tha l im ide  
(V II.44)
4-Bromo-7-trifluoromethyl-l,5-naphthyridine (0.174 g), W-(hex-5-en-l-yl)phtha- 
limide (0.144 g), tri-o-tolylphosphine (0.053 g), palladium acetate (0.011 g) and 
tributylamine (0.15 ml) in HMPA (1.0 ml) were allowed to react as for the preparation of 
VII.40 above, but heated at 150° for 15 h. The product was purified by PTLC (alumina; 
10% ethyl acetate) and recrystallisation from ethanol to afford a white crystal of the title 
compound, m.p. 112-114° (Found: C, 64.6; H, 4.7; N, 9.8. C23H20F3N3O2 requires C, 
64.6; H, 4.7; N, 9.8%). *H n.m.r. 5 1.49, 1.78, complex, H2,3,4,5; 3.31, t, J 9 Hz, 
H6; 3.69, t, J 9 Hz, HI; 7.58, d, J 5 Hz, H3'; 7.77, complex, phthalimido H; 8.66, br s, 
H8'; 8.96, d, J 5 Hz, H2'; 9.15, d, J 2 Hz, H6'.
CHAPTER VIII
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CHAPTER VIII Biological Evaluation of Antimalarial Activity
VIII-1 Introduction to Techniques for Antimalarial Testing
Adequate techniques for the efficient evaluation of candidate compounds in 
malaria chemotherapy are essential; moreover the choice of laboratory methods or 
screening procedures can be critical. History has revealed many discrepancies between 
promising laboratory results and clinical utility. Several major problems may arise in the 
evaluation of antimalarial drugs. These include the variations in drug susceptibility 
among life cycle stages of the parasites and the diversity of objectives. The latter 
involves treatment of the acute attack, radical cure, suppression, prophylaxis, and 
interrupting transmission.
Various experimental models are now available to evaluate the activity of 
established and new potential antimalarial compounds. These test procedures include the 
use of avian, rodent and simian malarias; also the development of techniques for the 
continuous in vitro culture of the human malaria Plasmodium falciparum. The latter have 
provided unprecedented opportunities to advance the search for new antimalarial drugs 
and for the examination of their mechanism of action.
In the work described in this thesis, test compounds were evaluated first in an in 
vitro test against P. falciparum (in which a semi-automated microdilution technique was 
employed), and then some of the more active compounds were screened (after 
appropriate toxicity tests) for in vivo activity against P. vinckei vinckei in mice.
The applicability of a morphological technique and a visual test microtechnique to 
determine in vitro activity against P. falciparum has also been examined.
V II-1.1 In vivo evaluation of antimalarial activity
Early methods using avian malarias (e.g. P. gallinaceum) in chicks have now 
been superseded by the use of rodent malarias268 such as P. berghei and P. yoelii in 
mice. A standard test for blood schizontocidal activity against drug-sensitive or drug-
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resistant isolates of P. berghei or P. yoelii was described by Peters.269 P. berghei is an 
excellent model for the evaluation of blood schizontocides and useful to forecast the 
potential drug activity against chloroquine-resistant P. falciparum.™
The rodent malaria models are often used as a primary and secondary screen 
before monkey malaria screens. Blood schizontocidal screens in rodent malaria are 
usually performed in single-dose regimens (these include the Rane test271 and Fink- 
Kretschmar test272) or multiple-dose regimens (these include the early test procedures, 
four-day test, drug-diet methods and the six-day test as summarised by Ager273).
The discovery that the South American owl monkey (Aotus trivirgatus) was 
susceptible to P . falciparum and P. vivax, permitted new studies by Schmidt on the 
activity of many antimalarial compounds against various drug-resistant lines of these two 
parasites in vivo.274 Another South American animal, the squirrel monkey (Saimiri 
sciureus), was also shown to be susceptible to P. falciparum.21 $ This small animal, 
which is relatively easy to colonise, may replace Aotus as a host for antimalarial drug 
research on human malaria parasites.
V III-1.2 In vitro evaluation of potential antimalarials
Short-term culture systems of P. berghei in an in vitro test for blood 
schizontocidal compounds were described by Richards and Williams in 1973.276 This 
method was based on the inhibition by the antimalarial of [3H]-leucine uptake by the 
parasite during a 24 h incubation. Later, Canfield et al,277 developed an in vitro test 
system involving P. knowlesi for screening potential antimalarial drugs. This technique 
was later adapted for use with P. falciparum and reported by Richards and Williams 278
The long-term (continuous) cultivation of P. falciparum was developed in 1976 
by Träger and Jensen14 (by use of the "candle jar" technique) and by Haynes et a l279; it 
provided the basis for several improved procedures in vitro for testing the response of the 
human parasite, P . falciparum to drugs. Another in vitro technique, the automated 
culture system, developed for massive screening of potential antimalarials has been 
described by Desjardins et a l222 This technique is an automated, computerised system,
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in which the incorporation of [3H]-hypoxanthine into the parasites nucleic acid is 
determined to provide a measure of parasite growth. More details are described in 
Chapter VIII-2.1.
For field-work, three important in vitro techniques have been used for 
determining the response of the human parasite, P. falciparum, to chloroquine. The 
original "macrotest" technique was described by Rieckmann et a/.280 This test required a 
large quantity of parasitised blood (10-15 ml), and the criterion of drug response in this 
macrotest was morphological (i.e. the failure of the asexual stages to develop to 
schizogony) when cultured (in air) for 24 h at 38-40°. A further application of the 
"candle jar" technique was the "microtest" also described by Rieckmann et a/.281 This 
microtest required only 50 |il of blood which can be easily collected from a finger-prick; 
this simplified the in vitro drug-susceptibility test, particularly in young children. The 
third technique, reported by Rieckmann,223 involves a visual test and a modification of 
the microtest (using capillary-blood specimens). The criterion for this test involves the 
determination by observation of the presence or absence of dark pigmented precipitates in 
the wells containing various concentrations of the drug.
VIII-2 Determination of Antimalarial Activity 
VIII-2.1 In vitro screen against P. falciparum
In this work, three different in vitro techniques have been employed for the 
determination of antimalarial activity against P . falciparum. These techniques were the 
[3H]-hypoxanthine uptake method modified from the semi-automated microdilution 
technique described by Desjardines et a l222 and others,98*282 the modified 
morphological microtest described by Rieckmann et al.,281 and the visual observation of 
pigment precipitation.223
Measurements of in vitro antimalarial activity against the chloroquine-sensitive 
FCQ-27 isolate of P. falciparum involving uptake of [3H]-hypoxanthine were carried out 
in the laboratories of Dr G.A. Butcher, Department of Zoology, Australian National
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University (ANU), Canberra; and at the Army Malaria Research Unit (AMRU) (Prof. 
K.H. Rieckmann), Milpo, Inglebum, NSW.
Studies involving other techniques with the FCQ-27 isolate as well as all 
measurements (in vitro) involving the chloroquine-resistant K-l strain were made at 
AMRU, Inglebum.
Parasites
The parasites used in this work were from the following sources:
FCQ-27 isolate: The FCQ-27 line of P. falciparum  (origin: Papua New Guinea,first
isolated at the Walter and Eliza Hall Institute, Melbourne)283 was 
routinely cultured by Dr G.A. Butcher, ANU;282 and also in 
continuous culture at the AMRU, under the supervision of Professor 
K.H.Rieckmann.14
K-l isolate: The K -l line (origin: Kanchanaburi, Thailand, isolated in
Bangkok)284 was maintained in routine culture at AMRU.14
(a) Incorporation of [3H]~hypoxanthine
The procedures used in this test at the ANU and AMRU were similar, as 
described low.
Test procedure
The compounds under the test were dissolved in ethanol and subsequently diluted 
in RPMI 1640 medium to the required highest drug concentration. Dilution of this 
solution with RPMI 1640 gave the range of drug concentrations required for the assay. 
Chloroquine diphosphate (as a standard) was dissolved in water. Microculture plates 
(Falcon, 96 well flat bottom) containing 50 \i\ of RPMI 1640 with or without inhibitor 
(test compound) and 50 jul of 2% haematocrit of unsynchronised (at Zoology, ANU) and 
synchronised (at AMRU, Inglebum) parasitise erythrocytes (Group O or A) (3-5% 
parasitaemia) were incubated in a gas mixture (5%CC>2, 5%C>2 and 90%N2) at 37.5°. At
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18-24 h, 20 |il of [3H]-hypoxanthine (10 [iCi/ml; prepared by dilution of the product of 
2.8 Ci/mmole supplied by Amersham, UK) in RPMI 1640 was added to all wells and the 
culture continued for a further 18-24 h. The drug concentrations in the test wells ranged 
from 200-1.6 nM, and triplicate or quadruplicate tests with each compound were carried 
out.
The contents of the wells were harvested on to filters (Chemtec, Australia) with a 
semi-automated cell harvester (Skatron harvester), washed through with distilled water 
for about 15 seconds, and suctioned for a further 15 seconds. After harvesting, the filters 
were dried at 37° for 2 h, placed in polyethylene scintillation vials (Packard) with phase 
combining system (PCS) scintillation fluid (Amersham) (2.5 ml) and the radioactivity 
was measured on a LKB 1217 or Packard Rack Beta liquid scintillation spectrometer. 
This gave a measure of the incorporation of [3H]-hypoxanthine into the nuclei acid of the 
parasites.
Analyses of the resulting data required application of non-linear curve fitting 
techniques. The data for each active compound were fitted to a generalised logistic- 
logarithmic function between various concentrations of inhibitor and percentage of 
inhibition of parasite growth.
The inhibition (%) of parasite growth was simply calculated from the following 
expression:
1 ™ \ c.p.m. in test wells I 1 „„ 
c.p.m. in control wells
and from these results the inhibitory concentration required to cause 50% inhibition of 
parasite growth (IC50) was calculated. In some cases IC90 values were also determined. 
These results are presented in Tables VIII-1 to VIII-7.
In an analysis of the data, the [3H]-hypoxanthine uptake (measured in counts per 
minute, c.p.m.) was plotted against the concentration of inhibitor for the test compounds 
VI.4e, VI.5d and chloroquine. The results are shown as sigmoidal curves in Figure 
Vn-l, and reveal a similar response to that obtained by Desjardines et al,222 in tests with 
chloroquine against "African-Uganda I" and "Vietnam Smith" strains of P . falciparum 
(chloroquine-sensitive and chloroquine-resistant strains, respectively).
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Figure VIII-1 [3H]-Hypoxanthine uptake in cultures of the
FCQ-27 isolate of P. falciparum in the presence of 
various concentrations of di-Mannich bases (VI.4c 
and VI.5d) and chloroquine
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(b) Modified morphological microtest
Tests using this technique were carried out at AMRU, Inglebum, as described by 
Rieckmann.281 Some selected compounds were tested against both the FCQ-27 and the 
K-l isolates of P . falciparum. For this method cultures were prepared as described 
below, and from these thick blood films were prepared (with Romanowsky strain285) 
and examined under an oil immersion microscope. The number of parasite infected red 
cells (as schizonts) per 200 erythrocytes was then determined by application of the 
following guide lines.
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The form of parasites were classified286 as follows: those parasites which did not 
yet contain any haemazoin were classified as ring forms; those parasites which contained 
haemazoin (dark-brown dot) with one piece of nuclear chromatin (pink dot) were 
classified as trophozoites; and those parasites containing haemazoin and at least two 
pieces of nuclear chromatin were classified as schizonts. In this work, to avoid problems 
due to multi-infection, schizonts were considered as containing at least three chromatin 
dots.
The IC50 value was the concentration of the inhibitor required to reduce the 
number of erythrocytes containing schizonts (as revealed on the control slide) to half that 
value on the slide from the culture containing the inhibitor under test.
Test procedure
The compounds under test were dissolved in methanol and sequently diluted with 
RPMI 1640 medium. Microculture plates (as mentioned above) were prepared with each 
well containing 20 \i\ of inhibitor solution and 80 |il of innoculum [i.e. 100 |il, which 
contained 2% heamatocrit and 0.5% synchronised culture (at young ring stage)]. The 
concentration of inhibitor in these tests against the FCQ-27 and the K-l strains of 
P. falciparum ranged from 100-1.6 nM; duplicate tests for each compound were also 
examined. Control wells consisted of 20 (il of RPMI 1640 medium in place of inhibitor 
solution; otherwise the procedure was the same. The cultures were incubated at 37.5° for 
24 h, then thick film slides were prepared with Romanowsky stain285 and the slides were 
examined under the microscope using the criteria outlined above. Thus it was possible to 
determine the concentration of compound (inhibitor) required to produce 50% inhibition 
(IC50) of growth of the parasite. The results from the use of this morphological 
technique are presented in Table Vm-8.
(c) Visual observation of pigment precipitation
A visual technique,223 modified by Prof. K.H. Rieckmann at AMRU, was also 
used in this work to determine by a simple procedure the minimum concentration at 
which the test compound was an effective inhibitor of the malaria parasite.
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Test procedure
Culture cells were prepared essentially as described in Section VIII-2.1a above 
but with the following modifications.
Each well of the microculture plate contained 50 fil of inhibitor solution and 50 pi 
of innoculum (4% haematocrit, 0.5% synchronised culture at ring stage) which was then 
incubated at 37.5° for 24 h. The concentration of inhibitor in the culture tests were in the 
range 200-12.5 nM, with duplicate tests for each compound.
After incubation, 20-25 pi of a mixture (1:1 of N sodium hydroxide and N 
sodium chloride) was added to each well and the plate was allowed to stand for 3-5 
minutes. The plates were then shaken for 5 minutes (at this time control wells gave a 
greenish-yellow hue with a turbid coagulum which presumably resulted from 
denaturation of serum and cell proteins). It was allowed to stand for 5-30 minutes and 
then tapped gently. The presence of a precipitate was then clearly visible under 
illumination. The dark-brown precipitates were present only in wells in which parasites 
had developed from ring stages to schizonts (the more mature pigment-containing 
stages). The results for this visual test are shown in Table VIII-9 against both the FCQ- 
27 and the K-l isolates.
VIII-2.2 In vivo screen against P. vinckei vinckei
In this work, P. vinckei vinckei was selected as the malaria parasite for use in 
the mouse. This parasite was isolated from Shaba, Zaire and adapted to mice in 1952. 
Since then it has been used successfully in numerous malaria studies.282»287
Animals:
Male CBA mice (6-8 weeks old) were bred and maintained in the John Curtin 
School of Medical Research Animal Breeding Establishment (under specific pathogen- 
free conditions) and fed normal laboratory diet pellets and tap water ad libitum. Average 
body weight was 20 g.
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(a) Toxicity test in mice
Selected compounds from each series described in Chapter II-V were tested for 
acute toxicity in three mice by injection intraperitoneally (ip.), each with a single dose in 
peanut oil at a dosage of 200 mg/kg of body weight*The results are shown in Table VIII- 
10 .
(b) Preliminary in vivo tests in mice
P. vinckei vinckei (originally from Dr D. Walliker, Institute of Animal Genetics, 
Edinburgh) was stored frozen in liquid nitrogen and had been passaged several times 
before experimental use in CBA mice.
Infection of mice:
All infections were initiated by intraperitoneal injection with 105 or 106 parasitised 
erythrocytes, containing P. vinckei vinckei (obtained from an infected donor mouse and 
diluted in sterile saline).* After 5 days (and daily thereafter) each mouse was examined 
for suitable parasitaemia levels (generally 10-20%). The percentage parasitaemia was 
monitored by thin blood smears taken from each mouse's tail vein; slides were fixed with 
methanol and stained with Diff-Quik stain; then examined under an oil immersion 
microscope. Counts of parasite-infected red blood cells were determined as the average of 
two or more counts in microscopic fields with approximately 200 cells per field in which 
few erythrocytes overlapped.
Drug treatment
Each test compound at a dosage at 200 mg/kg of body weight in 0.4 ml of peanut 
oil was given intraperitoneally to three mice with infection levels of preferably 10-20% 
and whose individual parasitaemias had just previously been determined. Thereafter, thin
Kindly supplied by Dr P.K. Halladay
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blood smears were taken from each mouse at the time intervals indicated in Tables VIII- 
11 and Vin-12, and the parasitaemia assessed as above.
As controls, some mice were treated with peanut oil and other mice were treated 
with chloroquine (as diphosphate; at a dosage 40 mg/kg of body weight in normal 
saline).
VIII-3 Results of Antimalarial Testing
The results of preliminary testing in vitro against the FCQ-27 (chloroquine- 
sensitive) isolate of P . falciparum  using the method of incorporation of [3H]- 
hypoxanthine (as described in Chapter VIII-2.1a; (at the Department of Zoology, ANU) 
for the compounds described in Chapters II, HI, IV and V are shown in Tables VIII-1 to 
VIII-5.
Comparative testing results against both the FCQ-27 and the K-l isolates (at 
AMRU) using the [3H]-hypoxanthine method for compounds described in Chapter VI 
and VII are reported in Table VTI-6 and VHI-7.
Results obtained from comparative testing against the FCQ-27 and K1 isolates 
using morphological techniques (as described in Chapter VIII-2.1b) (at AMRU) for 
selected compounds prepared in Chapter II-V are presented in Table VIII-8; and those 
obtained using the visual techniques (see Chapter VIII-2.1c) for compounds described in 
Chapter VI and VII are given in Table VM-9.
Table VIII-10 and Tables VIII-11 to VII-12 give the results for toxicity studies, 
and those of in vivo testing against P. vinckei vinckei in mice, respectively, for some of 
the more active compounds prepared in Chapter II-V.
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Table VIII-1 In  vitro antimalarial activity of some di-Mannich bases 
(11.48) of 4-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)phenol and its 
chloroquine analogue (11.51) against the FCQ-27 isolate of P. falciparum . 
Literature values98 for the corresponding 7-bromo analogues (I.43b) are 
also given for comparison.
CH,NR
11.48
HN—CH(CH2)3NEt2
11.51
Inhibitor IC50A of
11.48
CH-factorB
IC50 of 
corresponding
1.43b
11.48; NR2= 
a NEt2 12 0.9 5.4
b NPr2 17 0.6 3.8
c pyrrolidin- 1-yl 6 1.8 3.6
d piperidin-l-yl 7.5 1.5 34.8
e 3-methylpiperidin-l-yl 6 1.8 -
f 3,5-dimethylpiperidin-l-yl 5 2.2 1.9
g 4-methylpiperidin-lyl 8 1.4 >64
h 4-benzylpiperidin-l-yl 12 0.9 -
11.51 >200 - -
Chloroquine^ 11 1 13.0
A The IC50 values (the concentration of the inhibitor required to reduce parasite growth 
by 50%) are expressed as nmol l"1.
B The CH-factor (Chloroquine factor) is the comparative activity of the inhibitor under 
test compared to chloroquine; and is the ratio of the IC50 value for the inhibitor over 
that for chloroquine. 
c  As diphosphate salt.
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Table VIII-2 In vitro antimalarial activity of some di-Mannich bases 
(III.16 and VI.7) of 4-(7-trifluoromethylquinazolin-4-ylamino)phenol and 
4-(7-trifluoromethylquinolin-4-ylamino)phenol against the FCQ-27 isolate 
of P fa lc ip a ru m .
III.16, Z=N 
VI.7, Z=CH
Me
I
HN-CH(CH2)3NEt2
I I I .18
Inhibitor
Compounds III. 16
Corresponding 
compounds VI.7
ic 50a CH-factorB ICsoA CH-factorB
111.I 6 ; n r !r 2=
a NMe2 >200 <0.08
b NEt2 150 0.1 1.3c 11.0
c NPr2 50 0.3 1.7C 8.8
d N(C5H i i )2 90 0.2 175 0.09
e NBuMe 30 0.5 10 1.5
f pyrrolidin-1-yl 30 0.5 0.9c 16.7
g piperidin-l-yl 70 0.2 0.7c 21.4
h 3-methylpiperidin-l-yl 12 1.3 1.6° 9.4
i 4-methy lpiperidin-1 y 1 40 0.4 1.5 10
j 3,5-dimethylpiperidin-l-yl 20 0.8 1.4° 10.7
k 4-benzylpiperidin-1-yl 40 0.4 “ “
I II .18 >200 <0.08 - -
ChloroquineE 15 1
A The IC50 values (the concentration of the inhibitor required to reduce parasite growth 
by 50%) are expressed as nmol l"1.
B The CH-factor (Chloroquine factor) is the comparative activity of the inhibitor under 
test compared to chloroquine; and is the ratio of the IC50 value for the inhibitor over 
that for chloroquine.
c  Data from reference 98.
D H.V. Scott, G.B. Barlin, and S.J. Ireland, unpublished data.
E As diphosphate salt.
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Table VIII-3 In vitro antimalarial activity of 4'-chIoro-3-(substituted  
amino)methyl-5-(7-trifluoromethylquinol in-4-ylamino)biphenyl-2-ols (IV.3) 
and 5 - (7 - tr i f lu orom eth y lqu inazo l in -4 -y lam in o)b ip henyl-2 -o l  analogues  
(IV.4) against the FCQ-27 isolate of P. fa lc iparum .
IV.3; Y=CH 
IV.4; Y=N
Substituent
Compounds IV.3 Compounds IV.4
i c 50a CH-factorB ICsoA CH-factorB
NR!r 2= 
a NEt2 20 0.6 80 0.2
b NHCMe3 20 0.6 20 0.6
c pyrrolidin-1-yl 8 1.5 30 0.4
d piperidin-l-yl 24 0.5 120 0.1
e 3-methylpiperidin-1 -y 1 22 0.5 75 0.2
f 4-methylpiperidin-lyl 45 0.3 140 0.1
g 4-benzylpiperidin-l-yl 160 0.1 >200 <0.06
h 4-benzylpiperazin-1 -y 1 80 0,2 >200 <0.06
Chloroquinec 12 1.0
A The IC50 values (the concentration of the inhibitor required to reduce parasite growth 
by 50%) are expressed as nmol 1_1.
B The CH-factor (Chloroquine factor) is the comparative activity of the inhibitor under 
test compared to chloroquine; and is the ratio of the IC50 value for the inhibitor over 
that for chloroquine. 
c  As diphosphate salt.
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Table VIII-4 In vitro antimalarial activity of 4'-chloro-3-(substituted 
amino)methyl-5-(7-bromo-l,5-naphthylridin-4-ylamino)biphenyl-2-ols  
(IV.5) and 5-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)biphenyl- 
2-ol analogues (IV.6) against the FCQ-27 isolate of P. falciparum.
IV.5; X=Br 
IV.6 ; X=CF3
Substituent
Compounds IV.5 Compounds IV.6
ic50a CH-factorB ic50a CH-factorB
NR]R2=
a NEt2 60 0.20 170 0.07
b NHCMe3 30 0.40 50 0.24
c pyrrolidin-1-yl 70 0.17 70 0.17
d piperidin-l-yl 80 0.15 90 0.13
e 3-methylpiperidin-1 -y 1 90 0.13 150 0.08
f 4-methylpiperidin-lyl 160 0.08 40 0.3
g 4-benzylpiperidin-l-yl >200 <0.06 >200 <0.06
h 4-benztlpiperazin-l-yl 145 0.08 >200 <0.06
Chloroquinec 12 1.0
A The IC50 values (the concentration of the inhibitor required to reduce parasite growth 
by 50%) are expressed as nmol H .
B The CH-factor (Chloroquine factor) is the comparative activity of the inhibitor under 
test compared to chloroquine; and is the ratio of the IC50 value for the inhibitor over 
that for chloroquine. 
c  As diphosphate salt.
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Table VIII-5 In vitro antimalarial activity of a series of mono-Mannich 
base derivatives of 4-[7-bromo (and 7-trifluoromethyl)-l,5-naphthyridin-4- 
ylamino]-5,6,7,8-tetrahydronaphth-oIs (V.2 and V.3, repectively) against 
the FCQ-27 isolate of P. fa lc iparum .
V.2, X=Br 
V.3, X=CF3
Substituent
Compounds V.2 Compounds V.3
IC50a CH-factorB ic 5oa CH-factorB
N R iR ^  
a NEt2 42 0.3 c
b NPr2 - - c -
c NHCMe3 7 2.0 18 0.78
d pyrrolidin-1-yl 10 1.4 60 0.23
e piperidin-l-yl 40 0.35 200 0.07
f 3-methylpiperidin-l-yl 45 0.31 C -
g 4-methylpiperidin-1 yl 47 0.3 c -
h 4-benzylpiperidin-l-yl 50 0.28 c -
i 4-benzy lpiperazin- 1-yl 120 0.12 c -
Chloroquine0 14 1.0
A The IC50 values (the concentration of the inhibitor required to reduce parasite growth 
by 50%) are expressed as nmol H .
B The CH-factor (Chloroquine factor) is the comparative activity of the inhibitor under 
test compared to chloroquine; and is the ratio of the IC50 value for the inhibitor over 
that for chloroquine.
c  No activity at 200 nM.
D As diphosphate salt.
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Table VIII-6 In vitro antimalarial activity of a series of di-Mannich base 
derivatives (VI.4 and VI.5, and VI.6) of 4-[7-chloro (and 7-trifluoro- 
methyl)quinolin-4-ylamino]-3-methylphenols and 4-(7-bromo-l,5-naphthy-
ridin-4-ylamino)-3-methylphenol against 
falciparum.
the FCQ-27 and K-l isolates of P.
VI.4; X=C1, Y=CH 
VI.5; X=CF3, Y=CH 
VI.6; X=Br, Y=N
FCQ-27 K-l
Inhibitor ____________ ____________ Resistance factorA
IC50 IC90 IC50 IC90
VI.4; NR!r 2=
a NMe2 19 28 55 82 2.9
b NEt2 23 37 27 38 1.2
c NHCMe3 36 67 32 67 0.9
d pyrrolidin-1-yl 28 39 16 26 0.6
e piperidin-l-yl 22 36 12 19 0.5
VI.5; NR!R2=
a NMe2 23 31 46 76 2.0
b NEt2 29 39 32 47 1.1
d pyrrolidin-1-yl 23 37 9 32 0.4
e piperidin-l-yl 24 37 12 25 0.5
VI.6; n r !r2=
a NMe2 46 73 53 78 1.2
b NEt2 41 58 45 71 1.1
c NHCMe3 6 28 47 77 7.8
d pyrrolidin-1-yl 23 44 32 82 1.4
e piperidin-l-yl 30 69 28 88 1.0
ChloroquineB 23 31 221 304 10
A Resistance factor is the IC50 value against the K-1 isolate divided by that for the 
FCQ-27 isolate.
B As diphosphate salt.
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Table VIII-7 In vitro antimalarial activity of a-(piperidin-2-yl)-a-(7-  
trifluoromethyIquinolin-4-yl)methanol (VII.4), the V-oxide derivative 
(VII.5), mefloquine and chloroquine against the FCQ-27 and K-l isolates 
of P. falciparum.
VII.4 VII.5
Inhibitor FCQ-27 isolate K-l isolate
IC50A ic50a
VII.4 no activity at 80 nM 99
VII.5 no activity at 80 nM 172
Mefloquine 10. i b 4.9b
Chloroquine 23 221
A The IC50 values are expressed as nmol H .
B Data from H.V. Scott, W.L. Tan, and G.B. Barlin, Ann. Prop. Med. Parasitol., 1987, 
81, 85.
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Table VIII-8 In vitro antim alarial activity of some selected compounds 
against the FCQ-27 and K -l isolates of P. falciparum  determined by using 
the morphological method. Previous results determined for the FCQ-27 
isolate by the use of the [3H ]-hypoxanthine method are recorded for 
com parison.
Results (IC50 values) are expressed in nmol H .
Inhibitor
IC50 values 
Morphological method
Resistance-
factorA
IC50 values
[3H]-hypoxanthine method
FCQ-27 K-l FCQ-27
II.48a 50 22 0.4 13
II.48b - 19 - 17
II.48e 15 17 1.1 6
II.48g 29 - - 9
II.48h 44 52 1.2 21
III.16h 30 38 1.3 * 12
III . 16 j 36 29 0.8 25
IV.3b 40 _ 18
IV.5a - 69 - 60
IV.5b 75 54 0.7 30
IV.5c 71 - - 70
IV .6 b - 69 - 43
IV .6 f - 74 - 73
V.2c 31 _ _ 10
V.2d - 48 - 12
VI.7e 22 11 0.5 10
Chloroquine8 17 385 22.6 15
A Resistance factor is the IC50 value against the K-1 isolate divided by that for the 
FCQ-27 isolate.
B As diphosphate salt.
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Table VIII-9 Estimation of IC50 values from visual inspection of pigment 
precipitation in tests with the FCQ-27 and K-l isolates of P. falciparum 
against di-Mannich bases (VI.4-6) of V-substituted 4-amino-3-methyI- 
phenols and the a-(piperidin-2-yl)methanols (VII.4 and VII.5).
0 signifies no precipitate, i.e. complete inhibition of parasite growth;
± signifies some precipitate formation;
+ signifies precipitate formation, as in uninhibited parasite cultures.
The region between 0 and + indicates therefore the approximate IC50 value.
Inhibitor Isolate Concentrations of inhibitor (nmol l '1)
200 100 50 25 12.5
ChloroquineA FCQ-27 0 0 0 ± -1-
K -l + + + + +
VI.4d FCQ-27 0 0 0 + +
K -l 0 0 0 + +
VI.4e FCQ-27 0 0 0 0 +
K -l 0 0 0 0 +
VI.5a FCQ-27 0 0 0 ± +
K -l 0 0 ± + +
VI.6a FCQ-27 0 0 0 + +
K -l 0 0 ± + +
VII.4 FCQ-27 + + + + +
K -l + + + + +
V II.5 FCQ-27 + + + + +
K -l + + + + +
Control FCQ-27 + + + + +
(no inhibitor) K -l + + + + +
A As diphosphate salt.
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Table VIII-10 Toxicity testing in mice.A Times given are those after i.p. 
injection of the chemical (200 mg/kg) under test in peanut oil (0.4 ml). 
Time : h, hours; d, days. For formulae of compounds see Tables VIII-11 
and VIII-12.
Compound
No. of mice living at the following
No. of mice times after intraperitoneal injection
in test
0.5 h 1 h 24 h 7 d 60 d
II.48a 3 3 3 3 3 3
11.48c 3 3 3 3 3 3
II.48d 3 3 3 3 3 3
II.48g 3 3 3 3 3 3
II.48h 3 3 3 3 1 B
11.51 3 3 2 2 2 2
IV.3b 3 3 3 3 . 3 3
IV.3c 3 3 3 3 3 3
IV.4b 3 3 3 3 3 3
IV.5b 3 3 3 3 3 3
IV.6b 3 3 3 3 3 3
V.2c 3 3 3 3 3 3
V.3d 3 3 3 3 3 3
Control (peanut oil) 3 3 3 3 3 3
Amodiaquinec 6 1 1 1 1
Chloroquinec  (100 mg/kg) 2 0 0 0 0
A For details of test procedure see section VIII-2.2a.
B Two mice died on day 6.
C Results from reference 97. Amodiaquine hydrochloride and Chloroquine diphosphate 
in normal saline.
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Table VIII-11 Preliminary antimalarial screening results for compounds 11.48 and 11.51 
against P. vinckei vinckei in mice.A Times are those after injection of the 
chemical under test. Time : h, hours; d, days; Oh denotes pretreatment.
11.48 a; NR2=NEt2
c; NR2=pyrrolidin-l-yl 
d; NR2=piperidin-l-yl 
g; NR2=4-methylpiperidin-l-yl 
h; NR2=4-benzylpiperidin-l-yl
HNCH(Me)(CH2)3NEt2
11.51
Compound 
(IC50 nM)
Solvent;0
Dosage
(mg/kg)
Mouse 
no Oh 17h 24 h 48h 3d 4d 9d lOd l id 1 2 d 14d 15d 60d
II .4 8 a PO; 200 1 <1 <1 <1 <1 1 5 1 3 2 4 <1 <1 C
(12 nM) 2 8 4 1 <1 < 1 1 2 5 9 29 75 D
3 1 < 1 <1 <1 <1 1 2 4 6 2 <1 <1 C
11.48c PO; 200 1 <1 < 1 <1 <1 < 1 3 1 2 7 <1 <1 <1 c
(6  nM) 2 7 4 <1 <1 < 1 2 1 3 3 <1 <1 <1 c
3 6 < 1 <1 <1 < 1 1 1 1 2 <1 <1 <1 c
II .4 8 d PO; 200 1 2 < 1 <1 <1 < 1 1 6 31 60 75 D
(7.5 nM) 2 1 < 1 <1 <1 < 1 2 3 8 20 35 77 D
3 3 < 1 <1 <1 < 1 1 3 9 35 42 D
II .4 8 g PO; 200 1 1 <1 <1 <1 < 1 2 3 3 2 4 31 39e
(8  nM) 2 3 < 1 <1 <1 < 1 2 3 3 2 2 18 33E
3 1 < 1 <1 <1 < 1 1 1 1 5 2 <1 <1 c
II .4 8 h PO; 200 1 51 60 83 55 D
(12 nM) 2 48 71 6 6 59 D
3 40 71 76 64 D
11.51 PO; 200 1 46 D
(>200 nM) 2 1 1 1 7 24 50 F
3 32 32 25 24 17 30 23 43 42 c
Control PO 1 2 5 9 4 3 G
2 1 4 8 16G
3 6 14 19 48G
ChloroquineH NS; 40 1 <1 < 1 <1 <1 < 1 2 2 4 1 <1 <1 <1 c
(13 nM) 2 1 1 <1 <1 < 1 2 39 60 62 D
3 6 1 <1 <1 < 1 4 58(
A For details of test procedure see section VIII-2.2b. B PO, Peanut oil; NS, Normal saline.c Mouse alive at day 60. 
D Mouse dead. E Mouse dead at day 17. F Mouse dead at day 7. G Mouse was killed. H Diphosphate salt.
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Table VIII-12 Preliminary antimalarial screening results for compounds IV.3 to IV.6 and
V.2 toV.3 against P. vinckei vinckei in mice.A Times are those after injection 
of the chemical under test. Time : h, hours; d, days; Oh denotes pretreatment
IVJb; Y=CH, 
IV.3c; Y=CH, 
IV.4b; Y=N,
NR|R^NHBu* IV.5b; X=Br, NR1R2=NHBut
NRi^ ^ y r r o U d in -i-y i IVt6b; x=CF3, NRxR2=NHBu‘
V.2c; X=Br, NRXR2=NHBu‘
V.3d; X=CF3, NR1R2=pyrrolidin-l-yl
Compound 
(IC50 nM)
Solvent;3
Dosage
(mg/kg)
Mouse
no Oh 17h 24h 48h 3d 4d 9d lOd lid 12d 14d 18d 60d
IV .3b PO; 200 1 7 23 35 45 54c
(20 nM) 2 11 15 30 50 71C
3 11 34 33 38 48c
IV .3c PO; 200 1 10 16 32 50 67c
(8 nM) 2 17 32 49 75 51c
3 9 13 23 34 43 C
IV .4b PO; 200 1 20 16 15 29 62 52c
(20 nM) 2 19 8 16 16 26 54C
3 11 25 42 73 72c
IV .5b PO; 200 1 <1 <1 <1 <1 <1 3 1 2 7 <1 <1 <1 D
(30 nM) 2 7 4 <1 <1 <1 2 1 3 3 <1 <1 <1 D
3 6 <1 <1 <1 <1 1 1 1 2 <1 <1 <1 D
IV .6b PO; 200 1 13 39 44 54 28 9 3 7 10 3 1 <1 D
(50 nM) 2 <1 <1 <1 <1 <1 1 5 2 5 4 <1 <1 D
3 <1 <1 <1 <1 <1 3 3 4 6 4 <1 E
V .2c PO; 200 1 12 20 9 2 1 1 1 3 4 6 30 F
(7 nM) 2 8 10 6 1 1 1 2 3 6 2 17 F
3 7 7 1 <1 <1 1 2 3 6 2 <1 30G
V .3d PO; 200 1 35 43 E
(60 nM) 2 61 E
3 48 E
Control PO 1 53 78 81 E
ChloroquineH NS; 40 1 <1 <1 <1 <1 <1 2 2 4 1 <1 <1 <1 D
(13 nM) 2 1 1 <1 <1 <1 2 39 60 62 E
3 6 1 <1 <1 <1 4 58c
A For details of test procedure see section VIII-2.2b. B PO, Peanut oil; NS, Normal saline. c  Mouse was killed. 
D Mouse alive at day 60. E Mouse died. F Mouse dead at day 17.G Mouse dead at day 20. H Diphosphate salt
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VIII-4 Discussion of Results
Some results for the inhibition of parasite growth (as measured by the inhibition 
of [3H]-hypoxanthine uptake) plotted against concentration of inhibitor for some di- 
Mannich bases of N-substituted 4-amino-3-methylphenols (such as compounds VI.4d, 
VI.5d and VI.6d, selected as representative of the compounds tested) are shown in 
Figures VIII-2 and VIII-3 for tests against the K-l and FCQ-27 isolates, respectively. 
Each datum point was the mean for the sample tested in quadruplicate in a single 
experiment. The approximate IC50 value can be obtained from the sigmoidal curve by 
interpolation after logarithmic transformation of both concentration and percentage 
inhibition of parasite growth (at 50% inhibition).
Examination of Figures VIII-2 and VIII-3 indicates that with a common di- 
Mannich side chain, the response varies with different heterocyclic nuclei. In each case 
the best response was observed with compounds containing the 7-chloroquinolin-4-yl 
group (e.g. VI.4d).
V III-4 .1 In vitro test results against P. falciparum
(a) Results from incorporation of [3H]-hypoxanthine
The results given in Table VIII-1 for the testing of the series of di-Mannich bases 
(11.48) derived from 4-(7-trifluoromethyl-l,5-naphthyridin-4-ylamino)phenol against 
the FCQ-27 isolate of P . falciparum  revealed IC50 values in the range 5-17 nM 
(chloroquine, 11 nM). The most active compound was II.48f (IC50 5 nM) which was 
ca 2.2 times more active than chloroquine. The least active compound (II.48b; IC50 17 
nM) was 0.6 times as active as chloroquine.
A comparison of the activity of these compounds (11.48) with values published98 
for the corresponding bromo analogues (1.43b) revealed that the 7-bromo analogues 
were generally more active by 1.7-4.5-fold, except for compounds II.48d and II.48g 
which were more active than their bromo analogues.
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Figure VIII-2 Plots of the % inhibition of parasite growth in cultures 
of the K-l isolate of P. falciparum containing various 
concentrations of three different inhibitors 
(see Table VII-6 for relevant formulae).
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Figure VIII-3 Plots of the % inhibition of parasite growth in cultures 
of the FCQ-27 isolate of P. falciparum  containing 
various concentrations of three different inhibitors 
(see Table VII-6 for relevant formulae).
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The IC50 values for the di-Mannich bases (III.16) of 4-(7-trifluoromethyl- 
quinazolin-4-ylamino)phenol and the 7-trifluoromethylquinoline analogues (VI.7) are 
given in Table VIII-2. These reveal IC50 values in the range 12->200 nM and 0.7-10 nM 
for compounds III.16 and VI.7, respectively, except for compound VI.7d which gave 
an IC50 value of 175 nM.
Six of di-Mannich derivatives of 4-(7-trifluoromethylquinazolin-4-ylamino)- 
phenol (III. 16) gave IC50 values of less than 50 nM, and the two most active 
compounds, those from 3-methylpiperidine (III.16h) and 3,5-dimethylpiperidine 
(III.16j), gave IC50 values of 12 and 20 nM, respectively. The di-Mannich base from 
diethylamine (III.16b) was appreciably less active, with an IC50 value of 150 nM.
Examination of the new data in Table VIII-2 for the di-Mannich bases (VI.7) 
derived from 4-(7-trifluoromethylquinolin-4-ylamino)phenol revealed that compound 
VI.7e with the butylmethylamino group had an IC50 value of 10 nM and it was less 
active than the diethylamino analogue;98 this trend continued in the corresponding 
dipentylamino compound (VI.7d) which had an IC50 value of 175 nM. The 3- and 4- 
methylpiperidin-l-yl compounds (VI.7h and VI.7i) had activity comparable with the 
demethyl analogue (VI.7g).
Comparison of the quinazolines (III. 16) with the quinolines (VI.7) listed in 
Table VIII-2 revealed that, with the exception of the dipentylamino compound (III.16d), 
the quinazolines were less active than the corresponding quinolines. This lower activity 
of the quinazolines varied from ca 110-fold for the diethylamino compound (in. 16b) (in 
which it was most marked) to ca 3-fold for compound UI.16e.
Thus the presence of N-3 in the quinazolines (III. 16) reduces the antimalarial 
activity relative to the corresponding quinoline (VI.7). Likewise comparison of the 
trifluoromethylquinolines (VI.7) in Table VIII-2 with the 7-trifluoromethyl-l,5- 
naphthyridines (11.48) in Table VIII-1 reveals that the naphthyridines (with N-5) are 
from 3.6 to 10.7 times less active than the corresponding quinolines, except for 
compounds VI.7d and VI.7e.
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The generally lower antimalarial of the compounds 11.48 and III. 16 relative to 
the corresponding quinolines (VI.7) may be due to many factors including a lower 
basicity of N-l in compounds 11.48 and III.16 relative to VI.7.
The results for the "Tebuquine" analogues, compounds IV.3 and 4, and IV.5 
and 6 are reported in Table VIII-3 and Table VIII-4, respectively. The most active 
compound of these series was compound IV.3c (pyrrolidin-l-yl derivative), which had 
an IC50 value of 8 nM.
Inspection also revealed that, in each of the four series of compounds, the 
Mannich base containing a r-butylamino group was the most active (except for compound 
IV.3c and IV.6f), followed closely by those containing the pyrrolidin-l-yl group. 
Generally the least active compounds were those containing the benzylpiperidin-l-yl or 
benzylpiperazin-l-yl groups but this may be related to poor solubility under the test 
conditions.
A comparison of the activities of the quinolines (IV.3) with those of the 
quinazolines (IV.4) in Table VIII-3 revealed that the activities of the quinolines were 
generally higher (as also applied to the data in Table VHI-2). Perusal of the data in Table 
V m -4 revealed (despite some inconsistencies) relatively small differences between the 7- 
bromo and 7-trifluoromethyl-l,5-naphthyridine (IV.5) and (IV.6), respectively.
Inspection of the Mannich bases (IV.3) derived from 4-chloro-5-(7- 
trifluoromethylquinolin-4-yl)biphenyl reported in Table VIII-3 with the di-Mannich bases 
(VI.7) derived from 4-(7-trifluoromethylquinolin-4-ylamino)phenol listed in Table 
Vin-2 revealed that the di-Mannich bases (VI.7) are from 8.9 to 34.3 times more active 
than the corresponding "Tebuquine" analogues (IV.3).
The quinazolines (IV.4) (Table VIII-3), however did not show consistent or 
marked differences in activity compared with the corresponding di-Mannich bases 
(III.16) (Table VIII-2).
The results reported in Table VIII-4 for the compounds IV.5 when compared to 
those reported97»98 for the di-Mannich bases of 4-(7-bromo-l,5-naphthyridin-4- 
ylamino)phenol (I.43b, see also Table VIII-1) revealed that the di-Mannich bases
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(1.43b) were from 2.3 to 19.4 times the more active. For example, the IC50 value 
recorded for the di-Mannich compound (I.43b, NR2 = pyrrolidinyl) was 3.6 nM 
whereas that for the "Tebuquine" analogue (IV.5c) was 70 nM.
Data for the 7-trifluoromethyl-l,5-naphthyridines (IV.6) (Table VIII-4) and 
11.48 (Table VIII-1) revealed a similar pattern; the di-Mannich compounds (11.48) 
exhibited superior activity (5 to >40 times).
The results for a series of mono-Mannich base derivatives of 4-[7-bromo (and 7- 
trifluoromethyl)-l,5-naphthyridin-4-ylamino]-5,6,7,8-tetrahydronaphthols (V.2 and 
V.3), recorded in Table VIII-5, indicated that in each series the most active compound 
was that containing the r-butylamino group (V.2c, IC50 7 nM and V.3c, IC50 18 nm). 
Compounds containing the pyrrolidinyl group were the next most active.
The bromo compounds (V.2) were consistently more active than the 
corresponding trifluoromethyl compounds (V.3). This observation mirrors the 
conclusions reported above for di-Mannich base derivatives of 4-[7-bromo (and 7-tri- 
fluoromethyl)-1,5-naphthyridin-4-ylamino]phenol.
Results of testing the di-Mannich base derivatives of the V-substituted 4-amino-3- 
methylphenols (VI.4 to VI.6) for antimalarial activity in vitro (see Chapter VI) against 
the chloroquine-sensitive (FCQ-27) and chloroquine-resistant (K-l) isolates of 
P. falciparum are presented in Table VIII-6 .
Examination of these results revealed modest differences in activity only between 
the various Mannich bases with differing amines; for individual compounds there were 
no significant differences in activity between the FCQ-27 and K-l isolates except for 
compound VI.6c. The resistance factors (obtained by dividing for individual inhibitors 
the IC50 against the K-l isolate by that for the FCQ-27 isolate) for compounds VI.4 
were in the range 0.5-2.9; for compounds VI.5, 0.5-2.0; and for compounds VI.6 
(except VI.6c), 1.0-1.4 whereas that for chloroquine was ca 10.
Comparison of the results given in Table VIII-6 with those reported by Scott et 
al.97,98 for the relevant 3-demethyl analogues, revealed that the 3-methyl derivatives 
(such as VI.5 and VI.6) had lower activity than the analogues lacking the methyl group.
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For example the IC50 values for the FCQ-27 isolate for the compounds VI.5 were from 
5 to 34 times less active than their demethyl analogue97*98 (the largest difference of 34 
times related to Mannich bases derived from piperidine) whereas for the compounds 
(VI.6), it varied from 6 to 16 times except for compound VI.6e (piperidin-l-yl) which 
was slightly more active than its demethyl analogues.97
Whereas McCuastland and Cheng108 reported that the chloroquine analogue 
[(1.4lb), containing the 7-chloro-l,5-naphthyridine nucleus] possessed very good 
antimalarial activity against P. berghei in mice, and Chapman et a /.118 reported that the 
chloroquine analogue [(1.45), containing the 7-chloroquinazoline nucleus] revealed 
suppressive activity against P. gallinaceum in chicks at a dosage of 20 mg/kg, the 
chloroquine analogues (11.51) and (III. 18) (containing the 7-trifluoromethyl-l,5- 
naphthyridine and quinazoline nuclei, respectively) prepared in the present work revealed 
no activity at 200 nM in tests against P. falciparum in vitro.
The results of testing the mefloquine analogue, a-(piperidin-2-yl)-cc-(7- 
trifluoromethylquinolin-4-yl)methanol (VII.4) and its N-oxide (VII.5), against the 
FCQ-27 and K-l isolates of P. falciparum are reported in Table VIII-7. In tests against 
the K-l isolate, compounds VII.4 and VII.5 gave IC50 values of 99 and 172 nM, 
respectively. Against the FCQ-27 isolate both compounds were inactive at 80 nM. 
Compared to mefloquine (IC50 values of 10.1 and 4.9 nM against the FCQ-27 and K-l 
isolates, respectively), compound VII.4 was much less active.
Whereas di-Mannich bases derived from 4-(7-trifluoromethylquinolin-4-ylamino) 
phenol have been shown to possess high antimalarial activity,97*98 the compound VII.4 
was much less active and may indicate a different mechanism of action.
(b) Results from morphological evaluations
Some of the more active compounds reported in Tables VIII-1 to 6 were selected 
for testing against the FCQ-27 and K-l isolates using the morphological technique
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(Chapter VIII-2.1b), and the results are reported in Table VIII-8. For comparison, the 
IC50 values obtained from the incorporation of [3H]-hypoxanthine are also given.
Inspection of these results revealed differences in IC50 values which are probably 
due to differences in the experimental procedures (and in laboratory techniques) and to 
the different line of the FCQ-27 parasite (at ANU and AMRU). The results obtained 
from incorporation of [3H]-hypoxan thine consistently gave lower IC50 values.
However, the results of testing selected compounds against both isolates in Table 
VIII-8 showed that compounds II.48a, III.16j, VI.7b and IV.5b are slightly more 
active against the K-l than against the FCQ-27 strain by a resistance factor of 0.4-0.8; 
moreover compounds II.48e, II.48h and III.16h are slightly less active against the 
K-l than against the FCQ-27 strain by a resistance factor of 1.1-1.3. In contrast, the 
resistance factor for chloroquine against these two strains was 22 .6.
These small differences in activity towards different strains, When compared to 
the large difference in the chloroquine sensitivity, indicate that there is no significant 
cross-resistance with these selected compounds.
(c) Results from visual observation of pigment precipitation
The results from visual observation of pigment precipitation for selected 
compounds described in Chapters VI and VII against both the FCQ-27 and K-l isolates 
are given in Table VIII-9 (for comparison IC50 values obtained for these compounds by 
the use of [3H]-hypoxan thine are given in Tables VIII-6 and VIII-7).
As the concentrations of inhibitor were increased, chloroquine (as standard) 
showed activity around 25 nM against the FCQ-27 isolate and no activity at 200 nM 
against the K-l isolate (the IC50 values in Table VIII-6 are 23 and 221 nM, respectively). 
Compound VI.4d (IC50 values 28 and 16 nM against the FCQ-27 and K-l isolates, 
respectively, from Table VIII-6) first exhibited activity in the range 25-50 nM against 
both isolates; compound VI.4e (IC50 values of 22 and 12 nM) showed activity in the 
range 12.5-25 nM against both isolates; compound VI.5a (IC50 values of 23 and 46 nM) 
showed activity at approximately 25 and 50 nM against the FCQ-27 and K-l isolates,
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respectively; and compound VI.6a (IC50 values of 46 and 53 nM) exhibited activity in 
the range 25-50 nM and approximately 50 nM against the FCQ-27 and K-l isolates, 
respectively.
In the visual test, the Mefloquine analogue (VII.4) and its W-oxide (VII.5) (see 
Table VIII-9) revealed no activity at 200 nM against both strains whereas the results 
obtained with [3H]-hypoxanthine and recorded in Table VIII-7 revealed no activity by 
either compound at 80 nM against the FCQ-27 isolate but IC50 values of 99 and 172 nM 
for compounds VII.4 and VII.5, respectively against the K-l isolate.
Thus it appears that this visual technique may be used as a preliminary guide prior 
to primary screening for antimalarial activity of Mannich base type compounds such as 
compounds VI.4-VI.6. However its application to mefloquine type compounds has yet 
to be established. Then more accurate determinations of IC50 values could be made by 
use of the morphological method or by incorporation of [3H]-hypoxanthine.
VIII-4.2 In vivo test results in mice
(a) Toxicity tests in mice
The preliminary toxicity tests of thirteen selected compounds (preparations 
described in Chapter II to V) are reported in Table VIII-10. It is clear that most of 
selected compounds (11 of 13 compounds) did not produce any acute toxicity at a dosage 
of 100 mg/kg. Thus these eleven compounds are considerably less toxic than 
amodiaquine [reference 97 reported that when amodiaquine hydrochloride (200 mg/kg) 
was given ip. to 6 mice, one only survived to day 7] and chloroquine [neither of two 
mice injected ip. with chloroquine diphosphate (200 mg/kg) survived to 0.5 h].97
Compound 11.51 (a chloroquine analogue) was less toxic than chloroquine 
because two of three mice survived to day 60. However compound II.48h appeared to 
be the most toxic of those tested because two of three mice treated at 200 mg/kg were 
dead at day 6.
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(b) In vivo test results against P. vinckei vinckei in mice
The results for the preliminary in vivo studies of the thirteen compounds (tested 
for toxicity above) against P. vinckei vinckei in mice are recorded in Tables VIII-11 and 
VIII-12 (the IC50 values for their activity against P. falciparum are also recorded for 
comparative purposes).
An examination of the results obtained from these in vivo experiments revealed 
that all compounds except II.48h, IV.3b, IV.3c, IV.4b, and V.3d had a 
significantly beneficial effect in reducing parasitaemia levels and markedly increased 
survival times.
The results in Table VIII-11 (for 7-trifluoromethyl-l,5-naphthyridines) revealed 
that the di-Mannich bases (II.48a and II.48c) of 4-(7-trifluoromethyl-l,5-naphthyridin- 
4-ylamino)phenol were most effective whereas compounds II.48d and II.48g (which 
had similar IC50 values against P . falciparum) were somewhat less effective. Whereas 
compounds II.48h and II.48a had the same IC50 values against P . falciparum, 
compound II.48h had no beneficial effect in the in vivo tests. Compound 11.51 (the 7- 
trifluoromethyl-l,5-naphthyridine analogue of chloroquine) displayed some antimalarial 
activity against P. vinckei vinckei in mice although in vitro tests against P . falciparum 
revealed that the IC50 was greater than 200 nM.
The results of in vivo testing reported in Table VIII-12 reveal the highest activity 
in compounds IV.5b and IV.6b, both "Tebuquine" analogues derived from 7-bromo- 
and 7-trifluoromethyl-l,5-naphthyridines, respectively, whereas the "Tebuquine" 
analogues (IV.3b and IV.4b), containing the 7-trifluoromethylquinoline and 7- 
trifluoromethylquinazoline nuclei, did not show significant activity; nor did the 7- 
trifluoromethylquinoline (IV.3c). The 4-(7-bromo-l,5-naphthyridin-4-ylamino)-5,6, 
7,8-tetrahydronaphth-l-ol (V.2c) showed significant activity in in vivo tests but the 7- 
trifluoromethyl-l,5-naphthyridine (V.3d) was inactive.
A comparison of these results for activity against P. vinckei vinckei in vivo with 
the IC50 values for activity against P . falciparum in vitro reveals no obvious correlation. 
The most active compounds (IV.5b, V.6b and V.2c) for tests in vivo had IC50 values
204
of 30, 50 and 7 nM, respectively, whereas the less active compounds (IV.4b, IV.3b, 
IV.3c and V.3d) had IC50 values of 20, 20, 8 and 60 nM, respectively.
VIII-5 Closing Remarks
In this study only blood schizontocidal activity was examined. The development 
of new culturing techniques for the exoerythrocytic and gametocyte stages of the human 
malaria parasite in the 1980s288-291 means that drug testing assays against these stages 
could soon become commonly available. If this happens it would be interesting to 
determine the activity of the compounds reported in this work against other stages of 
parasite development.
The work described in this thesis and various literature relating thereto suggests 
that the more active Mannich bases contain the 7-halogeno or 7-trifluoromethylquinoline 
or the 7-halogeno-1,5-naphthyridine nucleus. These results, together with a recent 
observation in this laboratory that Mannich bases of 2-aminophenol show significant 
activity, has focused attraction on compounds such as VILI.1.
It is hoped to develop a new class of antimalarial which may overcome or at least 
alleviate the existing problems of drug resistance.
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Figure A l 2-D HETCOR spectrum of 2,6-bis(diethyIaminomethyl)- 
4-(7,-trifluoromethyI-r,5,-naphthyridin-4,-yIamino)phenoI 
(II.48a) in CDCI3
222
Figure A2 2-D HMBC spectrum of 2,6-bis(diethyIaminomethyl)-
4-(trifluoromethyl-l,^ ,-naphthyridin-4'-ylamino)phenol 
(II.48a) in CDCI3
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Figure A3 2-D COSY spectrum of 3-methyI-2,6-bis(piperidin-l'- 
yImethyl)-4-(7"-trifIuoromethylquinoIin-4"-ylamino)- 
phenol (VI.5e)
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Figure A3.1 Expansion of Figure A3 at region A
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Figure A3.2 Expansion of Figure A3 at region B
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THE MANNICH REACTION
The Mannich reaction consists of the condensation of ammonia or primary or 
secondary amines, mostly as the hydrochloride salt with formaldehyde (or paraformal­
dehyde) and a compound containing one (or more) hydrogen atoms of pronounced 
activity such as methyl ketones or phenols. The reaction essentially involves the 
replacement of an active hydrogen atom by an aminomethyl or substituted aminomethyl 
group. The products of the condensation are known as "Mannich bases".
For example the reaction of acetophenone with formaldehyde and a secondary 
amine is as follows:
PhCOMe + CH 20  + R 2NH.HC1 --------- - PhC O C H 2C H 2N R2.HCI + H 20
The earliest examples of the Mannich reaction were published by Tollens1»2 but 
Mannich3’4 was the first to recognise that the reaction was a general one. Numerous 
reports of Mannich reactions appear in the literature and many reviews of this reaction 
have been published.5-7
In the present work, di-Mannich base derivatives were prepared from 4-nitro- 
phenol and 3-methyl-4-nitrophenol (as shown in Scheme 1) and mono-Mannich base 
derivates from Ar-(4-hydroxy-5,6,7,8-tetrahydronaphth-l-yl)acetamide.
229
OH OH
EtOH
R ^ N C H c h ,n r !r2
+ (CH20 ) n + HNR*R2
Me 90-95 Me
NO NO
Schem e 1
3-Methyl-4-nitrophenol, as a compound containing active hydrogen atoms, 
reacted with excess paraformaldehyde and secondary amines (and r-butylamine) at reflux 
in ethanol to give 2,6-bis(dialkylaminomethyl)-3-methyl-4-nitrophenols (in Scheme 1).
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